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1 Introduction 
1.1 Therapeutic monoclonal antibodies 
For over a decade, monoclonal antibodies (mAbs) dominate the market of 
recombinant therapeutic proteins.1 About half of the sales of biological products, also 
known as biologics, in the year 2012 were achieved by therapeutic antibodies.2 
Furthermore, the top 6 biologics with blockbuster status were all antibody-related 
products,2 with adalimumab, etanercept, and infliximab directed against tumor 
necrosis factor (TNF), rituximab targeting CD20, trastuzumab binding to human 
epidermal growth factor 2 (HER2), and bevacizumab aiming at vascular endothelial 
growth factor (VEGF). The sales numbers underline the impressive impact of mAbs in 
the treatment of autoimmune and inflammatory diseases,3 as well as cancer.4,5 
Furthermore, many new products are in clinical trials and expect approval by the 
authorities with a high rate of success.6,7 
Antibodies are globular proteins of the family of immunoglobulins (Ig). From the five 
structurally similar classes of Igs (A, D, E, G, M), IgG is the most abundant in serum. 
The IgG function is related to the different domains of the antibody. The antigen-
binding site is located at the tips of each Fab fragment (fragment antigen binding), 
whereas the Fc fragment (fragment crystallizable) mediates various receptor 
functions. The fragments were historically obtained and investigated by enzymatic 
cleavage with papain.8 Two Fab fragments and one Fc are connected via a highly 
flexible hinge region to form the overall Y-shape of the antibody. Breaking it down to 
the primary structure, the mAb molecule is symmetrical, consisting of two pairs of 
identical amino acids chains of characteristic length and features.9 The longer one 
(heavy chain, H) consist of three domains with highly conserved, constant structure 
(CH1, CH2, CH3) and one domain which shows a high variability between mAbs with 
different specificity (VH). The shorter chain (light chain, L) similarly consists of a 
constant (CL) and a variable domain (VL). The variable and one constant region of 
heavy and light chain (VH+VL, CH1+CL) are connected via a disulfide bond and 
noncovalent interactions to form the stable Fab fragment. The remaining constant 
regions of the heavy chain (CH2, CH3) form the Fc fragment. The two halves of the 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
2 
full mAb molecule, each consisting of a heavy and a light chain, are linked with two 
disulfide bonds at the hinge region and noncovalent interactions of CH2 and CH3, 
which involve protein-protein interactions as well as interactions between glycans that 
are attached to the CH2 domain of each heavy chain. The molecular weights of light 
and heavy chain are about 25 and 50 kDa, leading to about 50 kDa of each Fab and 
Fc fragment, and consequently approximately 150 kDa of the full mAb molecule. 
The high specificity against antigenic epitopes and high adaptability of mAbs are 
realized by three hypervariable regions in VH and VL that form the complementarity-
determining region (CDR) of the Fab fragment. A monoclonal antibody is directed 
against only one target epitope via a specific CDR. Using the tools of molecular 
biology, recombinant mAb molecules are created with tailored primary sequence to 
capture therapeutic targets. The drawback of immunogenic reactions of the patient 
against the first mAbs from mice,10 was subsequently minimized by chimeric,11 
humanized,12 and fully human mAbs.13-15 
Moreover, the mAb structure was subject to various modifications and variations over 
the recent years. Tuning the Fc-receptor interactions might not only affect the 
clearance but also the efficiency. Furthermore, bispecific variants were investigated 
for advanced targeting. Full mAb molecules benefit from a long plasma half-live due 
to their molecular size and specific Fc mediated recycling. In contrast fragments of 
Fab down to single-chain variable fragments (scFv), minibodies, heavy chain 
antibodies, and single domain antibodies are examples for strategies to improve 
tissue penetration and distribution. Excellent reviews are available in literature about 
the second and next generation mAbs described in this paragraph.16,17 Last but not 
least, the success of mAbs is related to the advances of modern biotechnology that 
allow the production, purification and formulation of therapeutic proteins in large scale 
to meet the requirements of typically high doses in therapy.18 
1.2 The challenge of protein instabilities 
Safety and efficacy of therapeutic protein products are particularly challenging due to 
multiple instability reactions of the protein molecules. Protein instabilities are often 
divided into chemical and physical instabilities,19-21 whereas the latter are either of 
colloidal or conformational type. Chemical reactions such as oxidation, reduction, 
hydrolysis, and other covalent changes directly alter the primary structure of the 
1. Introduction 
3 
protein. In contrast, primary structure is maintained in case of physical instabilities but 
the higher order structure, the microscopic and/or the macroscopic appearance of the 
protein is affected. Both physical stability and instability are mediated by short (hard 
sphere, van der Waals, hydrophobic, H-bonds, etc.) and long-range (electrostatic) 
interactions. These are responsible for the proteins’ secondary and tertiary 
structure,22 but also govern the behavior of protein molecules in solution.23,24 
Colloidal instabilities from attractive protein-protein interactions lead to clustering of 
protein molecules known as protein aggregation. Protein aggregation renders a large 
and inhomogeneous group of instability products. Aggregation pathways, kinetics, 
and driving factors are complex, leading to usually an inhomogeneous aggregate 
population of varying size and morphology.25 Correspondingly protein aggregates can 
range from dimers to multimers, from native like associates to denatured precipitates, 
from ordered fibrils to amorphous structures, and from reversible clusters to stable 
particles.25,26 These categories are helpful to describe the characteristics of protein 
instabilities, but should not be considered as unique and independent. Chemical 
instabilities can lead to structural changes and also reduced activity when the CDR,27-
29 or the Fc-receptor binding sites are affected.30-34 Furthermore, structural changes 
can lead to aggregation, e.g., via exposed hydrophobic surfaces,35,36 but can also 
facilitate chemical reactions.37 Especially, inherent characteristics of the protein itself 
affect the quality and quantity of protein stability and instability, e.g., post-translational 
glycosylation,38 or structural hotspots for aggregation.39 Furthermore, heat, extreme 
pH, agitation, drying, freeze/thaw, adsorption/desorption, and other stress factors are 
major drivers of these protein instabilities.22,25 
1.3 The role of temperature in the context of protein stability 
Although organisms are known which can endure conditions of extreme temperature, 
like hyperthermophiles or psychrophiles, most organisms are mesophilic, i.e., their 
enzymes are active at temperatures between 25 and 50 °C.40 The highest 
thermodynamic stability, which is the largest free energy difference between the 
unfolded and folded state of the protein, is typically observed at physiological 
temperatures or slightly below.41,42 Moreover, the thermal stability reflected by the 
protein melting temperature (Tm), certainly above physiological temperatures, 
indicates the resistance against thermal unfolding. A high thermal stability is 
commonly beneficial for therapeutic proteins to maintain the active native state in 
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vivo, ex vivo, and upon storage. The Tm value, which is affected by the environment 
of the protein, is therefore very important during research and development (R&D). 
Therefore, the role of temperature in the context of thermodynamic and thermal 
stability, and upon storage is introduced in the following. 
1.3.1 Thermodynamic protein stability 
Thermodynamic stability is defined as the free energy change upon unfolding ΔGunf 
which is the difference in free energy of the unfolded and the folded state of the 
protein. Thus, thermodynamic stability arises from the native as well as the unfolded 
structure of the protein. A common expression of ΔGunf is the Gibbs-Helmholtz 
equation 
                       [          (
 
    
)] (1-1) 
with the change in enthalpy and entropy of unfolding ΔHref and ΔSref at an arbitrary 
reference temperature Tref, respectively. ΔCp is the change in heat capacity of the 
protein. The thermodynamic protein stability curve obtained from the Gibbs-Helmholtz 
equation has two intersections at which ΔGunf is zero that are referred to as the cold 
denaturation temperature (Tcd) and the melting temperature (Tm).
43 
1.3.2 Protein thermal stability 
In the simple case of a reversible two-step unfolding process, the protein molecule is 
either in the native or the unfolded state at a given temperature. The reaction is 
characterized by the equilibrium constant that describes the ratio of native and 
unfolded molecules. The temperature at equality between both states, that means 
when half of the protein is unfolded, is the Tm value and ΔGunf is zero. Consequently, 
the Tm value is an indicator of protein thermal stability. A higher Tm value means that 
fewer molecules populate the unfolded state at a given temperature. Thus, a higher 
Tm value is beneficial for therapeutic protein drugs as a high Tm value sustains the 
active, native conformation at physiological temperatures. Furthermore, it reduces the 
probability for conformational alteration potentially accompanied by chemical and 
colloidal instabilities. 
To obtain a higher intrinsic thermal stability, three different thermodynamic ways were 
proposed,44 that is a higher ΔH (larger stability curve), a reduced ΔCp (broader 
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stability curve), and a lower ΔS (right shift of the stability curve). Structural differences 
were studied on proteins from various thermophile organisms that have higher 
thermodynamic stability.41,45 The most common ways to increase the Tm value were a 
higher ΔGunf, a lower ΔCp, or both in combination.
45 Figure 1-1 presents the 
thermodynamic protein stability curve of a mAb which was investigated by Lazar et al. 
using intrinsic fluorescence changes upon guanidine hydrochloride (GnHCl) 
denaturation.46 The obtained ΔGunf values at various temperatures were used to 
calculate ΔH, ΔS, and ΔCp via the Gibbs-Helmholtz equation.
46 The highest 
thermodynamic stability of the mAb was observed at 18 °C (Figure 1-1). Most 
mesophilic proteins have a maximum ΔGunf value at ambient temperatures or at least 
below body temperature.41,42 The derived thermal stability with a Tm value of 60 °C is 
in the range of a typical therapeutic mAb. 
 
Figure 1-1. Protein stability curve of mAb1 reported by Lazar et al.
46
 The black line resembles 
the fitted Gibbs-Helmholtz equation (eq. (1-1)) to the obtained ΔGunf values at various 
temperatures obtained from GnHCl denaturation.
46
 The highest thermodynamic stability is 
observed at 291 K (ΔS = 0) with ΔH291K of 26.6 kcal mol
-1
, and ΔCp of 8 kcal mol
-1
 K
-1
. The data 
was used to calculate the stability curves of hypothetical variants with the same maximum 
ΔGunf but either ΔCp of 7 kcal mol
-1
 K
-1
 (dotted line) or ΔH of 30.1 kcal mol
-1
 (dashed line). In 
both cases a higher Tm value (and lower Tcd) of 3 K was obtained. 
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Intrinsic stabilization of the protein could be obtained from structural modifications, as 
ΔH can be increased by introducing more stabilizing interactions (H-bonds, salt 
bridges, etc.) and ΔCp is correlated to the accessible (hydrophobic) surface area 
which is exposed to the solvent upon unfolding.45 A more densely packed structure or 
structural elements which are maintained in the unfolded state reduce Cp.45 In both 
cases, a higher Tm value is obtained. Using the data from Lazar et al.,
46 a Tm 
increase of 3 °C was obtained from the Gibbs-Helmholtz equation when ΔH was 
exemplarily increased by 3.5 kcal mol-1 and ΔCp was decreased by 1 kcal mol
-1 K-1, 
respectively (Figure 1-1). Furthermore, extrinsic factors, which are maintained by the 
protein formulation, affect the thermal stability. Therefore, it is important to investigate 
the thermal stability of the protein during formulation development of therapeutic 
drugs. 
For thermal stability analysis, typically differential scanning calorimetry (DSC) is used 
to obtain Tm values of proteins in solution. DSC also reveals the thermodynamic 
properties ΔH and ΔCp that can be used to calculate the thermodynamic stability via 
the Gibbs-Helmholtz equation but only in cases of reversible two-state unfolding 
reactions, which are typically not observed for large and complex multi-domain 
proteins such as mAbs. Typically, noncooperative unfolding of unique domains and 
protein aggregation is observed. Therefore, the thermodynamic information is 
confined to the “apparent” Tm value. Finally, it has to be noted that a high 
thermodynamic stability (high ΔGunf) does not necessarily mean a high thermal 
stability (high Tm) and vice versa. 
1.3.3 Protein stability upon storage 
Storage stability over a certain time period is essential for a therapeutic product to 
provide appropriate shelf-life. The time dependence of instability processes is a 
challenge for drug product development. Commonly accelerated storage stability 
studies at elevated temperature are utilized as kinetics are assumed to increase with 
temperature according to Arrhenius law. In this case, a higher temperature raises the 
probability of a molecule to pass the activation energy barrier, leading to an 
increased rate constant and thus faster (instability) reaction. The complexity and 
quantity of the physicochemical protein instabilities often lead to nonlinear 
relationships between parental material and degradation products.47,48 
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If the accelerated storage temperature is above the onset of unfolding of the protein, 
also different processes can occur due to the altered structure and the results might 
not agree with storage data at lower temperatures. Therefore, the results from 
thermal stability analysis should be considered for the interpretation of storage 
stability data. Moreover, the Tm value is routinely analyzed in order to predict storage 
stability. If for example irreversible aggregation occurs after unfolding of a certain 
mAb domain, then a higher Tm value of this domain probably reduces the aggregate 
formation, because the likeliness of unfolded molecules at temperatures below Tm is 
decreased. This is true for all instability pathways that start from nonnative protein 
structure. 
In conclusion, a higher Tm value is beneficial and can enhance storage stability, but is 
predictive only in cases where degradation is linked to unfolded protein structure. 
Therefore, thermal stability screenings and accelerated stability studies can 
rationalize the development process and can support the investigation of degradation 
pathways, but real-time storage stability data is essential for filing a new product to 
the authorities to prove safety and efficacy. 
1.4 Formulation development of proteins 
The protein formulation can be described as the environment of the protein to 
maintain its function and to be finally administered to the patient. The size, charge, 
and physicochemical properties of multi-domain proteins such as mAbs primarily limit 
the routes of administration to intravenous or subcutaneous with a small number of 
exceptions. Although freeze- or spray-dried products are convenient to increase the 
shelf-life, the protein is finally administered in solution. Therefore, protein activity and 
stability in aqueous solution are essential for its therapeutic use. Special 
requirements due to parenteral administration like physiological tonicity or pH need to 
be considered. Moreover, subcutaneous injection may require high protein 
concentrations to administer the therapeutic dose in a small volume.49 In such high-
concentrated mAb solutions enhanced protein-protein interactions, self-association, 
and high viscosity present additional challenges.49-51 Additionally, during production 
(filtration, pumping, filling), shipping, storage, handling, and administration, the 
protein is exposed to various stresses. This involves unfavorable sheer forces, light 
exposure, and surface interactions. Thus, the protein formulation needs to be 
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optimized towards maintaining the active, native conformation of the protein, reducing 
unfavorable attractive and supporting repulsive protein-protein interactions, and 
protecting the protein from stress. 
Some common rules for formulation development have been established and 
extensively reviewed.19,22,52 The pH value of the solution defines the net charge of the 
protein. The colloidal stability is typically low at neutral net charge of the protein and 
increases at pH values where repulsive electrostatic forces occur. But extreme pH 
values induce unfolding by intramolecular repulsion and chemical degradation. To 
maintain the pH, organic and inorganic buffers are used. The choice of the substance 
is primarily related to the desired pH value of the solution for high buffer capacity. 
Specific stabilizing or destabilizing effects of different buffer substances at the same 
pH value can occur from direct interactions, ionic strength, or solvent effects. Salts 
modify the tonicity and ionic strength of the solution, and have shielding effects on 
charges. Furthermore, ions have specific effects on the protein solubility and stability 
described by the Hofmeister series. Typically, sugars, sugar alcohols, and polyols are 
used for tonicity adjustments. They can also nonspecifically enhance the stability of 
the protein by preferential exclusion of the excipient from the protein surface and thus 
preferential hydration of the protein. To reduce adsorption to surfaces and protein 
instabilities induced by interfacial stress, surfactants are added routinely. 
1.5 High-throughput screenings for protein stability 
The vast instability reactions of proteins (see chapter 1.2) demand a comprehensive 
physical and chemical characterization of the protein during R&D of therapeutic 
proteins. Even more, proteins are intentionally stressed to provoke protein instabilities 
in order to rank candidates and to identify instability mechanisms of most concern. 
Especially at an early development stage, the availability of purified drug substance is 
limited and furthermore, the cost of goods of the protein material is very high. It is 
essential for any assay that the amount of sample consumed by the analysis is as 
low as possible or that the sample might even be recyclable for further analysis. Over 
the recent years, many analytical techniques were adapted to multi-well plate formats 
and automated sampling to allow small sample volumes and high-throughput 
screenings (HTS).53,54 
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For analysis of protein aggregation, high performance size exclusion chromatography 
(HP-SEC) and dynamic light scattering (DLS) are prominent examples for good 
automation and well plate format analysis techniques in the small aggregate size 
range. Larger particles that scatter visible light and lead to turbidity of the solution are 
conveniently detected by assessing the transmission also on small scale an in well 
plate format. Furthermore, smart real-time image analysis and improved microfluidic 
systems are going to establish flow imaging techniques as HTS in the near future.55 
In contrast, the high-throughput analysis of chemical instabilities is challenging and 
complex mass spectrometry (MS) investigations are time consuming. In some cases, 
for example for the detection of oxidized species, straight liquid chromatography 
techniques are described.56,57 
Light absorption (circular dichroism, second derivative UV spectra) and both intrinsic 
and extrinsic fluorescence spectroscopy are routinely used to detect changes in 
secondary or tertiary structure arising from the spectral properties of mainly the 
aromatic residues of the protein. Optical spectrometers are available in both multi-
well plate and automated sampling formats. But vibrational (Fourier transform 
infrared, near infrared, and Raman) spectroscopy is challenging for HTS for technical 
reasons.54 
Automatized DSC with liquid sampling technologies is available from various 
manufacturers. The DSC technique is suffering from comparably high sample 
amounts and long analysis times due to single measurements and extensive cleaning 
procedures. In contrast, differential scanning fluorimetry (DSF) indirectly monitors 
protein unfolding of samples in parallel by means of an extrinsic fluorescent dye and 
a multi-well plate format.58 Thus, DSF is a powerful and promising technique for high-
throughput thermal analysis of therapeutic proteins.59-61 
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2 Aim and outline of the thesis 
The work in this thesis aimed at the analysis of protein unfolding, interaction, and 
aggregation of therapeutic mAbs upon heating. The objectives focused on the 
determination and interpretation of Tm with respect to formulation development. 
Furthermore, the results from temperature-ramped interaction parameter 
investigations, and the application of novel and unique techniques to study protein 
aggregation are presented with a focus on a deeper understanding of the thermal 
stability of mAbs and mAb domains. 
As a first objective, the DSF method is introduced and optimized in chapter 3 with 
respect of the requirements of protein formulation development. This includes 
hardware considerations, sample preparation, experimental parameters, and finally 
data analysis and automatized data handling. A robust DSF method is established 
using two different RT-PCR machines. 
In chapter 4, both intrinsic and extrinsic factors affecting the thermal stability of mAb 
samples are investigated by DSF and DSC. The influence of deglycosylation on the 
thermal stability is investigated on two mAbs which differ in an additional 
glycosylation site in the Fab region. Furthermore, the stabilizing or destabilizing 
effects of selected buffers, excipients like the basic amino acids arginine and 
histidine, and pH are studied. Finally, the correlation of DSF and DSC is evaluated 
and discussed. 
SYPRO® Orange is very popular for DSF experiments as it is very sensitive to 
protein unfolding based on interaction with hydrophobic patches which become 
exposed upon heating. However, surfactants present in the formulation also interact 
with SYPRO® Orange, disturbing the unfolding signal of the protein. The DSF 
method is challenged in chapter 5 with mAb samples containing surfactants and 
scenarios which typically occur during formulation development. Limitations and 
opportunities like the application of a rotor dye like DCVJ, which shows promising 
results due to less interaction with the surfactant micelles, are presented. 
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The observation in previous chapters that mAb aggregation is linked to the unfolding 
of certain domains raises the question of the driving forces of protein aggregation 
upon heating. Temperature-ramped DLS measurements are performed to determine 
the interaction parameter kD, related to the second osmotic virial coefficient that 
indicates net attraction or net repulsion of the protein molecules. Moreover, DLS and 
turbidity measurements additionally monitor particle formation upon heating. Thus, 
the experiments presented in chapter 6 link the investigations of thermal unfolding, 
aggregation, and interaction mAb molecules. 
The objective of chapter 7 is the investigation of aggregate growth via fluorescence 
correlation spectroscopy (FCS) and fluorescence cross-correlation spectroscopy 
(FCCS). Using mAb aggregates formed by heat stress, the adsorption of native and 
stressed mAb monomers to the existing aggregates is studied with fluorescently 
labeled mAb molecules. The interesting techniques allow the challenging analysis of 
heterogeneous species containing both monomers and aggregates. 
A completely new and orthogonal technique for the detection of protein aggregates is 
studied in chapter 8. A laser-induced breakdown detection (LIBD) setup is used to 
sense the formation of mAb aggregates upon thermal unfolding. Therefore, an optical 
setup using a strong laser is coupled with a temperature-controlled cuvette and the 
breakdown events caused by plasma formation of protein particles is monitored. The 
LIBD results are compared to previously performed temperature-ramped studies. 
Finally, a summary of the results is given. It highlights the benefits and drawbacks of 
the used analytical techniques and concludes the thesis. 
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3 Differential scanning fluorimetry (DSF) for the high-throughput 
analysis of protein melting 
3.1 Introduction 
In living organisms, proteins are typically in the native state which is folded to a 
certain conformation that facilitates the function of the protein. The enthalpy minimum 
is gained from stabilizing protein-protein and protein-solvent interactions against the 
unfavorable increase in entropy of the system. This leads to the fact that proteins 
typically form a hydrophobic core consisting of nonpolar and uncharged amino acids, 
whereas hydrophilic residues are exposed to the aqueous solvent. DSF is based on 
the environmental sensitivity of a fluorescent dye such as ANS, Bis-ANS, and 
SYPRO® Orange. These probes are quenched in water and show high quantum 
yields in solvents with low dielectric constant.1 Upon thermal unfolding, the protein 
structure is lost and the hydrophobic residues and patches are exposed to the 
solvent, facilitating interaction with the probe.2 Monitoring the fluorescence intensity 
as a function of the temperature shows a prominent fluorescence increase upon 
unfolding. The obtained fluorescence melting transitions are subsequently analyzed 
to obtain the apparent melting temperature (Tm) of the protein. This principle was 
introduced 2001 by Pantoliano and coworkers for the high-throughput screening 
(HTS) of small molecule binders to proteins.3 In this case, a low-molecular weight 
ligand will stabilize the native state and will lead to a higher thermal stability, and the 
positive Tm shift is used for hit identification. This thermal shift assay was spread after 
Lo et al. described the application of RT-PCR machines for DSF in 2004.4 In contrast 
to the custom setup built by Pantoliano et al.,3 which was registered as 
ThermoFluor® in the United States,5 the use of marketed RT-PCR allowed the 
application of DSF in common laboratories.4,6 Following up these publications, DSF 
evolved into an essential screening tool for fragment-based drug discovery (FBDD),7-
9 with numerous recent publications in this scientific area.10-18 
In a similar way as ligands binding to the native protein, other extrinsic factors like the 
buffer species, pH, ionic strength, and excipients affect the thermal stability of 
proteins. Stabilizing conditions lead to an increased Tm value, whereas destabilizing 
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conditions reduce Tm of the protein. In 2006 Ericsson et al. studied the Tm values of 
Escherichia coli proteins with the aim to find high thermal stabilities which promote 
crystallizability.19 DSF was applied by Mezzasalma et al. to increase the yield during 
production and purification of two proteins by finding stabilizing and avoiding 
destabilizing solution conditions.20 Crowther and coworkers investigated the effect of 
various buffers on the DSF melting curves and Tm value of recombinant proteins from 
Plasmodium parasites.21 A design of experiment (DOE) approach was chosen by 
Ablinger et al. to optimize the formulation of granulocyte colony stimulating factor (G-
CSF).22 Moreover, DSF was used by several authors for formulation development of 
therapeutic mAbs. A high-throughput thermal stability screening of four different mAb 
molecules was performed by He et al. in 2010.23 The conformational and colloidal 
stability of four different mAbs was investigated by Goldberg et al. later in the same 
year by DSF and temperature-ramped SLS experiments.24 In 2011, Li and coworker 
also studied colloidal and thermal stabilities of three mAb using several high-
throughput techniques (turbidity, fluorescence, DSF, DLS, and flow cytometry).25 King 
et al. investigated the predictability of thermal stability based on the DSF results of 77 
mAbs.26 
This chapter gives a comprehensive discussion on DSF method development. It 
considers the aspects of data analysis of the experimental data to obtain the outcome 
parameters Tm and Tm,onset. Furthermore, experimental parameters significantly 
influencing the results, such as fluorescent dye and protein concentration, are 
discussed. Although SYPRO® Orange is the most common fluorescent dye used for 
DSF, other popular dyes are reported. The hardware requirements necessary for 
DSF are discussed on the example of two RT-PCR machines. Finally, investigations 
on the validity of the obtained Tm values are presented. The DSF method evaluated 
in this chapter is applied for the analysis of various investigations presented in the 
chapters 4 through 6. 
3.2 Materials and methods 
3.2.1 mAb model protein 
A therapeutic IgG1 model monoclonal antibody (“MAb”) produced in CHO cells with 
ε280nm of 1.49 ml g
-1 cm-1 was used. 
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3.2.2 Differential scanning fluorimetry (DSF) 
The DSF method is introduced and developed in this chapter. Every step from, 
hardware requirements and setup, to sample preparation, experimental parameter 
influencing the outcome, and finally, the data analysis are comprehensively 
discussed. All experiments, if not stated otherwise, were performed on a RT7300 RT-
PCR machine (Applied Biosystems, Foster City, California, USA). In chapter 3.5, in 
which hardware aspects are discussed, also results from the qTower 2.2 (Analytik 
Jena AG, Jena, Germany) are presented. The qTower 2.2 is a RT-PCR machine 
used in addition to the RT7300 in chapter 4. For DSF experiments with the qTower 
2.2, two customized filter modules were supplied by the manufacturer that are both 
optimized for the detection of SYPRO® Orange. One filter module contains an optical 
density filter which reduces the overall fluorescence intensity to avoid saturation of 
the detector when higher protein concentrations are investigated. For differentiation, 
this filter module is referred to as the “attenuated” SYPRO® Orange filter. 
3.2.3 3D fluorescence spectra of fluorescent dyes used for DSF 
A standard (20 – 96°C) DSF experiment was performed to achieve a typical sample 
of denatured protein. The formulation in 10 mM sodium phosphate buffer at pH 5.0 of 
4 mg/ml MAb was selected due to low turbidity after exposure to high temperatures 
(see chapter 6). Samples with SYPRO® Orange, CCVJ, and DCVJ (all Sigma-
Aldrich, Steinheim, Germany) were investigated. Three wells of each 20 µl were 
pooled and transferred into a submicro fluorescence glass cuvette (Hellma Analytics, 
Müllheim, Germany). A Cary Eclipse spectrofluorimeter (Varian, now Agilent 
Technologies, Santa Clara, California, USA) with a temperature controlled cuvette 
holder was used (20 °C). Prior to the 3D scan, the optimal settings for the slids and 
the photomultiplier tube (PMT) voltage were evaluated to achieve a suitable signal 
intensity of the sample in the region of interest. The 3D scan was performed in steps 
of 1 nm with 1 s signal averaging, from 300 – 600 nm excitation and 400 – 700 nm 
emission wavelength to cover the entire spectroscopic characteristic of the dye in 
presence of the denatured protein. Although the solutions were clear to the naked 
eye, first and second order light scattering of the excitation light, which is many times 
stronger than the fluorescent light from the sample, was observed. For graphical 
illustration, the scattered light from a MAb sample without the extrinsic dye was 
subtracted as background. All calculations and graphing were performed using GNU 
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octave version 3.6.2 (https://www.gnu.org/software/octave/) under Debian Linux 
(http://www.debian.org/). 
3.3 Aspects of data analysis 
3.3.1 Analysis of the protein melting temperature 
In a simplified model, the protein molecule can populate either the native (N) or the 
unfolded state (U), and both states are linked by a reversible reaction. The native 
state is favored due to stabilizing (noncovalent) interactions of the protein. In 
thermodynamic equilibrium, each concentration is defined by the equilibrium constant 
of unfolding Kunf at the given temperature 
      
[ ]
[ ]
 (3-1) 
At low temperatures, the concentration of the unfolded protein is low and most 
molecules populate the native state. With increasing temperature, the reaction is 
shifted towards the unfolded state as the stabilizing interactions are compensated. 
The equilibrium constant is linked to the Gibbs (free) energy change of unfolding 
ΔGunf via equation (3-2) 
                 (3-2) 
where R is the gas constant and T the absolute temperature [K]. As can be seen from 
equation (3-2), ΔGunf of the system is zero when Keq equals one. The temperature at 
which both concentrations of native and unfolded protein are the same is defined as 
the protein melting temperature (Tm).
27 In a DSC scan, ΔGunf is zero at the midpoint of 
the endothermic unfolding transition (see chapter 4). 
DSF is based on the interaction of the environmental sensitive fluorescent probe with 
the unfolding protein structure upon heating. The exposure of hydrophobic structure 
leads to more pronounced interaction and higher fluorescence intensity. Assuming 
that the highest fluorescence intensity is observed in the unfolded state, the midpoint 
of the transition represents the apparent Tm value. This fluorescence increase can be 
monitored using a common RT-PCR machine (see chapter 3.5) that also facilitates 
the temperature ramp. In contrast to protein unfolding, DNA melting results in a 
descending fluorescence intensity of the probe upon heating, and thus a positive sign 
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of the first derivative. The possibility to invert the sign of the first derivative in most 
RT-PCR software allows Tm analysis of proteins. But performing HTS with numerous 
samples in multi well plates raise the need for automatized data analysis to handle 
the magnitude of data points in a reasonable amount of time. Using scientific 
graphing and data analysis software such as Origin® (Originlab Corporation, 
Northampton, Massachusetts, USA) as described below, or other programs,28-30 
scripts for automatized data analysis can be programmed. Furthermore, routines like 
nonlinear (Boltzmann) functions can be adapted for advanced data analysis, which 
are typically not supported by RT-PCR software. In the following paragraphs, two 
methods for the determination of the apparent Tm value will be demonstrated, which 
were automatized using LabTalk on Origin® 8 SR6 (Originlab) (see Appendix for the 
full LabTalk code of the “OpenTM” script). 
First, the sigmoidal shape of the fluorescence transition can be investigated by fitting 
a model function. The Boltzmann function was described in literature for Tm 
determination of DSF experiments.6,19 This equation describes the sigmoidal 
transition of the native protein with low fluorescence intensity values to the unfolded 
structure with high fluorescence intensity in a reversible, two-state one-step reaction. 
Despite the common irreversibility and noncooperativity of the unfolding process, the 
Boltzmann analysis is known to produce good results.4 The fluorescence intensity (I) 
is described by the Boltzmann function via four parameters:  
  ( )  
     
   (
    
  )
    (3-3) 
AL is the lower and AU the upper limit of the fluorescence intensity
*, Tm is the 
temperature at the midpoint of the transition, and dT is the slope factor. Figure 3-1 A 
exemplarily presents the fitted Boltzmann functions to both transitions of 4 mg/ml 
MAb in 25 mM histidine buffer pH 7.7. Initially, local minima and maxima of the 
fluorescence intensity were determined (54, 74, 77, 84 °C). These temperatures were 
then used as starting points for AL and AU. Next, χ
2 was minimized during the fit while 
all four parameters are free for maximum conformity. The apparent Tm values were 
determined as 68.26 °C and 81.31 °C for Tm1 and Tm2, respectively (Figure 3-1 A).  
                                            
*
 Note: To prevent confusion with the osmotic second virial coefficient (A2) from the parametric 
expansion of the osmotic pressure (chapter 6), the upper and lower limits A2 and A1 as published in 
Menzen and Friess
31
 (chapter 5) are renamed in this thesis to AU and AL, respectively. 
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Second, the midpoint can be determined by investigation of the first derivative of the 
fluorescence intensity. Figure 3-1 B illustrates the apparent Tm values of both 
transitions of 4 mg/ml MAb in 25 mM histidine buffer pH 7.7 with Tm1 and Tm2 of 
68.97 °C and 81.28 °C, respectively. These results were obtained by analysis of the 
first derivative for peak maxima. To obtain a higher temperature resolution, the first 
derivative was splined (interpolated). Furthermore, absolute values of the first 
derivative were necessary for the peakfind algorithm and thus negative signs were 
inversed (see inlet graph of Figure 3-1 B).  
A 
 
 B 
 
Figure 3-1. Common techniques to determine apparent Tm values from DSF melting transitions 
are illustrated in the example of 4 mg/ml MAb in 25 mM histidine buffer pH 7.7. The Boltzmann 
equation was fitted to both melting transitions (A). The Tm values as the midpoint of the fits are 
marked with a cross. The inflection point of the transitions were analyzed by the first derivative 
of the fluorescence data (B). The Tm values are the local maxima of the first derivative as 
illustrated in the insert graph. 
The results from Tm analysis of 96 samples of 4 mg/ml MAb in 25 mM histidine buffer 
pH 7.7 are presented in Figure 3-2. The histograms illustrate a small difference in the 
apparent Tm1 value between Boltzmann fit and first derivative analysis. Such 
difference was not observed for Tm2. Similar histograms were obtained for the 
RT7300 and the qTower 2.2 system. The standard deviations ranged between 0.2 
and 0.3 °C. A normal distribution of the obtained Tm values was confirmed by 
Shapiro-Wilk test (p = 0.05) for both analysis methods and both RT-PCR machines. 
Consequently, about 99.73 % of all values are within the range of three-sigma (3σ). 
That means with a typical standard deviation of a DSF experiment as described 
above (< 0.3 °C), 3σ is about 0.6 - 0.9 °C. Therefore, as a practical rule, a difference 
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of > 1 °C is with high probability a significant result, and the thermal shift is assumed 
to be caused by a stabilizing or destabilizing effect on the protein structure. 
A 
 
 B 
 
C 
 
 D 
 
Figure 3-2. Histograms of apparent Tm values of 4 mg/ml MAb in 25 mM histidine buffer pH 7.7 
determined by Boltzmann fit and first derivative analysis. Tm values of the first melting 
transition (A) and second melting transition (B) were obtained with the RT7300 (Filter C). Data 
from Tm1 (C) and Tm2 (D) were obtained with the qTower 2.2 (attenuated SYPRO® Orange filter).  
The interpretation of the melting transitions of the multi-domain mAb molecules will 
be discussed in detail in chapter 4. It is important to note that the Tm value depends 
on the formulation conditions of the protein such as pH and ionic strength. These 
effects can increase or decrease the Tm value due to stabilizing or destabilizing 
conditions, respectively, and can affect individually the domains of the mAb. It is 
therefore possible to obtain overlapping unfolding transitions. Overlapping transitions 
are difficult to analyze. In this case and also when apparent Tm values are close, first 
derivative analysis might be more sensitive and easier to automatize than Boltzmann 
fitting. Furthermore, the first unfolding transition is typically very strong, whereas 
higher transitions are often less pronounced. 
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3.3.2 Analysis of the onset temperature of unfolding 
The first investigation on a value similar to the onset temperature of unfolding was 
described by King et al.26 They studied the thermal stability of various mAbs and 
concluded that the temperature at which 1 % of the protein was unfolded (T1%), is 
more predictive than the common Tm value.
26 Their procedure included a novel 
approach to analyze the fluorescence transitions obtained by DSF. By simultaneous 
fitting of three Gaussian curves to the unfolding transitions, they were able to 
deconvolute the unfolding of each mAb domain. Based on the total area under the 
curve (AUC) of unfolding protein, the temperature at which 1 % of the area is reached 
is referred to T1%. Figure 3-3 illustrates this type of data analysis on the example of 
4 mg/ml MAb in 25 mM histidine buffer pH 7.7. Three Gaussians were fitted to the 
melting transitions of the MAb molecule using Origin® 8 SR6 (Originlab). After 
integration in temperature steps of 0.01 °C, the T1% value was determined as 
62.56 °C.  
 
Figure 3-3. Illustration of the procedure to determine T1% as described by King et al.
26
, on the 
example of 4 mg/ml MAb in 25 mM histidine buffer pH 7.7. Three Gaussian curves were 
simultaneously fitted to the unfolding transitions (54 – 96 °C). The resulting Gaussians suggest 
the unfolding of the three individual mAb domains (CH2, CH3, Fab; see chapter 4). The 
temperature at 1 % of the total AUC (T1%) is indicative for 1 % of unfolding.
26
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The advantage of the procedure from King et al. is the introduction of a parameter 
that is analogous to the energy from DSC experiments and which is not obtained by 
common Tm analysis. Furthermore, this AUC value enables the derivation of an onset 
temperature by defining a threshold, at which a certain percentage of unfolding has 
occurred (e.g., T1%). The disadvantage of the simultaneous Gaussian analysis is its 
complexity and nonrobustness with respect to the numerous shapes of melting 
profiles which typically appear for multi-domain proteins in HTS scenarios. Automated 
data analysis for this procedure is not available in marketed RT-PCR software so far. 
As Origin® supports nonlinear fitting including multiple Gaussian functions as 
presented in Figure 3-3, the analysis of T1% similar to King et al. could be 
automatized and included in the OpenTM LabTalk script presented in this work. 
The analysis of Tm by Boltzmann fitting is a common procedure for the analysis of 
DSF melting profiles (see chapter 3.3.1). It is therefore desirable to obtain the onset 
temperature based on the results of the Boltzmann fit. The following section will 
introduce a procedure to calculate Tm,onset from the fitted parameters of the Boltzmann 
function that allows the determination of Tm and Tm,onset in one step. The procedure is 
illustrated in Figure 3-4 on the example of 4 mg/ml MAb in 25 mM histidine buffer 
pH 7.7. The Tm,onset value is defined as twice the distance between Tm and the 
intersection of the tangents through Tm and the base line. The equation to obtain 
Tm,onset from the fitted parameters of the Boltzmann function is derived in the following 
section. 
The Boltzmann function f is used to describe the fluorescence intensity as a function 
of the temperature. The Boltzmann function was already introduced in equation (3-3) 
but should be repeated here for derivation of Tm,onset. 
  ( )  
     
   (
    
  )
    (3-4) 
AL and AU are the lower and upper fluorescence intensity limits, respectively. Tm is 
the temperature at the inflection point, and dT is a slope factor at Tm. Equation (3-4) 
was derived using Maxima version 5.26.0 (http://maxima.sourceforge.net/) to obtain 
f’(T) 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
26 
  
 ( )   
 (
    
  )(     )
  ( (
    
  )   )
  (3-5) 
The slope of the Boltzmann function at Tm is obtained from the derived function f’(T) 
with T=Tm 
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 (3-6) 
Next, the fluorescence intensity at Tm is obtained from the Boltzmann function f 
(equation (3-4)) 
  (  )  
     
 
    
     
 
 (3-7) 
Using the results from equation (3-6) and (3-7), the tangent g through Tm is described 
by a linear equation 
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   (3-8) 
whereas a is the intercept of the tangent. Subsequently, the intersection T’ of the 
tangent with the baseline (=AL) is obtained from 
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 (3-9) 
The onset temperature Tm,onset is calculated by subtracting twice the distance 
between Tm and T’ (equation (3-9)) from Tm 
              (    
 )  
   (   
     
  
     
     )
     
    
(3-10) 
Equation (3-10) is described only by parameters that are obtained from the fitted 
Boltzmann function, and therefore Tm,onset is calculated without further procedures. 
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Figure 3-4. DSF melting profile of 4 mg/ml MAb in 25 mM histidine buffer pH 7.7. The Boltzmann 
function was fitted to the first melting transition (black line). To restrain the data to the first 
transition, the local minimum and maximum at 54 °C and 74 °C were used as lower and upper 
limits, respectively. All four parameters were free during the fit. The obtained apparent Tm value 
at the inflection point is marked with a cross. Dotted lines mark the tangents leading to the 
Tm,onset value (upper arrow) as calculated by equation (3-10). 
Of course, Tm,onset can be calculated for every transition observed upon thermal 
unfolding of the protein. In this case, the nomenclature Tm1,onset, Tm2,onset, etc. is 
suggested to differentiate the events. For the HTS of therapeutic proteins, typically 
the lowest observed transition is of interest. Thus, Tm,onset is represented as the onset 
temperature of the first transition, i.e., the temperature at which the first change of the 
structure is detected by the fluorescent dye. Figure 3-5 illustrates the analysis of 
Tm2,onset of the second unfolding transition on the same example as presented in 
Figure 3-4 for the first unfolding transition. 
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Figure 3-5. Boltzmann fit to the second melting transition of the MAb of the same sample as 
presented in Figure 3-4. As the “overall” onset of unfolding is marked by the Tm,onset value, the 
value obtained at 77.13 °C is therefore not named. If onset temperatures of different domains 
are of interest, the value can be referred to as Tm2,onset. 
3.4 The effect of experimental parameters on the apparent Tm value 
SYPRO® Orange, which is sensitive to the increasing hydrophobicity upon protein 
unfolding, is the most frequently used fluorescent dye in DSF. However, the use of 
probes with different environmental sensitivity can change the outcome as different 
processes are monitored. As the measured fluorescence intensity originates from 
protein-dye interaction, also the influence of the concentration of both protein and 
SYPRO® Orange on the DSF results needs to be evaluated. Furthermore, the 
heating ramp affects the apparent Tm value as the process of unfolding during DSF is 
supposedly not in equilibrium. Consequently, experimental parameters were 
systematically varied to achieve an optimal DSF protocol. 
3.4.1 Popular dyes used for DSF 
The environmental sensitivity of a fluorescent dye is key for its applicability as a 
probe in DSF experiments. Upon protein unfolding, interaction of the dye with the 
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protein molecules must lead to a change in the fluorescence properties. In case of 
the dyes from the anilinonaphthalene sulfonic acid family (1,8-ANS; 2,6-ANS; Bis-
ANS; 2,6-TNS), the switchover from a medium with high dielectric constants (polar 
environment) to a medium with low dielectric constants (nonpolar, hydrophobic 
environment) leads to a blue shift in emission maximum and increase in quantum 
yield.1 The fluorescence spectra of other small molecules can interfere with the low 
excitation and emission wavelength of these dyes which limit their application. The 
sensitivity towards “hydrophobicity” is also the case for Nile red, Dapoxyl sulfonic 
acid, and SYPRO® Orange. SYPRO® Orange is the most often used dye for DSF,32 
due to its high photostability, chemical stability, and high fluorescence increase 
during DSF which is beneficial over Nile red and Dapoxyl sulfonic acid.6 Comparable 
results to SYPRO® Orange were also reported for the related dye NanoOrange®.33-36 
As these probes rely on an increase in protein hydrophobicity with unfolding, they 
have limitations for proteins which are rather hydrophobic by nature (high 
fluorescence intensity of the native protein) or when surfactants are present (high 
background fluorescence due to interactions with micelles or hydrophobic structures). 
In both cases, an increase in fluorescence intensity upon unfolding can be 
concealed. For these applications, dyes with different environmental sensitivity are 
reported. The use of CCVJ,37 and DCVJ,31 for DSF in the presence of surfactants 
was recently reported, which is comprehensively discussed in chapter 5. Alexandrov 
et al. described the application of CPM, a dye that reacts covalently with free thiol-
groups (cysteines) of the protein upon thermal unfolding.38 It allows the analysis of 
very hydrophobic proteins, such as membrane proteins, which are reported to be 
challenging.33,39 Although CPM could be applied for samples in the presence of 
surfactants, the reaction is limited to pH 6 to 8.38 Thioflavine T is a dye which is 
known to interact primarily with fibrils and amyloid structures.40,41 It was recently 
applied to DSF to monitor the formation of amorphous, fibrillar aggregates upon 
thermal unfolding.42 Especially for proteins with high β-sheet content, such as mAbs, 
Thioflavin T is a promising dye for the assessment of the conformational and colloidal 
stability.42 ProteoStat® (Enzo Life Science, Plymouth Meeting, Pennsylvania, USA) is 
a molecular rotor dye that was developed for DSF, and is proposed for the analysis of 
protein aggregation. Already applied during the structural characterization of first 
nucleotide binding domain (NBD1),35 the application of ProteoStat® for the 
development of therapeutic proteins, e.g., in the presence of surfactants, needs to be 
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shown. The analysis of a protein with a set of dyes with different environmental 
sensitivity may be promising to obtain both conformational and colloidal stability 
data.37,42 
3.4.2 Aspects of sample preparation 
The simple and direct sample preparation is one major advantage of the DSF 
method. Typically, there a no preparative steps on the protein sample necessary. In 
combination with the multi-well plate format, the fast forward sample handling is one 
of the key features to allow HTS with this method. For a DSF experiment, three single 
liquid handling steps are necessary: i) the protein containing sample solution needs 
to be dispensed into the well, ii) a working solution of the fluorescent dye needs to be 
prepared from a concentrated stock solution, and iii) the working solution of the 
fluorescent dye needs to be added and mixed. 
The necessary sample volume for one well depends on the well plate size and 
instrumental setup. It needs to be considered that with addition of the fluorescent 
probe as a solution, the total volume increases and a dilution of the sample is 
inevitable. Furthermore, other components like ligands or excipients can be spiked 
into the samples from stock solutions to prepare the final formulation directly in the 
wells. A sample volume of 20 µl was found to give robust results for the optical 96-
well reaction plates with the RT7300 RT-PCR. By addition of 1 µl of the working 
solution of the dye, the resulting dilution was minimized to 5 %. The influence of 5 % 
sample dilution on the apparent Tm value can be neglected for low concentration 
samples (compare Figure 3-6 B). 
Table 3-1 summarizes the results for three different ways of sample preparation, 
admixing 1 µl working solution of the dye to 20 µl protein solution, admixing 20 µl 
protein solution to 1 µl working solution of the dye, and admixing 10 µl working 
solution of the dye to 10 µl protein solution. With one exception at 2 mg/ml MAb, the 
standard error was very low for all samples prepared by mixing the 10 µl solutions. 
The drawback of this approach is that the MAb stock solution needs to be double 
concentrated, which might be a hurdle. Moreover, the working solution of the dye 
should be prepared in the corresponding placebo buffer to avoid changing the 
formulation parameters like ionic strength, excipient concentration, or pH value. This 
is cumbersome when many different formulations are to be screened. Starting with 
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the 1 µl drop of working solution bears the risk of drying while preparing the well 
plate. Furthermore, smaller volumes are more easily pipetted into a solution than the 
other way round. This is most likely responsible for the slightly lower standard 
deviation of the approach starting with a larger volume of protein solution. Finally, the 
working solution of the dye was freshly prepared immediately before the experiment, 
because a slight decrease in S/N ratio over time was observed upon storage of the 
aqueous solution. 
Table 3-1. Three different sample preparation protocols were compared. 
 20 µl MAb + 1 µl dye 1 µl dye + 20 µl MAb 10 µl MAb + 10 µl dye 
MAb 
conc. 
Tm1 (CH2) 
[°C] 
Tm2 (Fab) 
[°C] 
Tm1 (CH2) 
[°C] 
Tm2 (Fab) 
[°C] 
Tm1 (CH2) 
[°C] 
Tm2 (Fab) 
[°C] 
2 mg/ml 66.7±0.1 80.7±0.3 68.3±0.6 80.8±0.1 65.5±0.7 80.8±0.1 
800 µg/ml 66.6±0.2 80.7±0.1 67.1±0.2 80.9±0.1 66.7±0.1 80.8±0.1 
400 µg/ml 67.3±0.2 80.6±0.1 67.6±0.6 80.8±0.1 67.0±0.1 80.6±0.1 
160 µg/ml 67.2±0.2 80.3±0.1 67.9±0.8 80.4±0.2 67.1±0.1 80.4±0.1 
80 µg/ml 67.6±0.3 80.2±0.4 67.7±0.4 80.4±0.1 67.3±0.1 80.3±0.3 
40 µg/ml 67.5±0.2 80.1±0.2 67.0±0.3 80.4±0.1 66.3±0.1 80.7±0.1 
MAb in 25 mM histidine buffer pH 7.7 with 5x SYPRO® Orange. The presented Tm values are 
mean values with standard deviation of a sample triplicate. 
3.4.3 The effect of SYPRO® Orange and protein concentration 
The molecular structure and concentration of SYPRO® Orange are undisclosed. It is 
supplied by the manufacturer in a five thousand times (5000x) concentrated stock 
solution in dimethyl sulfoxide (DMSO). SYPRO® Orange was developed for gel 
staining after SDS-PAGE, and a dilution of 1:5000 (corresponding to 1x) is suggested 
by the manufacturer for this purpose.43 For DSF applications, SYPRO® Orange 
concentrations between 1 – 5x are most commonly used. The DSF method was 
designed as a screening platform with low material consumption, which is especially 
important when purified drug substance is limited or the cost-of-goods are high. In 
this case, the application of low protein concentrations is beneficial. In contrast, when 
the drug product concentration is high, the analysis without dilution is desirable. 
Figure 3-6 A shows the DSF melting profiles of a dilution series of the MAb in 25 mM 
histidine buffer pH 7.7 at various concentrations ranging from 80 µg/ml to 58 mg/ml. 
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With higher protein concentration more hydrophobic surface becomes available upon 
unfolding, and thus the fluorescence intensity increased because more dye 
molecules were able to interact. Additionally, the unfolding transition was shifted with 
increasing MAb concentration to lower apparent Tm values at higher initial and 
baseline fluorescence readings (Figure 3-6 B). Furthermore, lower Tm values were 
observed with 3x and 5x SYPRO® Orange. As SYPRO® Orange binds to the 
unfolded state of the protein, the interaction of the dye might be responsible for the 
reduced thermal stability of the MAb. However, DSC analysis of protein unfolding did 
demonstrate that Tm was not affected by the presence of up to 5x SYPRO® Orange 
(see chapter 4). 
A 
 
 B 
 
Figure 3-6. DSF melting profiles of various MAb concentrations in 25 mM histidine buffer pH 7.7 
between 0.08 – 58 mg/ml with 1x SYPRO® Orange (A). Apparent Tm values obtained by 
Boltzmann fitting to the first melting transition of the MAb samples with SYPRO® Orange 
concentrations between 1 – 5x (B). 
As the SYPRO® Orange stock solution is supplied in DMSO, residual amounts of the 
organic solvent are present in the sample. Sorrel et al. showed that DMSO has a 
negative effect on the stability of anthrax protein protective antigen, leading to a Tm 
values decreased by 3 °C and 4 °C in the presence of 1 % and 20 % DMSO, 
respectively.44 DMSO is a typical solvent used for small molecules during FBDD and 
Niesen et al. suggest a final DMSO below 2 % during DSF experiments.6 
To investigate the effect of DMSO on the apparent Tm values of the MAb, samples 
with 1x SYPRO® Orange were prepared and DMSO was spiked into the samples to 
obtain a concentration 0.06, 0.1, and 0.2 % DMSO, mimicking 3x, 5x, and 10x of the 
dye. The thermal stability of the MAb was not significantly reduced (Figure 3-7). 
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Especially the apparent Tm values of the low concentrated samples, where the effect 
of DMSO is expectedly high, were in good agreement. The large deviations for the 
samples in high MAb concentration of Tm2 illustrate the diminishing second transition 
as presented in Figure 3-6 A and are independent on the addition of DMSO. That 
means the presence of DMSO due to a high amount of SYPRO® Orange did not 
negatively affect the thermal stability of the MAb during DSF. This finding was 
confirmed by DSC experiments which are presented in chapter 4. 
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Figure 3-7. The Tm1 and Tm2 from Boltzmann analysis of the MAb in 25 mM histidine buffer 
pH 7.7 in the presence of 0.06, 0.1, and 0.2 % DMSO. 
The observation that the second melting transition is more difficult to detect at higher 
MAb concentration (Figure 3-6 A) suggests that the amount of SYPRO® Orange may 
have been too low to monitor the full unfolding process in these samples. Figure 
3-8 A shows the DSF melting profiles of 28 mg/ml MAb in 25 mM histidine buffer 
pH 7.7 with 5x and 25x SYPRO® Orange. Because the protein concentration was the 
same, the higher absolute mean fluorescence intensity of the 25x SYPRO® Orange 
suggests that a higher number of dye molecules could interact. The first fluorescence 
increase was much more pronounced than the second for both dye concentrations. It 
is important to note that the presented fluorescence curves were recorded at an 
emission wavelength of 530 nm because the high dye concentration in combination 
with a high protein concentration lead to saturation of the detector when the optimal 
filter settings at 578 nm were applied. This limitation by saturation will depend on the 
RT-PCR machine and the setting used. For 0.28 mg/ml MAb, the expected two 
subsequent transition profile was observed (Figure 3-8 B). Interestingly, a lower 
absolute fluorescence intensity of the second unfolding transition was obtained with 
0.1 1 10 100
60
62
64
66
68
70
 0.2% DMSO
 0.1% DMSO
 0.06% DMSO
 0.02% DMSO (= 1x SYPRO® Orange)
T
m
1
 [
°C
]
MAb concentration [mg/ml]
0.1 1 10 100
78
80
82
84
86
 0.2% DMSO
 0.1% DMSO
 0.06% DMSO
 0.02% DMSO (= 1x SYPRO® Orange)
T
m
2
 [
°C
]
MAb concentration [mg/ml]
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
34 
25x SYPRO® Orange. This may be due to attenuation of the incident light through 
absorption by the dye in solution (static quenching) and potentially interaction of the 
dye molecules with each other in the presence of only small protein amount 
(collisional quenching).45 
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Figure 3-8. DSF melting profiles of the MAb in 25 mM histidine buffer pH 7.7 with 5x and 25x 
SYPRO® Orange. Emission filter at 530 nm was used for the 28 mg/ml sample to avoid 
saturation of the detector (A). The 1:100 diluted sample was analyzed with the standard filter 
setting at 578 nm (B). 
Interestingly, the molecular rotor-dye DCVJ showed promising results for high 
concentration protein samples. As illustrated in Figure 3-9 A, at the high 35 mg/ml 
and 175 mg/ml MAb, the fluorescence increase upon thermal unfolding of the MAb 
resulted in a single transition for SYPRO® Orange (see also Figure 3-6 A). Probably, 
protein-protein interactions via the exposed hydrophobic patches of the highly 
crowded protein solution at this high concentration interfere with SYPRO® Orange. In 
contrast, the two expected transitions of the MAb were obtained when DCVJ was 
used (Figure 3-9 B). Furthermore, the fluorescence gain upon unfolding was much 
higher in case of DCVJ in comparison to SYPRO® Orange at 175 mg/ml MAb. A 
similar observation of higher signals with increasing protein concentration was made 
by Nashine et al. with Thioflavine T and referred to the formation of amorphous 
aggregates.42 Furthermore, the fluorescence drop and the disappearance of 
second/higher melting transitions with increasing MAb concentration (see Figure 
3-6 A) may be due to protein aggregation. Niesen et al. suggest that the fluorescence 
drop after unfolding is caused by aggregation of the protein. This aggregation is 
driven by the hydrophobic patches which become exposed upon unfolding, and 
consequently the hydrophobic surface for the interaction with SYPRO® Orange is 
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reduced.6 This would explain the higher sensitivity of DCVJ which monitors the 
consecutive process of protein unfolding and aggregation of the MAb molecule. 
A 
 
 B 
 
Figure 3-9. DSF melting curves of highly concentrated MAb formulations in 1 mM phosphate 
buffer pH 6.0. Results were obtained with 1x SYPRO® Orange (A) and 100µM DCVJ (B). 
In conclusion, for HTS at low protein concentration, it can be recommended to use 
the lowest applicable SYPRO® Orange concentration (1x). This ensures that the 
interference of the dye and its solvent is minimized (c(DMSO) = 0.02 %). The 
detector settings should be optimized to result in a high S/N ratio, which is typically 
achieved by choosing the optimum excitation and emission filters as long as 
saturation is excluded. DSF is not limited to diluted samples, although the apparent 
Tm values were found to be dependent on the MAb concentration. In case of high 
protein concentrations, higher dye concentrations might be beneficial to avoid 
depletion of free dye and more clearly resolve higher unfolding transitions. But the 
higher amounts of both dye and solvent might negatively influence the protein 
stability. Furthermore, the absolute fluorescence intensity needs to be monitored for 
saturation effects of the detector, and an emission wavelength setting aside the 
fluorescence maximum may be necessary. In case of very high MAb concentrations, 
also other probes like DCVJ can be beneficial to monitor the process of unfolding. 
3.4.4 The effect of the temperature ramp 
After a first heating of 0.8 mg/ml MAb in 25 mM histidine buffer pH 7.7 to 96 °C 
during DSC and cooling, the second heating scan did not show an endothermic 
transition (Figure 3-10 A). This indicates irreversible unfolding which is known for 
multi-domain proteins such as mAbs after thermal denaturation.46,47 In this case, no 
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equilibrium with a defined ratio between folded and unfolded state exists. As a 
consequence, the heating rate was observed to affect the apparent Tm value (Figure 
3-10 B). Applying a lower heating rate of 0.3 °C/min resulted in lower apparent Tm 
values, whereas higher values were observed when the rate was increased to 
1.5 °C/min. The extent of the shift was comparable for both DSC and DSF. At higher 
heating rate less time is available for the unfolding process, and thus the apparent Tm 
value is shifted to higher temperature. Interestingly, the scan rate dependence was 
more pronounced for the second unfolding transition (Figure 3-10 B). 
A 
 
 B 
 
Figure 3-10. Repetitive DSC scans of 0.8 mg/ml MAb in 25 mM histidine buffer pH 7.7 (A). Effect 
of the heating rate on the apparent Tm values by DSC and DSF (B). The MAb samples in 25 mM 
histidine buffer pH 7.7 had a concentration of 1 mg/ml for DSC and 2 mg/ml for DSF. 
The Microcal VP-DSC used (see chapter 4.2.10), is limited to a maximum heating 
rate of 1.5 °C/min, but the capillary models are capable of faster heating at 4 °C/min. 
In DSC experiments, a faster scan rate is commonly applied when small enthalpies 
are studied to narrow the unfolding range and thus increase the signal intensity. In 
contrast, slow heating may improve the resolution of multiple transitions.48 The quick 
thermo controllers of RT-PCR machines allow for very fast DSF experiments, but the 
optical detection system becomes rate limiting. A good resolution of the MAb 
unfolding transitions was obtained at 1 °C/min in reasonable runtimes, and therefore 
was applied for both DSC and DSF experiments to compare the results. 
3.5 Hardware settings and test for DSF 
There are two requirements of DSF that are matched RT-PCR machines, a precise 
and fast temperature controller as well as a fluorescence detector. In combination 
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with multi-well plate formats, RT-PCR machines represent ideal hardware for the 
DSF technique. 
3.5.1 Fluorescence excitation and emission settings 
RT-PCR machines are optimized for the detection of fluorescent probes which are 
either dyes covalently linked to sequence specific probes or dyes that bind 
nonspecifically to nucleic acids.49 These probes are used as reporter signal to 
monitor the progress of amplification. To serve in simple single-color to multiplex 
PCR assays,50 marketed machines are typically equipped with several filter sets to 
allow for the detection of various fluorescent dyes. These dyes have a high excitation 
and emission wavelength in common, to minimize background fluorescence effects 
from biologic material. In case of the RT3700, a single excitation filter at 490 nm and 
four emission filter (510, 554, 578, and 610 nm) are available, and a halogen lamp is 
used as light source. The qTower 2.2 uses three LED light sources (blue, white, and 
red) and excitation and emission filters. Incandescent lamps with their broad 
spectrum of irradiated light,51 offer a higher flexibility to customize filter modules with 
tailored excitation wavelength. LEDs, on the other hand, are more economic with 
lower price and very long life times. 
The spectroscopic properties of SYPRO® Orange and of the molecular rotor dyes 
CCVJ and DCVJ were investigated in the presence of denatured MAb to extract the 
optimal excitation and emission settings (Figure 3-11). The obtained excitation and 
emission maxima are presented in Table 3-2. Because of the high excitation and 
emission wavelengths that are similar to common PCR dyes like SYBR® Green, 
FAM, and TAMRA,50 SYPRO® Orange is applicable in all marketed RT-PCR 
machines. The highest fluorescence intensities with SYPRO® Orange were obtained 
with Filter C of the RT7300 (Ex. 490 / Em. 578 nm) and the SYPRO® Orange filter for 
the qTower 2.2 (Ex. 490 / Em. 580 nm). When saturation effects were observed with 
this very sensitive module, the yellow filter for TAMRA (Ex. 535 / Em. 580 nm) 
showed good results. In case of CCVJ and also DCVJ, the lower excitation and 
emission wavelengths, closer to the blue range of the visible spectrum, do not match 
common PCR dyes well and might raise the need for a customized filter module. As 
presented in chapter 5, Filter A (Ex. 490 / Em. 530 nm) of the RT7300 was suitable 
for the detection of DCVJ, and allowed for the application of DSF in the presence of 
surfactants.
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Figure 3-11. Three-dimensional fluorescence excitation and emission spectra of DCVJ (A), 
CCVJ (B), and SYPRO® Orange (C) in the presence of denatured MAb. The background 
spectrum of a MAb sample without the dye was subtracted to eliminate the effects from first 
and second order stray light in the graphs. 
Table 3-2. The excitation and emission maxima in the presence of denatured MAb were 
obtained from the 3D scans presented in Figure 3-11. 
 Excitation / emission maximum [nm] 
 
In the presence of 
denatured MAb 
Literature reports 
SYPRO® Orange 500 / 575 470 / 569 43 
DCVJ 470 / 500 450 / 480-505 52 
CCVJ 440 / 470 437 / 490 53 
The reported SYPRO® Orange data was obtained in an aqueous SDS-PAGE buffer with 0.05 % 
SDS and 150 µg/ml BSA.
43
 Kung et al. reported emission wavelengths of DCVJ dependent on 
the dielectric constant of the solvent (high dielectric constant (glycerol): 505 nm; low dielectric 
constant (benzene): 480 nm).
52
 The data of CCVJ was obtained in glycerol by Haviv et al.
53
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3.5.2 Homogeneity of the recorded fluorescence signal and apparent Tm within 
well plates 
Any analytical machine based on well plate sample handling is prone to variations 
from well to well due to temperature differences across the well plate, moving optics, 
or other aspects of hardware design. Figure 3-12 shows the distribution of the 
maximum fluorescence intensities and the apparent Tm1 values for the same sample 
of 4 mg/ml MAb in 25 mM histidine pH 7.7 across a 96-well plate. For the RT7300 
system, which uses a CCD camera that captures the fluorescence readings of the 
whole plate, spots of lower maximum fluorescence intensity occurred in the corners 
of the well plate (Figure 3-12 A). In contrast, horizontal lines of similar maximum 
fluorescence intensities were observed as the qTower 2.2 scans the eight wells of a 
column simultaneously via optical fibers and subsequently moves the detector head 
column by column across the plate. When the machine is initialized, detector settings 
for the eight fibers are verified and adjusted to an internal intensity reference. 
Therefore it is likely, that similar values occurred in the same row (Figure 3-12 B). 
But the absolute fluorescence intensity is less important than the obtained apparent 
Tm values. Since the relative fluorescence increase is analyzed for Tm determination, 
the Tm1 and Tm2 values were randomly distributed across the well plate (Figure 
3-12 C - F). Thus, also other variations, e.g., in the amount of fluorescent dyes in the 
wells leading to differences in absolute fluorescence intensity, show minor effects. 
Furthermore, Seo and coworkers recently demonstrated the application of DSF to 
quantify proteins in cell lysates using absolute fluorescence readings.54  
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Figure 3-12. Maximum fluorescence intensity distribution of 4 mg/ml MAb in 25 mM histidine 
buffer pH 7.7 across the 96-well plate from the RT7300 with Filter C (Em. 578 nm) (A) and from 
the qTower 2.2 (attenuated SYPRO® Orange filter) (B). In addition, the corresponding apparent 
Tm1 (C + D) and Tm2 (E + F) values from Boltzmann analysis are presented. 
3.6 Summary and conclusion 
An extrinsic fluorescent dye, most often SYPRO® Orange, is used to monitor the 
unfolding process of proteins upon heating in DSF. Especially for formulation 
development of therapeutic protein drugs, the onset temperature of unfolding is of 
interest as it marks the temperature where first structural changes are observed. A 
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method to calculate the Tm,onset value from the Boltzmann fit, which is routinely used 
to determine the apparent Tm value, was generated. Based on a RT7300 RT-PCR 
machine, a robust DSF method was developed and critical parameters were 
evaluated. For optimal sample handling and minimal dilution effects, the addition of a 
small volume of an aqueous working solution of the dye into the sample solution 
dispensed in the wells is beneficial. The dye concentration was kept as low as 
possible, to avoid saturation effects of the fluorescence detector, and to minimize the 
amount of DMSO, which is the solvent of dye in the stock solution. Protein 
concentrations as low as 40 µg/ml up to 175 mg/ml MAb were investigated. High 
protein concentrations are no limitation for DSF, although a higher dye concentration 
may be beneficial to monitor the unfolding process of multiple domains. In this case, 
and when surfactants are present, also probes with different environmental sensitivity 
like the molecular rotor dyes DCVJ and CCVJ are promising (see chapter 5). 
Because of aggregation and irreversible denaturation, the unfolding process upon 
heating was not at equilibrium, and increasing the heating rate resulted in higher 
apparent Tm values. Although faster heating rates are possible, the overall heating 
rate of 1 °C/min was applied to allow for comparison of the obtained results to DSC 
measurements. The multi-well plate format with low sample and time consumption, 
and automatized data analysis allows HTS of thermal stabilities. A standard deviation 
as low as 0.3 °C was found across a 96-well plate for both the RT7300 and the 
qTower 2.2. As the spectroscopic properties of SYPRO® Orange in the presence of 
denatured protein are well within the spectroscopic range of common dyes used for 
DNA analysis, probably all marketed RT-PCR machines are capable to obtain DSF 
data. 
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4 The application of DSC and DSF to the formulation development 
of therapeutic mAbs 
4.1 Introduction 
Analysis by means of differential scanning calorimetry (DSC) is the gold standard to 
investigate the thermal stability of proteins.1 The small energy amounts associated 
with structural changes of proteins ask for high sensitivity, and DSC is therefore often 
referred to as microcalorimetry. From a DSC thermogram, thermodynamic 
parameters such as the enthalpy of unfolding (ΔH), the change in heat capacity 
(ΔCp), and the midpoint of the melting transition, referred to as the protein melting 
temperature (Tm), are calculated.
2 A high Tm value is commonly considered as 
beneficial for the stability of therapeutic protein formulations, because the probability 
of conformational changes of the protein molecules is low (chapter 1.3). The Tm value 
depends on intrinsic factors of the protein, like primary sequence as well as 
secondary and tertiary structural elements. Furthermore, the protein environment 
affects the Tm value; consequently, during formulation development of therapeutic 
protein drugs, the influence of external factors like pH, ionic strength, and excipient 
addition at different concentrations are screened to assess the optimally stabilizing 
conditions. Moreover, the Tm value is suggested to be a predictor for long-term 
stability.3,4 
Although miniaturization,5 automation, and methodological improvements were 
achieved, DSC is still a time and material consuming technique, and the 
pharmaceutical industry is in need of high-throughput techniques which allow rapid 
thermal stability screenings of a high number of samples with low cost of goods.6,7 
In terms of stability screening for formulation development, differential scanning 
fluorimetry (DSF) was first described by He and coworkers.8 DSF analyzes the 
fluorescence intensity of a fluorescent dye that interacts with the protein as a function 
of temperature.9 Upon thermal unfolding of the protein, the fluorescence intensity 
increases and an apparent Tm value can be derived. In the meantime, DSF was 
successfully applied for thermal stability screening of therapeutic proteins and 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
48 
monoclonal antibodies (mAbs) in particular.10-12 For a detailed introduction into DSF, 
please refer to chapter 3. 
In this chapter, the fluorescence melting curves resulting from DSF are compared to 
the thermograms obtained by DSC. As the most important outcome parameter, the 
Tm and Tm,onset values are investigated in order to correlate both methods. Two model 
IgG1 type mAbs were investigated. Cetuximab (CX) is a human/mouse chimeric mAb 
against the epidermal growth factor receptor (EGRF) and is used for the treatment of 
EGFR expressing cancer types, such as colorectal cancer, and head and neck 
cancer.13 In 2007, the formulation of the marketed product was changed due to 
issues with colloidal instability.14 In contrast to the old PBS buffer, the new 
polysorbate 80 containing formulation is more stable.15 In a first step, it was 
necessary to purify the market product to remove the surfactant that otherwise 
interferes with DSF analysis. Additionally, a therapeutic mAb produced in CHO cells, 
which is referred to as “MAb”, was used. 
To understand the individual melting transitions of the multi-domain mAb, the 
molecules were cleaved into Fab and Fc via enzymatic digestion. After purification, 
the isolated fragments were investigated to characterize the thermal stability of the 
individual mAb domains. This enables a better understanding of results from 
excipient screenings for formulation development and the effects on the different 
domains in DSC and DSF of the full mAb molecule. 
Next, the effect of the glycans attached to the mAb molecules as an intrinsic factor of 
the thermal stability was investigated. The glycan moieties are crucial for the biologic 
activity and mediate receptor functions, e.g., at the Fcγ receptor and C1 component 
of the complement system for antigen clearance, and the neonatal receptor (FcRn) 
for catabolism and salvation.16 Thus, glycoengineering can be applied for prolonging 
the half-life. The antibody-dependent cellular cytotoxicity can be increased by 
defucosylation,17 or production in nonfucosylating cell lines.18 Thus, glycosylation is a 
promising target of mAb engineering to produce next-generation molecules with 
tailored characteristics.19,20 The effect of glycans on the chemical, colloidal, and 
conformational stability of therapeutic proteins was extensively reviewed by Solá and 
Griebenow.21 For many proteins including mAbs, an enhanced stability caused by 
glycosylation was reported.21,22 Correspondingly, cleavage of the Fc-glycan results in 
a reduced thermal stability of mAbs.8,23-28 Recently, Alsenaidy and coworkers focused 
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on the high-throughput aspect for formulation development, and screened the pH 
effect on the thermal stability of an IgG1 mAb upon complete and partial 
deglycosylation of the Fc part.29 In contrast, little is known about the role of 
glycosylation in the Fab region in thermal stability. CX is a therapeutic mAb with two 
glycosylation sites. The thermal stability of CX and its Fab and Fc fragments was 
investigated by DSF before and after deglycosylation. The results were compared to 
MAb which is only glycosylated at the Fc site. 
Subsequently, a broader variety of MAb formulations was studied in terms of the 
effect of pH, salt, and excipient on the thermal stability. Especially, the potentially 
stabilizing effect of arginine and also histidine was investigated. It has been reported 
by Falconer et al. that the basic amino acids in particular are beneficial excipients for 
mAb formulations.30 A special focus was on the effect of the counterions, which are 
essential for pH adjustment. 
Finally, the focus was on the comparability of the outcome of DSC and DSF. Tm and 
Tm,onset values of both methods were explored towards a correlation between DSC 
and DSF. The existence of such a correlation allows for a head to head comparison 
of results obtained with both techniques. This would render DSF a high-throughput 
screening method for the thermal stability of proteins with low time and material 
consumption, and also orthogonal to DSC for R&D of therapeutic protein drugs. 
4.2 Materials and methods 
4.2.1 mAb model proteins 
The therapeutic IgG1 model monoclonal antibody (“MAb”) produced in CHO cells is 
supplied in a 25 mM histidine buffer at pH 7.7 in a stock concentration of about 
55 mg/ml with ε280nm of 1.49 ml g
-1 cm-1. 
Erbitux® was purchased at the local pharmacy containing 5 mg/ml Cetuximab (CX) in 
a citrate buffer at pH 5.5 containing polysorbate 80, glycine, and sodium chloride 
(NaCl). Using a reference solution of 2 mg/ml CX, an ε280nm value of 1.39 ml mg
-1cm-1 
was determined via ultraviolet light (UV) absorption measurement with an Agilent 
8453 spectrophotometer (Agilent Technologies, Santa Clara, California, USA). Prior 
to further use, protein A affinity chromatography was applied for purification (see 
chapter 4.2.2). 
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4.2.2 Protein purification by protein A affinity chromatography 
Protein A affinity chromatography was applied to i) purify CX marketed product from 
polysorbate 80, ii) purify the mAb molecules after incubation with PNGase F, and iii) 
to separate the Fc fragment from Fab and other unwanted species after incubation 
with papain. 
Therefore, an ÄKTA purifier 10 (GE Healthcare, Uppsala, Sweden) was equipped 
with a Pierce Protein A chromatography cartridge (Thermo Fisher Scientific, Bonn, 
Germany) (column volume, CV = 5 ml). The binding buffer was composed of 100 mM 
sodium phosphate with additional 150 mM NaCl at pH 7.2. The column was 
equilibrated with 2 CV of binding buffer with a flow of 2 ml/min. The protein solution 
was mixed 1:1 with binding buffer and about 50 - 70 mg of the protein were loaded 
onto the protein A column at a flow rate of 2 ml/min. During the injection phase and 
additional 2 CV of washout, fractions were collected in 15-ml PP tubes using a 
Frac 920 fraction collector (GE Healthcare) capturing any unbound species (e.g., 
Fab). For surfactant removal from market CX, the flow was increased to 4 ml/min and 
the column was flushed with 40 CV of binding buffer to remove any unspecifically 
adsorbed material. Elution of the specifically bound protein from the protein A resin 
was achieved by switching to a 100 mM sodium phosphate buffer pH 3 at a flow rate 
of 2 ml/min with a linear gradient from 0 % to 100 % over 2 CV. The elution buffer 
was kept at 100 % over 7 CV. The eluting protein was collected in 15-ml PP tubes 
using the fraction collector, and was immediately neutralized with a 1 M sodium 
phosphate buffer pH 8.5 to result in approx. 175 mM sodium phosphate buffer at a 
measured pH value of 6.5. Finally, the column was reequilibrated for 6 CV with 
binding buffer at a flow rate of 2 ml/min. This purification protocol was performed 
several times, pooling the protein containing fractions, until the desired amount of 
purified protein was obtained. Typically, further preparative steps like volume 
reduction and dialysis followed as described in the corresponding methods chapters. 
4.2.3 Preparation of deglycosylated samples of MAb and CX and their 
fragments 
Deglycosylation of both mAb molecules was achieved by enzymatic cleavage using 
PNGase F. Therefore, 75 µl corresponding to 37.500 units PNGase F (New England 
Biolabs, Ipswich, Massachusetts, USA) were added to 33 ml of approx. 3 mg/ml mAb 
solution in a 50-ml PP tube. In case of MAb, a 50 mM sodium phosphate buffer 
4. The application of DSC and DSF to formulation development of therapeutic mAbs 
51 
pH 7.2 and in case of CX, a 175 mM sodium phosphate buffer pH 6.5 was used. The 
reaction mixture was incubated at 37 °C and gently shaken for 24 h using a Certomat 
IS (B. Braun Biotech International, now Sartorius AG, Göttingen, Germany). The 
enzymatic reaction was stopped by cooling the tube to 2 – 8 °C. Subsequently, the 
deglycosylated mAb molecules were purified using protein A affinity chromatography 
(see chapter 4.2.2). By this means, the Fc-carrying mAb species was retained while 
the cleaved glycans and PNGase F were washed out. After protein A affinity 
purification, parts of the neutralized mAb samples were further treated with papain to 
obtain the deglycosylated Fab and Fc fragments (see chapter 4.2.4). 
Finally, different formulations of the full mAb molecules and their Fab and Fc 
fragments were prepared. The same procedure was applied to both glycosylated and 
deglycosylated species. Vivaspin® 20 tubes (Sartorius Stedim Biotech, Göttingen, 
Germany) were used to reduce the volume and to dialyze the protein into a 10 mM 
sodium phosphate buffer pH 7.2 or pH 5.0. For full mAb molecules, tubes with a PES 
membrane of 30 kDa MWCO and for the fragments 10 kDa MWCO were applied. 
Afterwards, the pH of the protein solutions was adjusted, the solutions were filtrated 
through a 0.2 µm PVDF membrane filter (Aerodisc® LV, Pall Life Sciences, Port 
Washington, New York, USA), and the concentration was determined by A280nm 
measurements with the NanoDrop 2000 photometer (Thermo Scientific, Wilmington, 
Delaware, USA) and adjusted with the appropriate buffer. Next, the samples were 
split into two parts and concentrated stock solutions of NaCl in 10 mM phosphate 
buffers at pH 7.2 or pH 5.0 were added to one part of the protein solutions to obtain a 
set of samples at a final concentration of 140 mM NaCl. Protein concentrations of 
1.5 mg/ml of the full mAbs, 1.0 mg/ml of Fab, and 0.5 mg/ml of the Fc fragments were 
adjusted. Subsequently, the pH value of the samples was checked and adjusted if 
necessary. Finally, all samples were filtrated through a 0.2 µm RC membrane filter 
(Minisart® RC4, Sartorius Stedim Biotech). Untreated and deglycosylated MAb 
molecules were analyzed by SDS-PAGE. A slightly reduced molecular weight after 
removal of the glycans was found indicating the success of the deglycosylation 
procedure. 
4.2.4 Preparation and purification of Fab and Fc fragments 
Papain was used to prepare Fab and Fc fragments of both CX and MAb. A pilot study 
revealed that the digestion was independent of the buffer (phosphate or histidine) 
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and mAb concentrations of up to 20 mg/ml were successfully cleaved in 24 h of 
incubation time with 20 µg/ml papain. Excellent yields were achieved when 10 mM 
cysteine and 2 mM disodium ethylenediaminetetraacetate (Na2EDTA) were present 
in the reaction mixture.  
A reaction medium was prepared by addition of 10 µl of papain suspension (from 
papaya latex, Sigma-Aldrich, Steinheim, Germany) to 448 µl of a solution containing 
300 mM cysteine and 60 mM Na2EDTA. Of this reaction medium, 353 µl was added 
to 10 ml of 20 mg/ml MAb solution in 40 mM histidine buffer pH 7.0. The reaction 
mixture was incubated at 37 °C and gently shaken using a Certomat IS (B. Braun 
Biotech International, now Sartorius AG, Göttingen, Germany). For in-process 
control, aliquots of 60 µl of the reaction mixture were taken after 0 h, 2 h, and 21 h of 
incubation, and 20 µl of a 160 mM iodoacetamide solution was added to stop the 
reaction. After 24 h 3.3 ml of 160 mM iodoacetamide solution was added to the 
reaction mix, and the mix was stored at 2 – 8 °C until purification. The in-process 
controls and the terminated reaction mixture were analyzed by HP-SEC (chapter 
4.2.6). 
The analogous protocol was applied to fragment 50 ml of 2 mg/ml CX in phosphate 
buffer, and also 30 ml of deglycosylated MAb and CX after protein A affinity 
chromatography in 175 mM phosphate buffer at pH 6.5 at a protein concentration of 
about 3 mg/ml (see chapter 4.2.3). 
Purification of the reaction mixture was performed by means of protein A affinity 
chromatography in order to separate Fab from Fc (see chapter 4.2.2). The fraction 
containing the Fab fragment also contains the enzyme, iodoacetamide, cysteine, and 
Na2EDTA. To remove these reagents, ultrafiltration was applied using Vivaspin® 
tubes with a 10 kDa MWCO PES membrane (Sartorius Stedim Biotech, Göttingen, 
Germany). Success of the purification was monitored by HP-SEC (chapter 4.2.6). 
After acidic elution from the protein A resin, the fraction contains any species carrying 
Fc, which is the full mAb (“(Fab)2Fc”), Fc with a single cleaved Fab fragment 
(“(Fab)Fc”), and the completely cleaved Fc fragment. If HP-SEC analysis after 24 h 
revealed a content of more than 1 % of undigested mAb monomer, all fractions of the 
Fc species were pooled and the volume was reduced to approx. 100 – 200 µl. This 
concentrated protein solution containing the full mAb, (Fab)Fc, and the Fc fragment 
was purified by means of SEC. Therefore, a Sephacryl® 16/60 column (CV = 
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120 ml), was connected to an ÄKTA purifier 10 system (GE Healthcare, Uppsala, 
Sweden). The column was equilibrated with 0.4 CV of 100 mM sodium phosphate 
buffer with additional 150 mM NaCl pH 7.2 as mobile phase at a flow rate of 1 ml/min. 
The sample was injected using a 250 µl glass syringe (Hamilton, Reno, Nevada, 
USA) into a 500 µl sample loop, and upon injection, the loop was emptied with 2 ml 
mobile phase. The eluted species was fractionated by peak detection at 280 nm and 
collected in 15-ml PP tubes. The main fraction consisting of the pure Fc fragment, 
which eluted last due to the smallest molecular weight, was used for further 
preparative steps. 
Finally, different formulations of Fab and Fc were prepared with 10 mM sodium 
phosphate buffers at pH 7.2 and pH 5.0 with and without additional 140 mM NaCl. 
This was achieved by either buffer exchange using Vivaspin® tubes with a 10 kDa 
MWCO PES membrane (Sartorius Stedim Biotech) right into the final formulation 
buffer or by spiking a concentrated buffered NaCl solution into the sample solution, 
similar to the protocol described in chapter 4.2.3. 
4.2.5 Sample preparation for MAb formulation screening 
The stock solution of about 55 mg/ml MAb in 25 mM histidine buffer at pH 7.7 was 
dialyzed into 10 mM sodium phosphate buffer pH 7.2 using Vivaflow® 50 dialysis 
cassettes with a 30 kDa MWCO PES membrane (Sartorius Stedim Biotech, 
Göttingen, Germany) at 2 - 8 °C. Subsequently, the pH of the solution was adjusted, 
the solution was filtrated through a 0.2 µm PES membrane filter (VWR International, 
West Chester, Pennsylvania, USA), and the protein concentration was adjusted via 
A280nm measurements using the NanoDrop 2000 photometer (Thermo Scientific, 
Wilmington, Delaware, USA). Parts of this solution were used to prepare 10 mM 
phosphate buffer solutions at pH 5.0 using Vivaspin® tubes with a 30 kDa MWCO 
membrane (Sartorius Stedim Biotech). 
Twice concentrated stock solutions of arginine and histidine were prepared in 10 mM 
phosphate buffer, and the pH was adjusted with either hydrochloric acid, acetic acid, 
citric acid, aspartic acid, or glutamic acid to pH 7.2 and pH 5.0. The arginine stock 
solutions were filtrated through a 0.2 µm PES membrane filter (VWR). Subsequently, 
the arginine or histidine stock solutions were added at a 1:1 ratio to a stock solution 
of 8 mg/ml MAb in 10 mM phosphate buffer to obtain a final concentration of 4 mg/ml 
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MAb at both pH values with different types of counterions. As a reference, the same 
amounts of acid were added to 10 mM phosphate buffers at pH 5.0 and 7.2 to 
prepare formulations without arginine or histidine. In this case, the pH was adjusted 
with sodium hydroxide. 
4.2.6 High performance size exclusion chromatography (HP-SEC) 
HP-SEC was performed on an Agilent 1200 series HPLC system (Agilent 
Technologies, Santa Clara, California, USA). The autosampler and the column were 
temperature controlled at 18 °C and 20 °C, respectively. Of each sample solution, 
20 µl were injected onto a Tosoh TSKgel® G2000SWXL column (7.8x300 mm) (Tosoh 
Bioscience, Stuttgart, Germany) using a mobile phase of 100 mM sodium phosphate 
buffer with additional 100 mM sodium sulfate pH 6.8 at a flow rate of 0.5 ml/min. The 
eluted sample was detected by means of UV absorption at 280 nm. The 
chromatograms were analyzed regarding retention times and the area under the 
curve (AUC) with ChemStation® B.02.01-SR2 (Agilent Technologies). 
4.2.7 Hydrophobic interaction chromatography (HIC) 
An HIC protocol similar to Wakankar et al. was used.31 A Tosoh TSKgel® Phenyl-
5PW (7.5x75 mm) (Tosoh Bioscience, Stuttgart, Germany) was connected to an 
Agilent 1100 series HPLC system (Agilent Technologies, Santa Clara, California, 
USA). The temperature of the column was controlled at 40 °C. Channel B was loaded 
with a 10 mM sodium phosphate buffer at pH 7.2 and channel A was loaded with a 
10 mM sodium phosphate buffer with additional 2 M ammonium sulfate adjusted to 
pH 7.2. The protein samples were diluted with 10 mM sodium phosphate buffer + 2 M 
ammonium sulfate pH 7.2, and 10 – 25 µg of the protein were injected onto the 
column at a flow rate of 1 mg/ml. The mobile phase ratio was adjusted as the 
following: i) 5 min equilibration at 25 % B, ii) linear gradient from 25 % to 100 % B 
over 30 min, iii) 5 min at 100 % B, iv) linear gradient from 100 % B to 25 % B over 
5 min, v) 5 min reequilibration at 25 % B. Detection was performed via UV adsorption 
at 280 nm. The chromatograms were analyzed regarding retention times and AUC 
with ChemStation® B.02.01-SR2 (Agilent Technologies). The obtained 
chromatograms were corrected by subtraction of a chromatogram after injection of a 
placebo sample without protein using Origin® 8 SR6 (Originlab Corporation, 
Northampton, Massachusetts, USA). 
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4.2.8 Isoelectric focusing (IEF) 
The IEF protocol provided by the manufacturer Serva Electrophoresis (Heidelberg, 
Germany) was applied. The Servalyt Precotes® gel 125x125x0.3 mm pH 6-9 (Serva 
Electrophoresis) was cooled at 5 °C on a Multiphor II equipped with an MultiTemp III 
water bath (GE Healthcare, Buckinghamshire, UK). The samples in 10 mM 
phosphate buffers were diluted to 0.5 mg/ml, and 10 µl were loaded onto the gel in 
the center between the electrodes. In addition, 5 µl Serva marker mix 3-10 (Serva 
Electrophoresis) was applied 2 – 3 times across the gel. Using an Electrophoresis 
power supply EPS 3501 XL (GE Healthcare, Buckinghamshire, UK) 6 mA and 2000 V 
were applied for 5000 Vh. Next, the gel was immediately fixed with 20 % (w/V) 
trichloroacetic acid and stained with Serva Blue (Serva Electrophoresis) according to 
the manufacturer’s protocol. After background destaining, the gels were scanned in 
the wet state using an Epson Perfection V750 PRO (Seiko Epson Corp, Suwa, 
Japan) scanner. The isoelectric points (pI) of the proteins were obtained by relating 
the positions to the marker bands. Each sample was at least tested on two gels. 
4.2.9 Differential scanning fluorimetry (DSF) 
DSF was performed with two different RT-PCR machines. The qTower 2.2 (Analytik 
Jena, Jena, Germany) was exclusively used to analyze CX, including the 
deglycosylation study and the formulation screening study. The RT7300 RT-PCR 
(Applied Biosystems, Foster City, California, USA) was used initially to analyze MAb 
and its fragments. 
Typically, protein concentrations of 4 mg/ml of the full mAb molecules, 2.66 mg/ml of 
Fab, and 1.33 mg/ml of Fc were investigated. The protein concentrations were 
reduced to 1.5 mg/ml of the full mAbs, 1.0 mg/ml of Fab, and 0.5 mg/ml of the Fc 
fragments for analysis after deglycosylation. 
In either case, 20 µl of the sample was pipetted into 96-well reaction plates (Applied 
Biosystems) and skirted white plates (Biometra, Göttingen, Germany) for use with the 
RT7300 and the qTower 2.2 RT-PCR machine, respectively. An aqueous working 
dilution of SYPRO® Orange (Sigma-Aldrich, Steinheim, Germany) was prepared and 
1 µl of the working solution was added to the well plate and mixed by aspiration. The 
final SYPRO® Orange concentration in the well was 1x (1:5000 dilution of the 
supplied stock solution). The well plate was sealed with an optical adhesive (Applied 
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Biosystems; Biometra) and centrifuged at 2000 g for 2 min to remove air bubbles and 
to focus the volume on the bottom of the well plates. The RT-PCR machines were 
utilized to record the fluorescence intensity while heating the well plates. With both 
machines, a stepwise heating ramp of 1 °C with an overall heating rate of 1 °C/min 
was applied. The experiment was performed from 20 °C to 96 °C. The recorded 
fluorescence intensity raw data was exported from both machines, and subsequent 
data analysis was performed with Origin® 8 SR6 (Originlab Corporation, 
Northampton, Massachusetts, USA). The resulting melting curves were analyzed 
regarding transitions (increase in fluorescence intensity) by Boltzmann fitting and first 
derivative analysis. In case of the RT7300, data from Filter C (Em. 578 nm) and case 
of the qTower 2.2 data from color module 3 (Ex. 535 nm, Em. 580 nm) was used for 
determination of Tm and Tm,onset. The apparent Tm value is the temperature at the 
inflection point of the Boltzmann function fitted to the data. Furthermore, the apparent 
Tm value was obtained from the peak maximum of the interpolated first derivative. 
Tm,onset is the temperature at the onset of unfolding derived from Boltzmann fit data as 
described in chapter 3. Presented results are mean values of three wells with 
standard deviation of the mean. 
4.2.10 Differential scanning calorimetry (DSC) 
The sample and the reference cell of a VP-DSC MicroCalorimeter (MicroCal, 
Northampton, Massachusetts, USA; now Malvern Instruments) were filled with the 
protein formulation and the corresponding placebo, respectively. The investigated 
samples were at the same protein concentration as described in the DSF method. 
Using the ThermoVac station (MicroCal), sample and reference were degassed for at 
least 30 s. Subsequently, the solutions were injected at 25 °C using a gastight glass 
syringe (Hamilton, Reno, Nevada, USA). The prescan thermostat time was set to 
15 min to allow for equilibration of the sample. DSC thermograms were recorded from 
20 °C to 96 °C at a scan rate of 1 °C/min. After each protein scan, both cells were 
heated up with about 50 % (V/V) nitric acid to 90 °C. The cells were washed 
subsequently with 1 % (w/V) sodium dodecyl sulfate (SDS) solution and water. The 
thermogram of the protein scan was corrected by subtraction of a water-versus-water 
scan and normalized for the protein concentration using Origin® 7 SR2 (OriginLab 
Corporation, Northampton, Massachusetts, USA) with MicroCal VPViewer2000® 
version 1.4.10 (MicroCal). The Tm value is represented by the peak maximum of the 
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endothermic transition. To calculate Tm,onset, a linear baseline was subtracted and the 
Boltzmann function was fitted to the ascending slope of the first transition. From the 
obtained parameters of the fit, the Tm,onset value was calculated using the equation 
presented in chapter 3.3.2. 
4.2.11 DFFITS outlier test 
In the case of bivariate data sets, parameters like the Cook’s distance or DFFITS 
(“difference in fit, standardized”) can be used to identify outliers. The DFFITS 
parameter was calculated using the following equations.32 
The residuals ei of the i-th value were calculated as 
        ̂  (4-1) 
where yi is the true value from the experiment and ŷi is the predicted value based on 
the linear regression. The residual reflects the distance from the true value to the line 
of the linear regression in the direction of x. Subsequently, the leverage hi of every 
value i was calculated based on the following formula 
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where n is the total number of samples, xi is the true value i-th sample,  xi is the mean 
of all x, and SSx is the sum of squares of all x values. The leverage is a measure of 
the distance of the particular sample from the mean. From the residual and leverage, 
the scalar version of the Cook’s distance Di was derived according to 
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where k is the number of independent variable (k=1) and MSe is the mean square 
error which is the sum of squares of the residuals divided by the degrees of freedom 
n-k-1. To obtain the DFFITS value, the MSe of the data set with omitted potential 
outlier (MSe(i)) is calculated, which was achieved by means of the following equation 
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Next, the studentized residuals s was calculated based on the outlier omitted MSe(i) 
value 
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(4-5) 
Finally, the DFFITS parameter is given by the studentized residuals and the leverage 
as 
           √
  
    
 (4-6) 
The magnitude of DFFITS reflects the influence of the sample on the results of the 
linear regression. DFFITS is zero in the case when the omission of the i-th sample 
has no influence on the linear regression, which means that the prediction ŷi equals 
the true y value. In that case, the sample is exactly on the regression line. DFFITS 
shows a positive sign when yi > ŷi(i) and vice versa. Absolute values of DFFITS > 1 
indicate a large influence on the linear regression.33 
To identify values with a high influence on the linear regression in the interaction 
coefficients data set, DFFITS was calculated and the sample with the highest 
absolute DFFITS value was omitted. Subsequently, the DFFITS analysis was 
repeated with the obtained reduced data set until no sample resulted in absolute 
DFFITS values above the threshold of 1. 
4.3 Results and discussion 
4.3.1 General comparison of DSF melting profiles and DSC thermograms 
Figure 4-1 A presents the results of 4 mg/ml MAb in 25 mM histidine buffer pH 7.2. At 
this neutral pH, the thermogram obtained from DSC measurements showed two 
distinct transitions. The first transition (Tm1) occurred at about 72 °C and a second 
transition (Tm2) with a larger enthalpy was found at about 83 °C. Lower apparent Tm 
values were obtained when the pH of the solution was lowered to pH 5.0. 
Furthermore, the DSC method indicates that unfolding of the MAb occurred in three 
distinct steps, which were separated and resolved as single transitions (Figure 
4-1 C). In case of CX, the DSC transition with the largest peak had a much lower Tm 
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value compared with the MAb. This led to the observation of three distinct transitions 
at both pH values (Figure 4-1 B and D). A comprehensive study on the role of the 
mAb domains on the unfolding transitions is described in chapter 4.3.2. 
As can be seen from the graphs in Figure 4-1, the DSC thermograms and DSF 
melting profiles were in good agreement as reported by other authors.8,10,12 The DSF 
method predominantly detected the first melting transition with a strong fluorescence 
increase (see chapter 3). Additional unfolding transitions at higher temperature were 
hardly detectable, especially in the case of CX. The midpoint of the fluorescence 
increase, representing the apparent Tm value by DSF, showed that the values 
obtained by DSF were at 2 - 4 °C lower temperatures (dotted lines in Figure 4-1). 
A 
 
 B 
 
C 
 
 D 
 
Figure 4-1. DSC thermograms and DSF melting profiles of MAb and CX in 25 mM histidine 
buffer pH 7.2 (A + B) and 25 mM histidine buffer pH 5.0 (C + D). 
A discussion on the correlation and comparability of absolute Tm values obtained by 
DSC and DSF is given in chapter 4.3.4 and 4.3.6, respectively. Interestingly, all DSF 
melting curves reveal a decrease in fluorescence intensity after the energetically 
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most pronounced transition. It was suggested by Niesen and coworker that protein 
aggregation via the exposed hydrophobic patches diminishes the accessible 
hydrophobic surface. This effect leads to reduced interaction with the dye and 
subsequently a decrease in fluorescence intensity.9 Furthermore, the disruption of the 
DSC signal (drop/downshift of Cp) suggests that aggregates form, disturbing the heat 
convection in the cells. Thus, both phenomena indicate that protein aggregation 
occurs at this temperature and affects both DSC and DSF (see also chapter 4.3.2). 
4.3.2 Identification of mAb domains involved in the unfolding process 
In the following sections, the results from DSC and DSF analyses of enzymatic 
fragments of MAb and CX are presented. From the obtained thermograms, the 
transitions seen with mAbs were to be assigned to the distinct domains, and the 
changes in energy and hydrophobicity detected by DSC and DSF were to be 
correlated with the structural segments. 
4.3.2.1 Enzymatic fragmentation of the mAb molecules 
Enzymatic cleavage of the mAb molecules using papain and subsequent purification 
rendered the isolated Fab and Fc fragments. Both fragments with a similar molecular 
weight of about 50 kDa were analytically separated by hydrophobic interaction 
chromatography (HIC). The HIC chromatograms of the fragments from both MAb and 
CX demonstrate successful cleavage and purification (Figure 4-2). 
A 
 
 B 
 
Figure 4-2. HIC chromatograms of Fab, Fc, and a 1:1 mixture of Fab and Fc originating from 
MAb (A) and CX (B)  
Complete baseline separation, as demonstrated by Wakankar et al.,31 could not be 
achieved. The finding that especially the Fc fragment with different subspecies 
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showed charge or hydrophobic heterogeneity is in good agreement with the presence 
of (heavy-chain) variants with different N- or C-termini,34 different glycosylation 
patterns containing charged sugars (sialylation),34 asparagine isomerization (Asp → 
iso-Asp and cyclic imides),31,35-37 deamidation,34 oxidization (of methionine in CH2),36 
or reduction (disulfide residue reduction to free thiol groups).31 These modifications 
lead to the fingerprint characteristics observed especially by methods sensitive to 
charges,38,39 and corresponds to the IEF results (chapter 4.3.3.1). 
4.3.2.2 Identification of the distinct mAb domains by DSC 
Figure 4-3 and Figure 4-4 present an overlay of the DSC thermograms of both mAb 
molecules and their fragments at pH 5.0 and 7.2 with 140 mM and without NaCl. In all 
formulations two transitions of the Fc fragment were observed for both mAb 
molecules. The sequence and nature of the domain unfolding of the Fc fragment 
were investigated by Tischenko and coworkers.40 Using a fluorescent label, they 
were able to assign the first and second melting transition to the CH2 and CH3 
domain, respectively. The peak broadening of CH2 domain at low pH, which in some 
cases also forms a shoulder, suggests that the CH2 domain did not unfold in a 
cooperative manner. It was reported by Tischenko that the inter-chain interactions via 
glycans is rather weak, and that the stabilization of CH2 is mainly caused by inter-
domain interactions at the CH2-CH3 interface.40 In contrast, they found that the CH3 
domains of the Fc part forms a unique block with strong inter-chain interactions that 
unfolds cooperatively.40 Ghirlando and coworkers made another observation upon 
thermal unfolding of a Fc fragment. In contrast to Tischenko et al., they used PBS 
buffer pH 7.4 with high ionic strength and observed aggregation of the Fc fragment 
upon unfolding of the CH3 domain.28 Due to the aggregation, the reversible two-state 
model was not applicable and cooperativeness should not be investigated.28 These 
findings are in good agreement with the results presented in Figure 4-3. Furthermore, 
it has to be noted that the Fc sequence is conserved in most mAb molecules and 
thus the DSC thermograms of MAb and CX are similar. Differences in their melting 
thermograms can be assigned to differences in the glycosylation patterns. 
The Fab fragment, which is unique for both mAb molecules, is responsible for the 
characteristic DSC thermograms of MAb and CX. At pH 7.2, independent of the 
addition of 140 mM NaCl, a single melting transition of Fab from MAb is observed 
(Figure 4-3 A and C). An important study was performed by Ionescu et al., who 
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compared the DSC thermograms of different mAbs molecules and their Fab and Fc 
fragments.25 They demonstrated that the melting temperature of the Fab part can 
significantly vary between different mAbs due to their unique antigen binding 
domains.25 Furthermore, they found that the melting transition with the highest 
enthalpy is typically caused by the Fab fragment and therefore suggest to use this as 
an indicator when full mAb molecules with unknown structure are investigated.25 
Similarly, Fab of CX showed a strong unfolding transition, but with a leading small 
pre-peak before the main transition suggesting a noncooperative unfolding of the 
domains (Figure 4-3 B and D). 
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 D 
 
Figure 4-3. DSC thermograms of MAb and CX and their corresponding Fab and Fc fragments in 
10 mM phosphate buffers at pH 7.2 (A + B) and in 10 mM phosphate buffer pH 7.2 + 140 mM 
NaCl (C + D). “(Fab)2Fc (calculated)” represents the sum of the Fab and the Fc fragment at 2:1. 
Especially at the neutral pH of 7.2 and independent of the addition of NaCl, the 
melting transitions of the full mAb molecules and their fragments were in excellent 
agreement. The sum of the thermograms of (Fab)2Fc, representing the full mAb 
molecule, mirrored the DSC thermogram of the full intact molecules (Figure 4-3). 
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Therefore, a clear assignment of the transitions was possible: The first observed 
melting transition of MAb was caused by the CH2 domain. The second transition was 
represented by an overlay of CH3 and Fab, which both melt at about the same 
temperature (Figure 4-3 A and C). This was in contrast to the CX molecule where Tm 
of Fab was lower and three transitions were observed. In this case, the first transition 
was composed of the pre-transition of Fab. The large main peak was represented by 
the main transition of Fab and CH3. The CH3 domain formed the third transition 
(Figure 4-3 B and D). 
When the pH was lowered to 5.0 (Figure 4-4), a strong destabilization of the Fc part 
was observed. The Tm values were several degrees lower than for the samples at 
pH 7.2. In contrast, the Tm of the Fab fragment was less affected by pH, and even a 
small shift to higher temperature was observed in case of MAb. These pH effects 
resulted in slightly changing orders in the unfolding sequence. In case of MAb, 
unfolding of CH3 was resolved at pH 5.0, and the three transitions were assigned to 
CH2, CH3, and Fab (Figure 4-4 A and C). In case of CX at pH 5.0, the unfolding of 
the CH2 domain did overlap with the pre-transition of Fab, followed by the main Fab 
and CH3 transitions (Figure 4-4 B and D). Furthermore, the absence or presence of 
140 mM NaCl significantly changed the results. At low ionic strength, the net positive 
charge of MAb at pH 5.0 resulted in repulsive electrostatic interactions which 
prevented the protein from aggregation (suggested by the absence of Cp signal 
breakdown). When NaCl was added, repulsive charges were shielded and the 
breakdown of the Cp signal suggested strong protein precipitation. Similar effects 
were observed for the CX molecules (compare Figure 4-4 A, B and C, D). 
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Figure 4-4. DSC thermograms of MAb and CX and their corresponding Fab and Fc fragments in 
10 mM phosphate buffers at pH 5.0 (A + B) and in 10 mM phosphate buffer pH 5.0 + 140 mM 
NaCl (C + D). “(Fab)2Fc (calculated)” represents the sum of the Fab and the Fc fragment at 2:1. 
The effect of presumably electrostatic protein-protein interactions at low pH was also 
observed for a 2:1 Fab and Fc mixture from MAb in DSC, as presented in Figure 4-5. 
A good agreement between full MAb, the calculated sum of the fragments, and the 
mixture in solution was obtained at pH 7.2 (Figure 4-5 A and B). This suggests that 
each domain unfolds individually without interference. In contrast, at the low pH of 
5.0, a strong destabilizing effect on each domain was observed as indicated by a shift 
of the melting transitions to lower temperature (Figure 4-5 C and D). The mismatch of 
the DSC thermograms of full intact MAb and the fragment mixture points to the fact 
that the cleaved protein was able to interact at interfaces which were not accessible 
when the hinge region of the mAb molecule was intact. Interestingly, the presence of 
140 mM NaCl at pH 5.0 increased the Tm value of the CH2 domain of the Fab and Fc 
mixture. Both effects of pH and salt demonstrate the importance of electrostatic 
forces.  
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Figure 4-5. DSC thermograms of the full MAb, the calculated curve from the results of the 
isolated Fab and Fc fragments at 2:1 (“(Fab)2Fc”), and the experimental results of the 2:1 
mixture of both fragments in solution. 10 mM phosphate buffer pH 7.2 (A) and with 140 mM 
NaCl (B). 10 mM phosphate buffer pH 5.0 (C) and with 140 mM NaCl (D). 
4.3.2.3 Unfolding of mAb fragments in DSF 
The results from DSF experiments, studying the Fab and Fc fragments, are 
presented in Figure 4-6 and Figure 4-7 for the formulations at pH 7.2 and 5.0, 
respectively. Especially for the full MAb, the melting process of multiple domains is 
reflected by two fluorescence transitions at pH 7.2 (Figure 4-6 A and C) and three 
transitions at pH 5.0 (Figure 4-7 A and C). Due to the overlapping melting transitions 
of the CX domains, only one transition was observed for CX (Figure 4-6 B and D, 
Figure 4-7 B and D). Interestingly, the melting profile of the purified Fc fragment from 
both mAb molecules showed one transition at the expected temperature of the CH2 
domain. Thus, in contrast to the DSC thermograms, unfolding of the CH3 domain was 
not recorded with DSF (compare Figure 4-3). Thermal unfolding of the Fab fragment 
resulted in one transition. The high Tm value of the Fab fragment from MAb, and the 
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matching Tm values of the Fab fragment and the CH2 domain from CX were 
confirmed. Furthermore, the two melting transitions of the full MAb were obtained 
when both fragments were mixed in a 2:1 ratio in solution. Thus, the first and second 
melting transitions could be identified as the Fc (CH2) and Fab part of MAb, 
respectively. 
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Figure 4-6. DSF melting profiles of MAb and CX and their corresponding Fab and Fc fragments 
in 10 mM phosphate buffers at pH 7.2 (A + B) and in 10 mM phosphate buffer pH 7.2 + 140 mM 
NaCl (C + D). 
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Figure 4-7. DSF melting profiles of MAb and CX and their corresponding Fab and Fc fragments 
in 10 mM phosphate buffers at pH 5.0 (A + B) and in 10 mM phosphate buffer pH 5.0 + 140 mM 
NaCl (C + D). 
Overall, the structural changes observed by DSC and DSF were in good agreement 
despite their different physicochemical principles. For example, the strong 
destabilization of the Fc fragment at the low pH of 5.0, especially in the presence of 
NaCl, was observed by both DSC and DSF. But DSF did not show a high resolution 
of the multiple transitions of all mAb domains when compared with DSC and 
unfolding of the CH3 domain was not observed. The finding that the CH2 domain and 
also Fab fragment lead to a strong fluorescence transition might be helpful for the 
identification and interpretation of melting profiles of unknown mAb molecules. 
Furthermore, the low sample and time consumption of DSF allows for the analysis of 
Fab and Fc fragments after rapid cleavage and purification at small scale. A 
comprehensive discussion on the correlation of DSC and DSF results is given in 
chapter 4.3.4. 
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4.3.3 The effect of deglycosylation on the thermal stability of mAbs and their 
Fab and Fc fragments 
Pioneering work of Mimura and coworkers revealed that complete deglycosylation 
significantly reduced the thermal stability of the CH2 domain of an IgG1 mAb.23 
Deglycosylation of mAb molecules was also performed by Ionescu et al.25 They used 
the shift of the first DSC melting transition due to sugar removal as a proof that the 
first transition is caused by the CH2 domain at which the protein is glycosylated. An 
interesting study was performed by Ha and coworkers investigating the effect of a 
hemi-glycosylated mAb, i.e., one heavy chain is glycosylated whilst the other is 
glycan-free.41 They observed a slightly reduced thermal stability of the asymmetrical, 
hemi-glycosylated form in comparison to the symmetrical, full-glycosylated mAb 
molecule. Wen et al. tried to investigate the effect of the glycosylation site.24 They 
presented data for a mAb molecule that is also glycosylated in the variable region 
and its nonglycosylated form. Unfortunately, their model antibody showed an overlap 
of all three main transitions of the CH2 domain, the CH3 domain, and the Fab 
fragment, so that a shift of Tm is difficult to assign to one of the domains. They 
concluded, after careful inspection of the DSC thermograms, a small reduction in 
thermal stability upon deglycosylation of the Fab site.24 
In this study, CX was used as a model protein to investigate the effect of the glycan 
on the thermal stability of the domains of the full mAb and of the domains of the 
isolated Fab and Fc fragments. The CX molecule of IgG1 type is glycosylated at two 
sites of the heavy chain, at the asparagine residue Asn299 within the CH2 domain, 
and at Asn88 of the variable region of Fab.42 Glycosylation at Asn299 is a distinctive 
feature of CX, as most IgGs are glycosylated at Asn297.42 The composition of the 
CH2 domain-glycan of CX was reported to be similar to the N-glycans found in other 
recombinant therapeutic mAb molecules.43 Interestingly, the Fab-glycans show a high 
amount of galactose-α-1,3-galactose structures,44 which are unfavorable due to 
potential immunogenic reactions.45 
PNGase F was used to prepare a completely deglycosylated form of the mAb 
molecule. By means of the papain cleavage after the deglycosylation procedure, Tm 
values of the isolated fragments were obtained. DSF was chosen as a material and 
time saving technique for Tm analysis. Moreover, the results from CX were compared 
to a second model protein MAb, an IgG1 type mAb molecule, with common Fc 
glycosylation pattern. 
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4.3.3.1 Determination of the isoelectric point of the mAbs and their fragments 
Isoelectric focusing (IEF) was performed to investigate the isoelectric point (pI) of the 
proteins (Figure 4-8). Several isoforms of the full mAbs, as well as of both Fc 
fragments, and the Fab fragment of CX were observed (Table 4-1). Because of a 
lower resolution in the high pH range of the gel (pH > 9), the Fab fragment of MAb 
supposedly consisted of one (probably two) isoforms. The appearance of charge 
isoforms is in good agreement with the results obtained from HIC analysis (see 
Figure 4-2). The different pI values of the mAb molecules can be explained by their 
unique primary sequence. The Fab fragment of MAb showed a much higher pI value 
compared with the CX Fab fragment. Interestingly, basic amino acids seemed to 
prevail in the Fab region, whereas the net charge of Fc was in the neutral pH range. 
As a result, the pI of the full mAb molecules settled in between the pIs of their Fab 
and Fc fragments. After deglycosylation, a small shift of the protein bands towards 
lower pI values was observed, especially in case of the full mAb molecules. Thus, the 
observed isoforms are presumably not caused by varying glycosylation pattern (e.g., 
sialylation). 
Table 4-1. Results from IEF experiments with glycosylated and deglycosylated full mAb 
molecules and their Fab and Fc fragments. 
Species Appearance pI value 
MAb 4 bands 8.3 – 9.5 
Fab (MAb) 1 (-2) band(s) 9.5 – 10.7 
Fc (MAb) > 4 bands 6.9 – 7.8 
CX 7 bands 7.4 – 8.0 
Fab (CX) 3 (-4) bands 8.0 – 9.5 
Fc (CX > 4 bands 6.9 – 7.8 
pI, Isoelectric point. 
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A B 
Figure 4-8. Decolorized scans of the IEF gels after Serva blue staining. The full mAb molecules 
and their fragments were tested before and after deglycosylation. Cathode (-) and anode (+) 
were located at the top and bottom of the scans, respectively. 
4.3.3.2 Effect of deglycosylation on the Fc fragment 
The Tm1 values from the first melting transition obtained by DSF, resembling the 
unfolding of the CH2 domain of both mAb molecules (compare chapter 4.3.2) and the 
isolated Fc fragments, were analyzed before and after removal of the glycans. For a 
better comparison, the thermal shift ΔTm of untreated minus deglycosylated form was 
calculated, and the results are presented in Figure 4-9. All samples showed a 
negative shift of Tm suggesting a reduced thermal stability upon deglycosylation. 
Thermal stability was lowered independently of the formulation, although the degree 
of the Tm shift and the absolute Tm values were pH and salt dependent. Both mAb 
molecules in 10 mM phosphate buffer pH 7.2 showed a reduction of Tm of 
about -4 °C. The effect of deglycosylation was less pronounced when the isolated Fc 
fragments were investigated with a ΔTm of approx. -1 °C. The Fc fragment of MAb 
and the full CX molecule were particulary sensitive to low pH. Addition of 140 mM 
NaCl negatively affected the thermal stability in all cases. This suggests that higher 
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ionic strength was detrimental even at neutral pH where charge effects and 
subsequent charge shielding by salt addition are less pronounced. 
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Figure 4-9. Thermal shift (ΔTm) as the result of deglycosylation of the Fc fragment. The ΔTm 
value was calculated for Fc of the full mAb as well as the purified Fc fragment. A negative ΔTm 
value means a reduced thermal stability after removal of the glycan structure. The effect of 
deglycosylation on the thermal stability was investigated in different formulations (A – D). 
The CH2 domain of the mAb showed a strong destabilization at the low pH of 5.0 
compared with the formulation at pH 7.2. This holds true for the full MAb and CX, as 
well as the isolated Fc fragments (compare chapter 4.3.2). Deglycosylation further 
reduced the Tm value of both species (Figure 4-9). The same effect of pH and 
deglycosylation on CH2 was also reported by other authors.8,24,26,29 Thus, it is likely 
that the observed unfavorable trends of low pH and deglycosylation are common to 
all mAbs, and IgG1 in particular. It was proposed that the glycans attached to the 
CH2 domain are located in a groove between both heavy chains of the Fc 
fragment.16,23,46 A closed conformation of the CH2 domain was found after removal of 
the glycans,46 whereas large glycan moieties lead to a more open CH2 domain 
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structure.46,47 Truncation of the glycans also influences the FcγR binding which is 
mediated via the carbohydrates.46 Furthermore, it was concluded that the α-1,6-
mannose branch is firmly bound to the protein surface.46,48 A recent NMR study 
suggests that the CH2-glycan is more dynamic and exposed to the solvent than 
initially expected, and may switch between a bound and an unbound state.49  
Considering these interaction of the glycans with the protein structure, it is 
reasonable that the thermal stability is (negatively) affected by deglycosylation. Either 
stabilization of the native state or destabilization of the unfolded state would lead to a 
higher overall thermal stability.21,22,50 Stabilization of the native state, which is most 
likely, could be achieved by additional noncovalent attractive interactions and a 
decrease in structural dynamics.22 The results from Mimura et al. with truncated 
glycan forms confirm that the reduction in thermal stability is supposedly due to a loss 
of protein-glycan interactions.23 Similarly, Ionescu et al. suggest that the reason for 
the lower Tm might not be an “intrinsic” destabilization but rather omission of 
stabilizing inter-domain interactions.25 Additional destabilization of the unfolded state 
might be possible due to steric hindrance.22,51 
4.3.3.3 Effect of deglycosylation on the Fab fragment 
The Tm shift of the Fab domain after deglycosylation is presented in Figure 4-10. For 
MAb, where no glycans are attached to this domain, no change of the Tm value was 
expected. The results demonstrate that no significant change was observed, either 
for the full mAb or the isolated Fab fragment. Furthermore, this finding confirmed that 
the enzymatic digestion with PNGase F and the subsequent purification procedure 
did not negatively affect the thermal stability of the protein. Unfortunately, the 
overlapping melting transitions of the native CX molecule inhibit the discrimination 
between the unfolding of the CH2 domain and the Fab fragment (see chapter 4.3.2). 
Additionally, the CH2 domain was found to be strongly destabilized after removal of 
the glycans. Therefore, it was not possible to refer the Tm values before and after 
deglycosylation to the Fab domain in the full CX molecule. The results of the purified 
Fab fragment, however, clearly indicate that no significant Tm shift occurred upon 
removal of the glycans in the Fab region of CX (Figure 4-10). Thus, glycosylation of 
the protein at the site of Asn88 did not enhance the thermal stability of the mAb 
molecule. 
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Figure 4-10. Thermal shift (ΔTm) as the result of deglycosylation of the Fab fragment. In case of 
full MAb where the melting transition of Fab is resolved with DSF, ΔTm of the full mAb was 
calculated. A negative ΔTm value means a reduced thermal stability after removal of the glycan 
structure. The effect of deglycosylation on the thermal stability was investigated of the protein 
in different formulations (A – D). 
The Fab-glycan was reported to be larger than the CH2-glycan and contains also α-
galactose and N-glycolylneuraminic acid, which are not involved in CH2-glycan 
structure.42-44 In contrast to the conserved, symmetrical, dimeric Fc fragment with its 
identical heavy chains, the Fab fragment is inherently more heterogeneous in 
structure. The dimeric form of Fc allows also for interaction of the glycans with each 
other via H-bonds,46 which is not possible for the Fab-glycan. Furthermore, only 15 - 
20 % of human serum IgG is approximately glycosylated at the Fab domain,52 
suggesting that glycosylation at this site is less important in vivo. The crystal structure 
of Fab from CX was resolved by Li and coworkers using X-ray crystallography,53 and 
is available via the RCSB Protein Data Bank (1YY8, http://www.rcsb.org). 
Investigation of the crystal structure using the PyMOL Molecular Graphics System 
version 1.3 (Academic license, Schrodinger LLC, http://pymol.sourceforge.net) 
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revealed that Asn88 is located on the outside of a small α-helix and is oriented 
towards the environment (Figure 4-11). Although in proximity to the gap between the 
Fab domains, the exposed position suggests that the glycans are easily accessible 
by solvent molecules. Thus, the glycans attached to Fab might be less shielded and 
less interactive with the protein surface compared with the Fc-glycans. Subsequently, 
deglycosylation is supposedly less affecting the thermal stability of the Fab part in 
contrast to the Fc part. 
 
Figure 4-11. 3D structure of Fab from CX. The observer is looking onto the domains of the light 
chain (“front row”). The heavy chain is settled behind in the “back row”. Asn88 is located on a 
small α-helix facing upwards into the solvent space (dark color). The structure originates from 
PDB 1YY8 and was generated using PyMOL. 
In conclusion, it was demonstrated that the stabilizing effect of the glycan moieties on 
the mAb molecules is domain specific. Both mAbs showed a reduced thermal stability 
after deglycosylation of the CH2 domain. The negative shift of Tm was more 
pronounced for MAb in comparison to CX. The effect was immanent for both the full 
mAb and the isolated Fc fragment. Thus, the presence of the glycan is important for 
the overall thermal stability of the full mAb but the stabilizing effect is limited to the 
CH2 region. The Tm values of Fab were not significantly changed upon 
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deglycosylation. Thus, CX did not gain a higher thermal stability due to the glycan 
attached to the VL domain. 
4.3.4 Thermal screening for the effect of excipients on the Tm value of MAb 
Formulation screenings for optimal thermal stability typically consider pH, ionic 
strength, and selected excipients at varying concentrations. It is known that arginine 
interacts with and stabilizes or destabilizes protein structure presumably due to the 
guanidine-group. Unlike guanidinium hydrochloride (GdnHCl), it was demonstrated by 
Ishibashi et al. that arginine is not a denaturant.54 Although there is evidence that the 
Tm value is lower for some proteins in the presence of arginine,
55,56 Falconer et al. 
reported basic amino acids to be beneficial for the stability of a mAb resulting in an 
increase in Tm.
30 Consequently, we investigated arginine and histidine for their 
potential application as stabilizing agents for MAb against thermal unfolding. First, 
increasing amounts of arginine were added to analyze the concentration dependency 
of any effect. Next, the effect of the counterion was studied at either 100 mM arginine 
or histidine. 
4.3.4.1 Effect of arginine concentration in the presence of chloride 
Figure 4-12 shows the Tm values obtained by DSF for the CH2 domain and the Fab 
part, and DSC thermograms of MAb at pH 7.2 and 5.0. Using a 4 mg/ml MAb sample 
in 10 mM phosphate buffer as a reference, an increasing amount of arginine resulted 
in a Tm (CH2) lowering by up to 7 to 8 °C for the 1 M arginine containing formulation 
at both pH values. This was confirmed by the DSC measurements (Figure 4-12). 
Yancey also demonstrated lower Tm values up to 2 °C for bovine pancreatic 
ribonuclease upon addition of 0.4 M arginine.56 No change of Tm of lysozyme was 
observed by DSC, but only up to 60 mM arginine was tested.57 The thermal stability 
of the Fab part was marginally increased at low arginine concentrations (apparent Tm 
increase by 1.1 °C at 50 mM arginine pH 5.0 in DSF). As demonstrated by the DSC 
thermograms, the higher apparent Tm values of the Fab part were likely due to an 
increased colloidal stability as the Tm analysis was less perturbed by protein 
aggregation (chapter 4.3.2). At pH 5.0, the positive net charge of the MAb molecules 
led to repulsion and higher colloidal stability as long as the charges were not shielded 
by the addition of salt (100 mM arginine). In presence of 1 M arginine, the DSC 
thermogram returned to baseline after unfolding of the Fab part at both pH values 
suggesting reduced precipitation (Figure 4-12). For the two model proteins RNase 
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and lysozyme Arakawa et al. found a concentration dependent Tm reduction of 1 - 
3 °C but an increase in solubility of the thermally unfolded protein.55 They suggested 
that arginine suppresses the aggregation of the unfolded species supposedly via 
binding of the guianidino-moiety to the protein.55 Shiraki et al. found arginine to be the 
best candidate among 15 amino acids in the prevention of aggregation upon thermal 
denaturation of proteins, and speculate that the guanidine-group might interfere with 
intermolecular or intramolecular H-bonds.57 In conclusion, arginine reduced the 
apparent Tm value of the CH2 domain, but supposedly stabilized the MAb via 
solubilization upon thermal unfolding of the Fab fragment with reduced aggregation of 
the protein. 
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Figure 4-12. Apparent Tm values obtained by DSF and DSC thermograms of 4 mg/ml MAb in 
10 mM phosphate buffer and with additional 10 mM to 1 M arginine at pH 7.2 (A + B) and pH 5.0 
(C + D). The pH was adjusted with hydrochloric acid. 
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4.3.4.2 Effect of the counterion of arginine after pH adjustment 
Adjustment of the solution pH is necessary to maintain a desired value after addition 
of the basic amino acid to the 10 mM phosphate buffer that corresponds to the buffer 
of the MAb stock solution. Ishibashi and coworkers have noted that the choice of acid 
needs to be considered during pH adjustment of arginine solutions due to possible 
counterion specific effects.54 The DSF results of the samples at pH 7.2 are presented 
in Figure 4-13 A. Compared with the arginine-free reference sample of the MAb in 
10 mM phosphate buffer, all 100 mM arginine containing samples showed a 
Tm (CH2) which is reduced at an average of 2.5 °C, regardless of the acid used for 
pH adjustment. Tm of the Fab fragment was slightly increased by about 1 °C for all 
samples except the citrate containing formulation. This finding was confirmed by DSC 
measurements which especially promote the stabilizing effect in the presence of 
aspartate and glutamate (Figure 4-13 B). At pH 5.0, the effects of the different ion 
partners were more pronounced (Figure 4-13 C). Citrate in the presence of 100 mM 
arginine reduced Tm (CH2) by about 5 °C, whereas a reduction about 2 - 3 °C was 
seen for the other samples. Interestingly, Tm (Fab) was reduced in case of chloride, 
acetate, and citrate. In agreement with the result obtained at pH 7.2, the amino acids 
aspartate and glutamate increased Tm (Fab) about 1 °C. The DSC thermogram of 
arginine-free MAb sample showed the expected progression without signal 
breakdown due to the net repulsion at the low pH value (Figure 4-13 D). The addition 
of 100 mM arginine in the presence of chloride, acetate, or citrate as the counterion 
resulted in the breakdown of the Cp signal suggesting aggregation. Interestingly, the 
samples containing either aspartate or glutamate were again supposedly stabilized. 
Possibly, the smaller chloride and acetate counterions lead to a more efficient 
shielding effect and subsequently the net repulsion at the low pH is reduced. Citrate 
with its three carboxyl moieties has a strong effect on the ionic strength of the 
solution. The acidic amino acids aspartic acid and glutamic acid also have a strong 
effect on the ionic strength and their positive stabilizing effect suggests a specific 
interaction. In conclusion, the presence of a specific ion partner for arginine was more 
important at the low pH compared with neutral pH value. Thus, presumably 
electrostatic interactions play a role in the observed synergistic stabilizing effect of 
arginine and both acidic amino aspartate and glutamate in case of the Fab fragment. 
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Figure 4-13. Apparent Tm values obtained by DSF and DSC thermograms of 4 mg/ml MAb in 
10 mM phosphate buffer and with additional 100 mM arginine at pH 7.2 (A + B) and pH 5.0 (C + 
D). The pH was adjusted with hydrochloric acid (Cl), acetic acid (Ac), citric acid (Cit), glutamic 
acid (Glu), or aspartic acid (Asp). 
4.3.4.3 The effect of histidine and different counterion partners 
Amino acids including both arginine and histidine were reported by Tian et al. to 
protect mAbs from conformational changes upon freeze-drying via noncovalent 
interactions.58 Furthermore, histidine was found to increase the stability and enhance 
the physical properties of an IgG2 mAb in both lyophilized and liquid state.59 Finally, 
Falconer reported that especially histidine among the basic amino acids increased 
the Tm values of a mAb.
30 At pH 7.2, the addition of 100 mM histidine did not result in 
a significant change of Tm (CH2), and Tm (Fab) was increased by about 1 °C 
independent of the counterion (Figure 4-14 A). Thus, the addition of histidine resulted 
in a similar stabilizing effect of the Fab fragment but in contrast to arginine, no 
destabilization of the Fc part was observed. An increase of Tm (Fab) comparable to 
the one in the arginine study was observed for the 100 mM histidine samples 
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containing aspartate and glutamate at pH 5.0 (Figure 4-14 B). Interestingly, the 
combination of histidine and chloride was found to be particularly perturbing with a Tm 
reduction of about 8 °C for the CH2 domain. A rather pronounced destabilization of 
5.5 °C was observed when the formulations at 25 mM histidine buffer and 10 mM 
phosphate buffer at pH 5.0 were compared (chapter 5). A control experiment was 
performed without the presence of the basic amino acids in which the tested acids 
were neutralized with sodium hydroxide and showed that the anions alone did hardly 
effect the apparent Tm values of the MAb (Figure 4-14 C and D). These findings 
suggest that a broad excipient screening is necessary to comprehensively study 
individual specific formulation effects. 
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Figure 4-14. Apparent Tm values obtained by DSF of 4 mg/ml MAb in 10 mM phosphate buffer 
and with additional 100 mM histidine at pH 7.2 (A) and pH 5.0 (B). The pH was adjusted with 
hydrochloric acid (Cl), acetic acid (Ac), citric acid (Cit), glutamic acid (Glu), or aspartic acid 
(Asp). As a control, sodium hydroxide was used to neutralize the tested acids in 10 mM 
phosphate buffer at pH 7.2 (C) and pH 5.0 (D). 
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4.3.5 Correlation of Tm and Tm,onset values from DSF and DSC 
The protein melting temperature (Tm) is defined as the temperature at which half of 
the protein is in the unfolded state. This point is represented by the peak maximum of 
an ideally Gaussian shaped DSC melting transition for a two-state reaction from the 
native to the unfolded state. In a case where multiple unfolding processes occur 
simultaneously, mathematical models might be applied to analyze Tm values of 
overlapping transitions. As extensively discussed in chapter 3 and in this chapter, the 
apparent Tm value of DSF is based on a different physicochemical principle. 
However, it was reported by many authors that a linear correlation between Tm values 
from DSC and DSF exist, particularly for mAb molecules.8,10-12 Moreover, it was also 
reported that DSC lead to higher values compared to DSF.
8,10,12 Figure 4-15 A 
presents the results of a Tm screening of nine different formulations of 4 mg/ml MAb. 
The formulations included six 10 mM phosphate buffer systems at pH 7.2 and pH 5.0 
with or without additional 280 mM mannitol or 140 mM NaCl. Additionally, three 
25 mM histidine buffers at pH 7.7, pH 7.2, and pH 5.0 were analyzed. The 
interpretation of the Tm values is comprehensively discussed in chapter 5. The linear 
fit to the data with a coefficient of determination (R2) of 0.979 suggests that the 
outcome parameters of both methods were in very good agreement. Therefore, Tm 
values obtained by DSF can be correlated to the results from DSC and vice versa as 
long as the detected melting transitions can be directly assigned to a specific mAb 
domain, as it is the case for MAb. 
Figure 4-15 B shows the correlation between the onset temperatures determined by 
DSC and DSF. The Tm,onset values were in both cases determined via the empiric 
equation based on tangents from Boltzmann fit data, which is derived in detail in 
chapter 3.3.2. A linear correlation between both methods for both model mAbs with 
the equation of the linear fit of 
         (   )                (   )         (4-7) 
suggests that both values were in good agreement (R2 = 0.884). One sample of MAb 
(10 mM phosphate pH 5.0 + 140 mM NaCl) did not fit into the observed linear 
correlation and a much lower Tm,onset was observed by DSC measurements. Possibly, 
the unfavorable sample conditions of low pH and high salt concentration were 
responsible for the early energetic changes. Furthermore, a broad transition with a 
slow ascending slope also lead to a very low Tm,onset value using the tangent based 
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approach. In such an extreme case, the presented equation tends to overestimate 
(value too low) the Tm,onset of the transition. For equation (4-7), this sample was 
omitted after a positive DFFITS outlier test result. 
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 B 
 
Figure 4-15. Linear correlation of the results from DSF and DSC. Tm values from 4 mg/ml MAb 
(A) and Tm,onset values from 4 mg/ml MAb and 4 mg/ml CX (B) in various formulations (His 7.7; 
His 7.2; His 5.0; Phos 7.2 +/- NaCl, mannitol; Phos 5.0 +/- NaCl, mannitol). 
It is worth noting that the results presented in Figure 4-15 B for MAb and CX were 
obtained on different RT-PCR machines. MAb samples were analyzed using the 
RT73000, whereas the qTower 2.2 was exclusively used for the CX samples. 
Therefore, the comparison of onset temperatures is likely to be a very robust method 
in terms of protein molecule and hardware setup. Furthermore, the scientific 
conclusions from Tm,onset in comparison to Tm might be stronger: In contrast to the Tm 
value, Tm,onset takes also the width of the transition into consideration. A sharp 
transition, i.e. a small T1/2 value, is indicative for cooperative unfolding,
60 and would 
result in a higher Tm,onset value in contrast to broad transitions. As the onset value 
corresponds to the temperature at which first structural changes occur, it is highly 
evident that this parameter is a better indicator and probably predictor of overall 
thermal stability of proteins.10 It is therefore highly recommended to include Tm,onset 
analysis into thermal stability screenings, especially during formulation development 
of therapeutic protein drugs. In conclusion, trends of stabilization or destabilization 
obtained by Tm screenings of various samples during pharmaceutical R&D can be 
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easily performed by DSF with low time and material consumption. The finding that 
values from DSF are systematically lower than those from DSC is discussed in the 
following chapter (4.3.6). 
4.3.6 Investigation on the absolute comparability of Tm values 
It was demonstrated in the previous chapter that the Tm results from DSF are 
consistently lower compared to the results from DSC. This finding was also reported 
by other authors for mAb molecules.8,10,12 The Tm of a protein is related to its 
thermodynamic equilibrium between the folded and the unfolded state. There are 
presumably three main reasons for systematically lower Tm values arising from DSF 
experiments in direct comparison to DSC: i) method variations, such as heating ramp 
or protein concentration, ii) a strong interaction of the dye with the unfolded protein, 
and iii) the physicochemical difference of both methods to monitor the unfolding 
process. In the following paragraphs, each aspect is individually discussed. 
4.3.6.1 Method variations 
The effect of method variations are extensively discussed in chapter 3 during the 
development of the DSF method. Especially, the heating ramp and the protein 
concentration were found to affect the apparent Tm value of the same protein in the 
same formulation. It is therefore important to maintain a comparable environment 
when directly correlating Tm values between both methods. Therefore, the heating 
ramp of DSF was optimized to achieve an overall heating rate of 1 °C/min despite 
stepwise temperature increments. Although, only results of samples of the same 
protein concentrations were directly compared, method variations are assumed to be 
not responsible for the observed systematic deviation between the Tm results from 
DSC and DSF. 
4.3.6.2 Strong interaction of the dye with the unfolded protein 
Assuming the simplest case of a one-step reaction between a single/unique native 
(N) and a single/unique unfolded state (U), any ligand (L) binding to and thus 
stabilizing the unfolded protein, should lead to a destabilization of the native state by 
shifting the equilibrium to the right hand side of the equation 
 [ ]  [ ]  [ ]  [ ]  [  ] (4-8) 
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As a result, the Tm value is shifted to lower temperatures in the presence of the 
destabilizing ligand. This scenario represents just the opposite case of a typical 
ligand screening, where any low molecular weight species binding to the native state 
of the protein leads to a positive shift of Tm. Considering the fact that SYPRO® 
Orange binds to the hydrophobic sites of the protein, which become exposed upon 
thermal unfolding, it its suspected that the probe leads to a negative shift of Tm. This 
effect might therefore be responsible for the systematically lower apparent Tm values 
observed by DSF (compare chapter 4.3.4). In order to investigate the effect of 
SYPRO® Orange on the Tm, DSC thermograms of the MAb in the absence and the 
presence of dye were analyzed. Furthermore, the influence of DMSO was checked, 
because the organic solvent is always present in the same volume fraction as the dye 
in any sample. In case of the typical SYPRO® Orange concentration of 1x, meaning 
a 1:5000 dilution of the stock solution supplied by the manufacturer, the protein is 
exposed to 0.02 % DMSO. Figure 4-16 A shows the results of a DSC scan of 4 mg/ml 
MAb in 25 mM histidine buffer pH 7.7 with either 0.1 % DMSO or 0.1 % SYPRO® 
Orange (= 5x) and also a reference scan of a sample spiked with the same amount of 
water. Both water and DMSO scans showed a perfect overlay with matching Tm 
values (Table 4-2). The Tm values of the SYPRO® Orange containing sample were in 
excellent agreement, although a minimally lower enthalpy of the first melting 
transition was observed. Furthermore, the study was performed with 4 mg/ml MAb in 
10 mM phosphate buffer at pH 7.2 (Figure 4-16 B). The presence of 0.1 % DMSO did 
not show an effect on the DSC results similar to the findings in the histidine 
formulation. Interestingly, 5x SYPRO® Orange was found to slightly alter the shape 
of the thermogram, leading to a lower Tm,onset value, whereas Tm1 and Tm2 were 
unchanged. Lowering the SYPRO® Orange concentration to 1x, which is the typical 
concentration used for DSF in this study, no significant effect could be demonstrated. 
These results confirm the claim of He et al. who observed no change in the melting 
transitions investigated by intrinsic fluorescence, SLS, and DSC in their work.8 In 
terms of a practical application of DSF, a significant influence of SYPRO® Orange on 
the Tm value can be ruled out. 
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Figure 4-16. DSC thermograms of 4 mg/ml MAb spiked up to 5x SYPRO® Orange, 0.1 % DMSO, 
and 0.1 % water in 25 mM histidine buffer pH 7.7 (A) and 10 mM phosphate buffer pH 7.2 (B). 
Table 4-2. Tm values obtained from the DSC scans presented in Figure 4-16. 
4 mg/ml MAb Tm,onset [°C] Tm1 [°C] Tm2 [°C] 
His 7.7 + 0.1 % water 60.0 72.8 83.9 
His 7.7 + 0.1 % DMSO 59.5 72.7 83.8 
His 7.7 + 0.1 % SYPRO® Orange (5x) 58.5 72.7 83.8 
Phos 7.2 + 0.1 % water 59.4 72.3 81.3 
Phos 7.2 + 0.1 % DMSO 59.1 72.3 81.1 
Phos 7.2 + 0.02 % SYPRO® Orange (1x) 59.1 72.3 81.3 
Phos 7.2 + 0.1 % SYPRO® Orange (5x) 56.3 72.0 81.2 
 
4.3.6.3 Analysis of different physicochemical end points 
To investigate the physicochemical differences of DSC and DSF, one first needs to 
consider the process of protein folding and unfolding. Theories regarding the process 
of protein folding are extensively reviewed and only a rough description of current 
understanding should be given in this work. A method referred to as “zipping and 
assembly method” (ZAM) for the molecular dynamic simulation of protein folding 
recently showed promising results to match in silico calculations with experimental 
results.61 Beginning with a random coil, the algorithm detects starting points where 
initial secondary structure elements form in parallel, mainly driven by hydrophobic 
interaction. These blocks will grow and interact with each other in order to form larger 
structures (“zipping and assembly”). In this process native as well as nonnative 
interactions unite and break as the tertiary structure forms. This finalization process 
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of the conformation can induce secondary structure changes so that those elements 
are subject to changes until the end of the folding process. Due to computational 
limitations, although impressive results were recently obtained using supercomputers 
as well as distributed computing platform, complex proteins such as mAbs are still 
challenging to simulate. The same is true for simulation of protein unfolding. Ren and 
coworker simulated the thermal unfolding of Rhodanase, a 2-domain protein of 
33 kDa, and found that the α-helix is more sensitive to heat than β-sheets.62 Another 
simulation revealed that the cofactor binding site of E. coli dihydrofolate reductase (1 
domain, 19 kDa), which is formed by an α-helix and β-sheet, was most susceptible to 
heat, and the protein subsequently formed molten globule like intermediates with 
decreasing secondary structure, until the structure at high temperature was 
completely depleted.63 Consequently, the secondary structure elements play a crucial 
role during thermal unfolding. Figure 4-17 illustrates the amino acid composition 
involved in secondary structure elements based on the data reported by Otaki and 
coworkers.64  
 
Figure 4-17. The composition of the amino acids in α-helix, β-sheet, and random coil structure. 
The amino acids are grouped into charged polar (open squares), uncharged polar (closed 
squares), and nonpolar (closed circles) characteristic. Aliphatic and nonpolar residues are 
involved in all secondary structure elements. The graph is based on the data from Otaki et al.
64
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Several amino acids show a tendency towards certain secondary structure 
elements.64,65 The α-helix is the preferred secondary structure. In cases of steric 
hindrance due to bulky side chains, β-strands are favored (valine, threonine, 
isoleucine). Competing H-bonds are unfavorable for α-helix structures (serine, 
aspartic acid, asparagine) and proline is known as a secondary structure breaker due 
the restricted angle of the ring structure. It was stated that the α-helix tends towards 
aliphatic and hydrophilic amino acids, whereas β-strands are likely consisting of both 
aliphatic and aromatic residues (Figure 4-17).64 Fluorescent probes like Bis-ANS and 
SYPRO® Orange are assumed to interact mainly with the hydrophobic, nonpolar 
residues that are present in all secondary structure parts. 
In analogy to the postulated process of protein folding, thermal unfolding is 
presumably starting with a perturbation of secondary structure elements. 
Subsequently, the conformation is loosened to molten globule like intermediate which 
finally break contact and a random coil would be obtained if not for other interfering 
processes. Aggregation is typically observed upon unfolding of the protein via 
hydrophobic interactions of the exposed hydrophobic patches (see chapter 6). 
Whereas DSC monitors every subtle energy change upon thermal unfolding, DSF 
relies on the interaction of the fluorescent probe. That means the unfolding process is 
monitored by DSF as long as a change in exposed hydrophobic structure occurs. In 
case all interaction sites are accessible to the dye, no further fluorescence intensity 
increase is possible. The hypothesis is that this stage of unfolding is reached before 
the last structural interaction is abolished. Furthermore, the initiation of protein 
aggregation upon unfolding, as discussed in chapter 6, will perturb the end point. 
While the protein molecules aggregate via the exposed hydrophobic patches, this 
surface is no longer accessible for the interaction with the dye.9 In all the cases, the 
maximum of hydrophobic exposure is reached before a completely unordered, 
random coil structure is obtained. This can explain the observation that the apparent 
Tm value, where half of the observed change occurred, is lower in case of 
hydrophobic exposure (DSF) compared to enthalpy change (DSC).  
However, the suggested endpoint detection at lower temperatures in case of DSF 
cannot explain all effects, because also Tm,onset values from DSF were found to be 
lower compared to the results from DSC (Figure 4-15 B). DSF might be particularly 
sensitive to the suggested initial perturbation of secondary structure elements. Thus, 
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small deviations from the native structure associated with low enthalpies would give a 
higher signal in DSF compared to DSC, and thus detect the onset of unfolding at 
lower temperatures. 
Finally, both methods are based on different physicochemical processes but the 
results are in good agreement and can be linearly correlated. DSC and DSF can be 
stated as orthogonal methods for the assessment of protein thermal stability. 
Especially Tm,onset is very promising to detect thermal instability issues during high-
throughput screenings. Interesting candidates, e.g., with particularly low or high 
values, could be crosschecked by one or the other method. 
4.4 Conclusion 
Thermal analysis is essential for the assessment of the thermal stability of proteins. 
Especially with multi-domain molecules such as mAbs, the process of unfolding 
consists of multiple steps. The melting profiles of DSF and the thermograms from 
DSC enabled a more detailed characterization with respect to the thermal sensitivity 
of the different fragments and domains. Typically, a different thermal stability of Fab 
and Fc is observed. Intrinsic factors, for instance, the glycosylation pattern of the Fc 
that interacts with the protein structure, affect the Tm value. Enzymatic removal of the 
Fc-glycans resulted in a reduction of the thermal stability of both the isolated Fc 
fragment and Fc of the full mAbs. Host cells and process parameters therefore have 
an influence on the thermal stability of the mAb. Furthermore, this suggests why Fc 
fragments from humanized mAbs can show different melting profiles. At the same 
time, the thermal stability of the Fab fragment is unique for every mAb molecule. The 
Fab fragment of MAb had higher Tm values compared to Fab of CX. Interestingly, the 
additional glycosylation of CX in the Fab region did not affect the thermal stability. 
Presumably the Fab-glycans are not involved in the conformational structure of the 
Fab domains as suggested by the crystal structure (PDB 1YY8). The low sample 
amounts necessary for a DSF experiment and the high-throughput design allowed 
the investigation of costly samples (e.g., the deglycosylated fragments) or screenings 
of various external factors that influence the thermal stability. Different pH values, 
ionic strength conditions, and excipients were investigated. Interestingly, lower Tm 
values of the CH2 domain were observed at pH 5.0 in the presence of arginine and 
histidine, including a significant effect of the counter-anions. Moreover, arginine and 
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histidine showed a stabilization of the Fab part supposedly via reduced aggregate 
formation upon thermal unfolding, with special synergistic effects by the counter-
anions aspartate and glutamate. It was demonstrated that the results from DSC and 
DSF can be linearly correlated, although consistently lower values were obtained by 
DSF. Especially, the Tm,onset value indicating the first change in conformational 
structure, which is supposedly a better predictive parameter than Tm,
10 can be 
obtained from both methods. Because of the different physicochemical 
measurements, DSC and DSF are valuable, orthogonal, and complimentary methods 
for thermal stability analysis of therapeutic proteins. 
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5 High-throughput Tm analysis of a mAb by DSF in the presence of 
surfactants 
This chapter has been published as Tim Menzen and Wolfgang Friess, 2013, High-
throughput melting-temperature analysis of a monoclonal antibody by differential 
scanning fluorimetry in the presence of surfactants, J Pharm Sci 102(2): 415-428. 
5.1 Abstract 
Differential scanning fluorimetry (DSF) is successfully used as a high-throughput 
screening method for the analysis of the protein melting temperature (Tm) in the 
development of therapeutic monoclonal antibody (mAb) formulations. Typically, 
surfactants are utilized in mAb formulations as a stabilizer, but the commonly applied 
polarity sensitive dye SYPRO® Orange shows bright fluorescence in the presence of 
micelles, concealing the signal of protein unfolding. Studying various mAb 
formulations containing polysorbate 20, polysorbate 80, or poloxamer 188, the 
molecular rotor probe DCVJ (9-(Dicyanovinyl)julolidine) was investigated. Although 
limited to higher mAb concentrations, DCVJ enabled the determination of Tm in many 
formulations where SYPRO® Orange failed. It is important to note that careful 
background correction of placebo formulations is essential for the precise 
determination of Tm and especially Tm,onset. Thermal shifts of Tm1 (lowest observed 
thermal transition) indicating stabilizing or destabilizing effects of pH or excipient were 
in good agreement across all tested formulations and correlated well with DSC 
measurements. Additionally, the micellization temperature of poloxamer 188 was 
confirmed, which leads to a nonproteinous transition. With this new method, it is 
possible to apply DSF during the development of therapeutic proteins in surfactant 
containing formulations. 
5.2 Introduction 
Since the introduction of the first generation of therapeutic monoclonal antibodies 
(mAbs) to the market in the 1990s, a variety of products were approved by the 
authorities and many more are in late stages of development.1 Protein stability is a 
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crucial parameter during development and production. Besides chemical instability, 
conformational and colloidal instability can lead to aggregation which is often linked 
to a loss of efficiency.2 Furthermore, immunological reactions are most likely 
dependent on protein aggregates.3 Because of the complex structure of proteins as 
compared to small molecules, a large arsenal of analytical tools is necessary for 
comprehensive analysis. Conformational structure can be typically studied with 
spectroscopic methods like intrinsic and extrinsic fluorescence, circular dichroism 
(CD), Fourier transform infrared (FTIR), and Raman4,5. By analysis of structural 
changes of the protein upon thermal unfolding, a protein melting temperature (Tm) 
can be defined at which half of the protein is in an unfolded state. Tm is commonly 
associated with conformational stability.6 Typically differential scanning calorimetry 
(DSC), tracing thermal events during heating, is used to determine Tm (Tm DSC).
7,8 
However, DSC is limited to low sample throughput and comparably high sample 
volumes. Consequently, there is a demand for alternative, high-throughput screening 
(HTS) methods of stabilizing or destabilizing factors. In 2001, Pantoliano and 
coworkers introduced a HTS based on extrinsic fluorescence to screen large libraries 
of small molecule ligands.9 The polarity sensitive dye 1-anilinonaphthalene-8-sulfonic 
acid (ANS) is used to analyze protein unfolding as ANS changes its fluorescence 
properties upon binding to newly exposed hydrophobic surfaces that appear upon 
denaturation. Already utilized in cuvettes with common spectrofluorimeters,10,11 
Pantoliano et al. adapted a special instrumental setup to analyze samples in 
microplates. The thermal transitions observed by the interaction of the fluorescent 
dye with the unfolding protein do not represent melting transitions from DSC, but the 
obtained apparent melting temperatures can be closely interpreted in terms of the 
calorimetric values. Since the introduction of this method in literature, referred to as 
ThermoFluor® or differential scanning fluorimetry (DSF), substantial development 
occurred. Making use of the temperature controller and fluorescence detector of 
common real-time polymerase chain reaction (RT-PCR) machines,12 in the last 
decade, DSF found its application in the wide field of protein science, ranging from 
identification of stabilizing buffer conditions,13-15 optimal crystallization parameters16 
or ligands,12,17,18 to the determination of binding constants19 as well as protein-protein 
complexes.20 A review was dedicated to this topic by Senisterra et al. this year.21 
More recently, various authors, predominately from the pharmaceutical industry, 
reported that DSF is a powerful tool for the development of mAb formulation. By 
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comparing the data from accelerated stress tests, Goldberg et al. could demonstrate 
that both DSF and differential static light scattering (DSLS) are HTS methods to 
screen conformational and colloidal stability and are synergistic for mAb formulation 
optimization and stability prediction.22 Li and coworkers applied DSF, among other 
methods, and extensively studied the aggregation propensity of three mAbs. They 
found that Tm alone is not able to predict aggregation pathways, e.g., when 
aggregate growth is the rate determining kinetic step, but is essential in combination 
with a size-based assay to understand the aggregation behavior of the protein.23 He 
and coworkers similarly analyzed the formulation conditions of mAbs by DSF,24,25 
whereas King et al. collected thermal stability data for numerous mAbs with this 
method.26 All these DSF studies in formulation development have used SYPRO® 
Orange as fluorescent dye because of its environmental sensitivity, bright 
fluorescence, chemical stability, and spectral properties in the range of the typical 
RT-PCR machine filter sets. However, none of the authors included surface active 
excipients, although surfactants are often used as stabilizing agents during 
production and storage of therapeutic proteins.27 This is because in the presence of a 
surfactant above the critical micelle concentration (CMC), SYPRO® Orange is 
transferred into the hydrophobic core of the micelles resulting in bright fluorescence 
of the dye and consequently high background. The comparatively small increase of 
the fluorescence intensity due to the unfolding of the protein is concealed. To 
overcome this major limitation in DSF as HTS in formulation development, the aim of 
this study was to implement the use of a fluorescent probe which is sensitive to 
protein folding but shows less micelle interaction. As a so called fluorescent 
molecular rotor, 9-(Dicyanovinyl)julolidine (DCVJ) shows environmentally sensitive 
properties. Nonradiative relaxation after twisted intramolecular charge transfer (TICT) 
is dependent on the system. In a low viscosity polar environment, radiationless decay 
after intramolecular rotation is favored, and thus only weak fluorescence occurs. In 
solvents of high viscosity and “spatially restricted” environment, torsional 
rearrangement is suppressed and an increased fluorescence is observed.28,29 The 
general feasibility of DCVJ in the analysis of protein unfolding and aggregation in the 
presence of a surfactant has been shown many times.30,31 Therefore, we tested 
whether the physicochemical and photochemical properties of DCVJ enable its 
application for Tm determination with DSF of a mAb in the presence of a surfactant 
with a common RT-PCR machine. Concentrations of 0.8 mg/ml, 4 mg/ml, or 40 mg/ml 
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of the mAb were formulated with and without either polysorbate 20 (PS 20), or 
polysorbate 80 (PS 80), or poloxamer 188 (PX 188) in pharmaceutically relevant 
concentration in nine different buffer systems based on either phosphate or histidine, 
including sodium chloride (NaCl) or mannitol. Tm DSF values obtained with DCVJ and 
SYPRO® Orange after careful background correction in the presence of surfactants 
were compared with the values of surfactant-free formulations. Furthermore, the 
effect of background correction on the resulting apparent onset temperature of 
unfolding in the presence of surfactants based on the Boltzmann fit (Tm,onset) was 
evaluated. In addition, Tm measurements by DSC were performed to confirm the DSF 
results and to understand the formulation effects. Furthermore, the temperature 
dependent micelle formation of PX 188 was analyzed by dynamic light scattering 
(DLS) measurements. 
5.3 Materials and Methods 
DCVJ (9-(Dicyanovinyl)julolidine) and SYPRO® Orange were purchased from Sigma-
Aldrich (Steinheim, Germany). Lutrol® F-68 (poloxamer 188, PX 188) was purchased 
from BASF (Ludwigshafen, Germany), Tween® 80 (polysorbate 80, PS 80) and 
Tween® 20 (polysorbate 20, PS 20) by Merck (Darmstadt, Germany). All other 
excipients were purchased from BDH Prolabo/VWR (Darmstadt, Germany) and were 
of HPLC grade or better. Highly purified water was prepared by an ELGA Purelab 
system (ELGA LabWater, Celle, Germany) and exclusively used as a solvent if not 
otherwise mentioned.  
5.3.1 Sample preparation 
The formulations at 0.8 mg/ml, 4 mg/ml, and 40 mg/ml of a humanized IgG1 type 
monoclonal antibody (“MAb”) produced in CHO (ε280 nm = 1.49 ml mg
-1 cm-1) in 25 mM 
histidine at pH 7.7, 7.2, and 5.0 as well as in 10 mM phosphate buffer with and 
without 140 mM NaCl or 280 mM mannitol at pH 7.2 and pH 5.0 were prepared from 
stock solutions. All formulations were filtrated through a 0.2 µm PES syringe filter 
prior to use. Surfactant containing formulations were prepared by either adding 
8.4 mg of PX 188, or 10 µl of PS 20 or PS 80 working solutions to 1000 µl MAb 
solution to achieve a surfactant concentration of 0.84 % PX 188 and 0.18 % or 
0.04 % PS 20 and PS 80, respectively.  
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
98 
5.3.2 Differential scanning fluorimetry (DSF) 
For DSF, a 220 mM DCVJ stock solution in dimethyl sulfoxide (DMSO) was prepared. 
SYPRO® Orange was supplied by the manufacturer as a 5000x concentrated stock 
solution in DMSO. Working solutions of both fluorescent dye stock solutions were 
prepared in water immediately prior to the experiment. 1 µl fluorescent dye working 
solution was pipetted to 20 µl sample solution in MicoroAmp® Optical 96-Well 
Reaction Plates (Applied Biosystems, Foster City, California, USA) and mixed by 
aspiration. The final dye concentrations were 100 µM for DCVJ or 1x (corresponding 
to a 1:5000 dilution of the provided stock solution) for SYPRO® Orange. Well plates 
were sealed with MicroAmp® Optical Adhesive Film (Applied Biosystems) and 
centrifuged at 2000 g for 1 min to remove air bubbles. A RT 7300 Real-Time PCR 
machine (Applied Biosystems) at a temperature ramp of 1 °C/min from 20 °C to 96 °C 
in steps of 1 °C was utilized. The emitted fluorescence intensity was read out across 
all 96 wells at every step. Raw data were exported for further processing with Origin® 
8 SR6 (Originlab Corporation, Northampton, Massachusetts, USA) to obtain melting 
curves of fluorescence intensity at 530 nm for DCVJ and 578 nm for SYPRO® 
Orange as a function of temperature. A placebo sample without MAb was recorded 
for each system and subtracted from the melting curve of the verum samples. The 
background corrected melting curves were differentiated, smoothed (polynomial order 
= 1, number of points = 5), and splined (cubic spline with 99 interpolated points in 
between two data points). Peak centers of the resulting first derivative were used as 
melting temperatures (Tm DSF). The presented Tm DSF are the mean of three 
independent values. Using Origin®, the Boltzmann function17 was fitted to the 
averaged fluorescence traces of three independent samples. The local minimum and 
maximum of the fluorescence intensity associated with the apparent transition were 
used as input values, while all parameters were unconstrained during the fit. The 
onset temperature Tm,onset was calculated using the following empiric equation 
 
         
   (   
     
  
   (     )
   )
     
     
(5-1) 
with T’m the inflection point, dT the slope factor, AL the lower fluorescence intensity, 
and AU the upper fluorescence intensity of the sigmoidal curve. Tm,onset resembles 
twice the distance on the x-scale of T’m, and the point of intersection between the 
tangents through T’m and AL (see also chapter 3.3.2). 
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5.3.3 Differential scanning calorimetry (DSC) 
The sample and the reference cell of a VP-DSC MicroCalorimeter (MicroCal, 
Northampton, Massachusetts, USA, now Malvern Instruments) were filled with the 
4 mg/ml MAb formulation and the corresponding placebo, respectively. Prescan 
thermostat time was set to 15 min to allow for equilibration of the sample. DSC 
thermograms were recorded from 20 °C to 96 °C at a scan rate of 1 °C/min. After 
each protein scan, both cells were heated up with nitric acid and washed 
subsequently with 1 % SDS solution and water. The thermogram was corrected by 
subtraction of a water-versus-water scan and normalized for the protein concentration 
using Origin® 7 SR2 (Originlab) with MicroCal VPViewer2000® version 1.4.10. 
Tm DSC is represented by the peak maximum of the endothermic transition. 
5.3.4 Dynamic light scattering (DLS) 
A DynaPro Plate Reader from Wyatt Technologies (Dernbach, Germany) with 
Dynamics software version 7.1.5.6 was used to determine the hydrodynamic radius 
of particulate species in solution. A sample solution of 20 µl was pipetted into a 384 
well plate (Corning Incorporated, Corning, New York, USA), covered with paraffin and 
centrifuged at 2000 g for 2 min. Each well was analyzed with five acquisitions and an 
acquisition time of 5 s. A continuous temperature ramp from 20 °C to 80 °C with a 
temperature rate of 0.1 °C/min was applied with analysis of each well every 1 °C. 
5.4 Results 
At first, the DSF results obtained with DCVJ of the 40 mg/ml MAb formulations with 
and without surfactant were compared to DSC results followed by the application of 
DCVJ and SYPRO® Orange in the presence of a surfactant at decreasing MAb 
concentrations. Supplementary results characterizing the micellization of PX 188 will 
be presented. Finally, the effect of background correction on Tm DSF and Tm,onset was 
investigated. 
Depending on the formulation pH, the mAb showed 2 or 3 unfolding transitions and 
the Tm values were enumerated, beginning with the lowest protein unfolding transition 
observed. The DSC thermogram of the histidine formulation is exemplarily presented 
in Figure 5-1. At pH 7.7 as well as pH 7.2, the first transition (Tm1 DSC) was caused by 
the melting of the CH2 domain, whereas the second transition (Tm2 DSC) represented 
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the unfolding of the CH3 domain and the Fab fragment.32-34 Decreasing the pH value 
to 5.0 resulted in a shift of the Tm DSC of both CH2 and CH3 domain to lower 
temperatures leading to a distinct transition for CH3 (Tm2 DSC) and Fab (Tm3 DSC). 
 
Figure 5-1. DSC melting curves of 4 mg/ml MAb in histidine buffer at pH 7.7, 7.2, and 5.0. With 
decreasing pH, the first transition (Tm1 DSC) corresponding to the CH2 domain is shifted to lower 
temperatures and the second transition splits into Tm2 DSC (CH3) and Tm3 DSC (Fab). In contrast, 
the transition with the highest area resembling the Fab fragment is shifted to higher 
temperatures at lower pH value. 
Independent of the addition of a surfactant, the transitions observed by DSF with 
DCVJ and DSC were in good agreement, as represented in Figure 5-2 A, with Tm DSF 
consistently 4 °C lower than Tm DSC. The thermal shift of Tm1 (ΔTm1) of the different 
formulations related to the histidine pH 7.7 system is presented in Figure 5-3 A and B 
for DSF and DSC, respectively. The common trends of stabilizing and destabilizing 
effects of the varied formulation parameters were in good agreement. Both methods 
revealed a large negative ΔTm1 at low pH, also in presence of sodium chloride. 
Mannitol reduced the negative ΔTm1 and even resulted in a positive ΔTm1 in case of 
the mAb formulated in phosphate buffer at pH 7.2. Although Tm1 DSF values were 1 - 
2 °C higher in the presence of a surfactant than in the surfactant-free formulation, 
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Tm1 DSC was lower in some samples, especially at pH 5.0. This discrepancy between 
both methods is also responsible for the outliers of the presented correlation in Figure 
5-2 A. 
A 
 
 B 
 
Figure 5-2. Linear correlation of Tm1 DSF with DCVJ of 40 mg/ml and Tm1 DSC of 4 mg/ml MAb in 
formulations with and without surfactant (A). Linear correlation of Tm1 DSF determined by DSF 
with SYPRO® Orange and with DCVJ of 40 mg/ml MAb of the surfactant-free formulations and 
in the presence of PX 188, PS 80, and PS 20 (B). 
A 
 
 B 
 
Figure 5-3. Thermal shift ΔTm1 of the different MAb formulations in relation to the histidine 
pH 7.7 formulation obtained by DSF with DCVJ (40 mg/ml) (A) and DSC (4 mg/ml) (B). 
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To estimate the error of the DSC values, the histidine pH 7.2 sample was injected 
four times, and the standard deviation was found to be 0.02 °C for both Tm1 DSC and 
Tm2 DSC. This confirms the reported high reproducibility of DSC,
35 and justifies the 
validity of single measurements for the sake of time and material. The Tm DSF values 
obtained with SYPRO® Orange and DCVJ were in excellent agreement, and a linear 
correlation of Tm1 DSF was found resembling all nine different formulations of 40 mg/ml 
MAb with and without surfactant (Figure 5-2 B). 
 Figure 5-4 exemplarily presents the fluorescence signal trace of the histidine 
samples at pH 7.2 analyzed with SYPRO® Orange (A - D) and DCVJ (E - H).  
A 
 
 B 
 
C 
 
 D 
 
Figure 5-4. DSF melting curves of MAb in histidine pH 7.2 without surfactant (A) and with 
PX 188 (B), PS 80 (C), and PS 20 (D) obtained by SYPRO® Orange. The graphs show the raw 
data traces of the placebo sample (diamonds) and with 0.8 mg/ml (squares), 4 mg/ml (circles), 
and 40 mg/ml MAb (pyramids). The black arrow indicates the signal caused by the interaction 
of the dye with PX 188 at the critical micellization temperature. The small inserted graphs show 
the protein transition after background correction by subtraction of the placebo signal from the 
raw data. 
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Without a surfactant, the increase of the fluorescence intensity is more distinct with 
higher protein concentration. SYPRO® Orange resulted in a significant signal even at 
the lowest applied MAb concentration of 0.8 mg/ml (Figure 5-4 A), whereas 4 mg/ml 
MAb was necessary for DCVJ (Figure 5-4 E). 
The presence of a surfactant resulted in an interfering background fluorescence 
signal. In case of PS 80 (Figure 5-4 C and G) and PS 20 (Figure 5-4 D and H), high 
initial background fluorescence was observed, which declined with increasing 
temperature. In case of PX 188, the background signal showed a sharp and intense 
fluorescence increase when the critical micellization temperature of the poloxamer 
was exceeded at about 50 °C (Figure 5-4 B and F, black arrow). 
E 
 
 F 
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 H 
 
Figure 5-4 (continued). DSF melting curves of MAb in histidine pH 7.2 without surfactant (E) 
and with PX 188 (F), PS 80 (G), and PS 20 (H) obtained by DCVJ. The graphs show the raw data 
traces of the placebo sample (diamonds) and with 0.8 mg/ml (squares), 4 mg/ml (circles), 
and 40 mg/ml MAb (pyramids). The black arrow indicates the signal caused by the interaction 
of the dye with PX 188 at the critical micellization temperature. The small inserted graphs show 
the protein transition after background correction by subtraction of the placebo signal from the 
raw data. 
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The transformation of single surfactant molecules to micellar structures was further 
investigated by means of DSC and DLS. Figure 5-5 shows the results from a protein 
free solution of PX 188 in histidine buffer at pH 7.2. 
 
Figure 5-5. Micellization behavior of PX 188 in histidine pH 7.2 analyzed by DSF with DCVJ 
(solid line) and with SYPRO® Orange (dashed line), DSC (dotted line), and DLS (circles). 
The fluorescence increase of DCVJ was sharper and occurred at slightly lower 
temperatures than that of SYPRO® Orange. The endothermic transition observed by 
DSC was in good agreement although the midpoint of the transition occurred at 
higher temperatures compared to DSF. In DLS, the association of single PX 188 
molecules with an apparent hydrodynamic radius of about 2.4 nm to micellar 
structures of an apparent hydrodynamic radius of about 8 nm started at a slightly 
higher temperature (52 °C). With respect to nonequilibrium conditions, the 
temperatures at which the micellization process starts was in overall good accord 
between the different methods. 
Background correction was performed by subtracting the fluorescence trace of a 
placebo sample from the signal of the protein containing formulation (inserted graphs 
in Figure 5-4), and the obtained Tm DSF values are presented in Table 5-1.   
20 30 40 50 60 70 80 90 100
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
C
p
 [
m
c
a
l/
°C
]
Temperature [°C]
1
2
3
4
5
6
7
8
9
 H
y
d
ro
d
y
n
a
m
ic
 r
a
d
iu
s
 [
n
m
]
0.0
0.5
1.0
 N
o
rm
a
liz
e
d
 f
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
5. High-throughput Tm analysis of a mAb by DSF in the presence of surfactants 
105 
 
T
a
b
le
 5
-1
. 
T
m
 D
S
F
 o
f 
M
A
b
 (
0
.8
 m
g
/m
l,
 4
 m
g
/m
l,
 a
n
d
 4
0
 m
g
/m
l)
 i
n
 n
in
e
 d
if
fe
re
n
t 
fo
rm
u
la
ti
o
n
s
 w
it
h
 a
n
d
 w
it
h
o
u
t 
s
u
rf
a
c
ta
n
t 
a
n
a
ly
z
e
d
 b
y
 D
S
F
 w
it
h
 e
it
h
e
r 
S
Y
P
R
O
®
 O
ra
n
g
e
 o
r 
D
C
V
J
. 
M
A
b
 c
o
n
c
. 
4
0
 m
g
/m
l 
4
 m
g
/m
l 
0
.8
 m
g
/m
l 
F
lu
o
re
s
c
. 
d
y
e
 
D
C
V
J
 
S
Y
P
R
O
®
 O
ra
n
g
e
 
D
C
V
J
 
S
Y
P
R
O
®
 O
ra
n
g
e
 
D
C
V
J
 
S
Y
P
R
O
®
 O
. 
F
o
rm
u
la
ti
o
n
 
n
o
 
s
u
rf
a
c
t.
 
P
X
 1
8
8
 
P
S
 8
0
 
P
S
 2
0
 
n
o
 
s
u
rf
a
c
t.
 
P
X
 1
8
8
 
P
S
 8
0
 
P
S
 2
0
 
n
o
 
s
u
rf
a
c
t.
 
P
S
 8
0
 
P
S
 2
0
 
no PX 188 
n
o
 
s
u
rf
a
c
t.
 
P
S
 2
0
 
no PX 188, PS 80 
n
o
 
s
u
rf
a
c
t.
 
no PX 188, PS 80, PS 20 
n
o
 
s
u
rf
a
c
t.
 
no PX 188, PS 80, PS 20 
 
T
m
1
 D
S
F
 [
°C
] 
T
m
1
 D
S
F
 [
°C
] 
T
m
1
 D
S
F
 [
°C
] 
T
m
1
 D
S
F
 [
°C
] 
" 
" 
H
is
 7
.7
 
6
8
.2
±
0
.1
 
6
9
.1
±
0
.1
 
6
8
.3
±
0
.1
 
6
8
.6
±
0
.1
 
6
7
.0
±
0
.3
 
6
8
.6
±
0
.1
 
6
7
.4
±
0
.1
 
6
8
.2
±
0
.1
 
6
8
.9
±
0
.1
 
6
9
.3
±
0
.2
 
7
2
.2
±
1
.1
 
6
8
.5
±
0
.5
 
6
9
.5
±
0
.1
 
6
9
.6
±
0
.4
 
6
9
.3
±
0
.2
 
H
is
 7
.2
 
6
8
.2
±
0
.1
 
6
9
.6
±
0
.1
 
6
8
.3
±
0
.1
 
6
8
.7
±
0
.1
 
6
6
.8
±
0
.3
 
6
8
.9
±
0
.1
 
6
7
.5
±
0
.1
 
6
8
.3
±
0
.1
 
6
8
.8
±
0
.1
 
6
9
.7
±
0
.1
 
6
9
.0
±
1
.0
 
6
9
.3
±
0
.2
 
6
9
.4
±
0
.1
 
6
8
.9
±
0
.8
 
6
9
.6
±
0
.1
 
H
is
 5
.0
 
5
7
.3
±
0
.1
 
5
8
.4
±
0
.1
 
5
7
.8
±
0
.1
 
5
8
.3
±
0
.3
 
5
8
.7
±
1
.4
 
6
1
.6
±
0
.8
 
5
7
.9
±
0
.1
 
5
9
.3
±
0
.4
 
5
6
.2
±
0
.1
 
5
7
.0
±
0
.2
 
5
6
.1
±
0
.3
 
5
9
.2
±
0
.3
 
5
8
.6
±
0
.2
 
5
6
.2
±
0
.1
 
6
0
.1
±
0
.2
 
P
h
o
s
 5
.0
  
+
 N
a
C
l 
5
6
.8
±
0
.1
 
5
8
.0
±
0
.1
 
5
7
.3
±
0
.2
 
5
8
.3
±
0
.3
 
5
6
.7
±
0
.3
 
5
8
.6
±
0
.7
 
5
7
.2
±
0
.2
 
6
2
.8
±
0
.1
 
5
7
.7
±
0
.1
 
5
9
.2
±
0
.2
 
5
5
.1
±
0
.3
 
6
0
.2
±
1
.5
 
6
0
.2
±
0
.1
 
 
6
2
.3
±
0
.6
 
P
h
o
s
 7
.2
  
+
 N
a
C
l 
6
6
.0
±
0
.1
 
6
7
.1
±
0
.2
 
6
6
.1
±
0
.1
 
6
6
.5
±
0
.3
 
6
4
.8
±
0
.1
 
6
6
.4
±
0
.4
 
6
5
.6
±
0
.1
 
6
6
.5
±
0
.1
 
6
6
.1
±
0
.2
 
6
7
.0
±
0
.1
 
6
6
.1
±
0
.2
 
6
8
.9
±
0
.5
 
6
7
.3
±
1
.1
 
 
6
7
.7
±
0
.2
 
P
h
o
s
 5
.0
  
+
 m
a
n
n
it
o
l 
6
2
.5
±
0
.1
 
6
3
.4
±
0
.1
 
6
3
.0
±
0
.1
 
6
3
.3
±
0
.3
 
6
3
.0
±
0
.3
 
6
3
.5
±
0
.8
 
6
3
.0
±
0
.2
 
6
4
.1
±
0
.3
 
6
3
.5
±
0
.2
 
6
4
.1
±
0
.2
 
6
4
.1
±
0
.7
 
6
5
.5
±
1
.5
 
6
5
.7
±
0
.1
 
 
6
6
.2
±
1
.9
 
P
h
o
s
 7
.2
  
+
 m
a
n
n
it
o
l 
6
8
.9
±
0
.2
 
7
0
.3
±
0
.1
 
6
8
.8
±
0
.1
 
6
9
.1
±
0
.1
 
6
7
.7
±
0
.3
 
6
8
.7
±
0
.1
 
6
8
.1
±
0
.1
 
6
9
.0
±
0
.1
 
6
8
.3
±
1
.1
 
6
9
.4
±
0
.3
 
7
0
.5
±
1
.0
 
6
9
.6
±
0
.9
 
6
9
.5
±
0
.8
 
 
6
9
.6
±
0
.2
 
P
h
o
s
 5
.0
 
6
0
.7
±
0
.1
 
6
2
.4
±
0
.2
 
6
1
.3
±
0
.1
 
6
1
.9
±
0
.1
 
6
0
.8
±
0
.3
 
6
2
.7
±
0
.5
 
6
1
.7
±
0
.1
 
6
2
.6
±
0
.1
 
6
2
.1
±
0
.4
 
6
2
.7
±
0
.4
 
6
4
.9
±
0
.1
 
6
4
.7
±
0
.1
 
6
3
.9
±
1
.0
 
5
6
.9
±
1
.1
 
6
5
.1
±
0
.2
 
P
h
o
s
 7
.2
 
6
7
.3
±
0
.1
 
6
8
.4
±
0
.1
 
6
7
.5
±
0
.1
 
6
7
.8
±
0
.1
 
6
5
.0
±
1
.0
 
6
7
.5
±
0
.2
 
6
7
.1
±
0
.1
 
6
7
.9
±
0
.1
 
6
8
.0
±
0
.7
 
6
8
.6
±
0
.1
 
6
8
.7
±
0
.3
 
6
8
.3
±
0
.3
 
6
8
.9
±
0
.5
 
6
1
.5
±
0
.4
 
6
8
.3
±
0
.1
 
 
T
m
2
 D
S
F
 [
°C
] 
T
m
2
 D
S
F
 [
°C
] 
T
m
2
 D
S
F
 [
°C
] 
T
m
2
 D
S
F
 [
°C
] 
" 
" 
H
is
 7
.7
 
7
7
.3
±
0
.1
 
7
8
.7
±
0
.1
 
7
7
.6
±
0
.2
 
7
7
.8
±
0
.1
 
 
8
2
.4
±
0
.1
 
8
2
.4
±
0
.2
 
8
2
.2
±
0
.1
 
7
8
.5
±
0
.1
 
7
9
.1
±
0
.1
 
7
9
.4
±
0
.2
 
8
1
.1
±
0
.2
 
8
1
.8
±
0
.1
 
7
8
.8
±
0
.1
 
8
1
.3
±
0
.1
 
H
is
 7
.2
 
7
8
.4
±
0
.2
 
8
0
.2
±
0
.1
 
7
8
.8
±
0
.1
 
7
9
.2
±
0
.1
 
 
8
3
.5
±
0
.1
 
8
2
.5
±
0
.4
 
8
3
.3
±
0
.1
 
7
9
.7
±
0
.1
 
8
0
.7
±
0
.1
 
8
0
.8
±
0
.2
 
8
1
.9
±
0
.1
 
8
2
.6
±
0
.1
 
8
0
.6
±
0
.4
 
8
2
.1
±
0
.1
 
H
is
 5
.0
 
7
7
.8
±
0
.1
 
7
8
.8
±
0
.1
 
7
7
.9
±
0
.1
 
7
8
.3
±
0
.1
 
 
 
 
7
9
.4
±
0
.2
 
7
6
.9
±
0
.1
 
7
6
.7
±
0
.2
 
7
7
.2
±
0
.1
 
7
6
.4
±
0
.1
 
7
6
.6
±
0
.2
 
7
6
.5
±
0
.1
 
7
6
.6
±
0
.2
 
P
h
o
s
 5
.0
  
+
 N
a
C
l 
7
7
.3
±
0
.1
 
7
9
.4
±
0
.1
 
7
7
.3
±
0
.2
 
7
6
.3
±
0
.1
 
6
6
.9
±
1
.2
 
8
4
.7
±
1
.3
 
8
4
.6
±
0
.2
 
8
4
.5
±
0
.6
 
7
9
.3
±
0
.1
 
7
9
.5
±
0
.6
 
8
0
.0
±
0
.4
 
8
5
.6
±
0
.2
 
8
5
.8
±
0
.1
 
 
8
0
.2
±
0
.1
 
P
h
o
s
 7
.2
  
+
 N
a
C
l 
7
6
.3
±
0
.1
 
7
7
.1
±
0
.1
 
7
6
.7
±
0
.1
 
7
7
.2
±
0
.1
 
 
8
1
.6
±
0
.3
 
8
1
.7
±
0
.1
 
8
1
.5
±
0
.1
 
7
8
.1
±
0
.3
 
7
9
.4
±
0
.3
 
8
0
.1
±
0
.1
 
8
1
.7
±
0
.1
 
8
1
.9
±
0
.1
 
 
8
1
.6
±
0
.1
 
P
h
o
s
 5
.0
  
+
 m
a
n
n
it
o
l 
8
1
.4
±
0
.1
 
8
2
.0
±
0
.1
 
8
1
.5
±
0
.1
 
8
1
.7
±
0
.1
 
 
8
7
.1
±
0
.2
 
 
8
7
.3
±
0
.1
 
8
3
.3
±
0
.1
 
8
3
.4
±
0
.1
 
8
4
.5
±
0
.2
 
8
2
.3
±
0
.1
 
8
1
.6
±
2
.0
 
 
8
1
.9
±
0
.3
 
P
h
o
s
 7
.2
  
+
 m
a
n
n
it
o
l 
7
6
.8
±
0
.1
 
7
7
.6
±
0
.1
 
7
7
.5
±
0
.1
 
7
8
.0
±
0
.2
 
8
1
.7
±
0
.1
 
8
2
.2
±
0
.1
 
8
2
.3
±
0
.1
 
8
2
.2
±
0
.1
 
8
0
.3
±
0
.1
 
8
0
.2
±
0
.3
 
8
0
.7
±
0
.2
 
8
1
.5
±
0
.1
 
8
2
.1
±
0
.1
 
 
8
1
.7
±
0
.2
 
P
h
o
s
 5
.0
 
8
0
.3
±
0
.1
 
8
1
.2
±
0
.1
 
8
0
.4
±
0
.1
 
8
0
.7
±
0
.1
 
 
8
6
.0
±
0
.1
 
8
6
.0
±
0
.1
 
8
6
.8
±
0
.1
 
8
2
.0
±
0
.2
 
8
2
.1
±
0
.2
 
8
3
.9
±
0
.2
 
7
2
.0
±
1
.5
 
8
1
.5
±
0
.9
 
8
1
.4
±
0
.1
 
8
2
.0
±
0
.3
 
P
h
o
s
 7
.2
 
7
6
.3
±
0
.1
 
7
6
.6
±
0
.1
 
7
6
.7
±
0
.1
 
8
0
.2
±
0
.1
 
8
0
.6
±
0
.1
 
8
1
.4
±
0
.1
 
8
1
.5
±
0
.2
 
8
1
.3
±
0
.1
 
7
9
.3
±
0
.2
 
7
9
.5
±
0
.1
 
7
9
.8
±
0
.1
 
8
0
.9
±
0
.1
 
8
1
.3
±
0
.1
 
8
0
.5
±
0
.1
 
8
0
.8
±
0
.1
 
 
T
m
3
 D
S
F
 [
°C
] 
T
m
3
 D
S
F
 [
°C
] 
T
m
3
 D
S
F
 [
°C
] 
T
m
3
 D
S
F
 [
°C
] 
" 
" 
H
is
 5
.0
 
 
8
5
.5
±
0
.1
 
8
5
.2
±
0
.2
 
8
4
.6
±
0
.4
 
 
 
 
 
8
3
.6
±
0
.4
 
8
4
.4
±
0
.1
 
8
4
.4
±
0
.1
 
8
5
.3
±
0
.1
 
8
5
.3
±
0
.1
 
8
3
.5
±
0
.3
 
 
P
h
o
s
 5
.0
  
+
 N
a
C
l 
 
 
8
5
.9
±
0
.4
 
8
5
.3
±
0
.3
 
 
 
 
 
8
5
.4
±
0
.1
 
8
5
.1
±
0
.1
 
8
5
.1
±
0
.1
 
 
 
 
8
5
.1
±
0
.8
 
P
h
o
s
 5
.0
  
+
 m
a
n
n
it
o
l 
 
 
 
 
 
 
 
 
 
 
 
8
6
.9
±
0
.3
 
8
7
.5
±
0
.5
 
 
8
7
.4
±
1
.3
 
P
h
o
s
 5
.0
 
 
 
 
 
 
 
 
 
 
 
 
8
1
.1
±
0
.5
 
8
6
.9
±
0
.1
 
8
5
.6
±
0
.2
 
8
5
.9
±
0
.1
 
B
la
n
k
 c
e
ll
 m
e
a
n
s
 d
a
ta
 a
n
a
ly
s
is
 r
e
v
e
a
le
d
 n
o
 T
m
 D
S
F
 v
a
lu
e
. 
H
is
, 
h
is
ti
d
in
e
 b
u
ff
e
r;
 P
h
o
s
, 
p
h
o
s
p
h
a
te
 b
u
ff
e
r 
w
it
h
 a
n
d
 w
it
h
o
u
t 
a
d
d
it
io
n
a
l 
s
o
d
iu
m
 c
h
lo
ri
d
e
 o
r 
m
a
n
n
it
o
l;
 P
X
, 
p
o
lo
x
a
m
e
r;
 P
S
, 
p
o
ly
s
o
rb
a
te
 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
106 
After background correction, it was possible to determine Tm1 DSF precisely for all 
formulations with both dyes at 40 mg/ml MAb. As expected, the data analysis was 
hindered when the protein concentration was reduced, because the fluorescence 
intensity of the background conceals the lowered protein signal. Consequently for 
some formulations, the Tm DSF values could not be determined (Table 5-1). Although it 
was possible with DCVJ to analyze Tm DSF for both polysorbates at 4 mg/ml MAb, 
SYPRO® Orange allowed the determination only in presence of PS 20. The 
nonproteinous signal of PX 188 hampered the determination of Tm DSF at lower 
protein concentrations, and no Tm DSF values were obtained even after careful 
background correction. A further reduction of the protein concentration to 0.8 mg/ml 
completely concealed the protein transition in the presence of a surfactant. The 
appearance of Tm2 DSF was more distinct with DCVJ, especially at higher MAb 
concentrations. In contrast, Tm2 DSF could be clearly detected with SYPRO® Orange 
at low MAb concentration but diminished at 40 mg/ml. The change in fluorescence 
intensity resembling Tm3 DSF in case of MAb formulations at pH 5.0 was very weak, 
thus difficult to analyze and only precisely detectable in a few cases (Table 5-1). 
The influence of background correction on Tm1 DSF and Tm,onset was investigated and 
the difference between the values obtained from raw data and after placebo 
subtraction is presented in Table 5-2 for 40 mg/ml MAb. Whereas background 
correction of the surfactant free samples did not result in marked changes, the 
pronounced background fluorescence signal in case of formulations containing 
surfactant was expected to render a shift. Although Tm1 DSF values obtained from 
Boltzmann fitting shifted between 0.1 and 0.5 °C, the values resulting from analysis of 
the first derivative showed the smallest difference ranging from 0 to 0.3 °C. The onset 
of Tm DSF was calculated based on the Boltzmann function fitted to the fluorescence 
traces. As the calculated value Tm,onset depends on the slope factor of the transition, it 
is more susceptible to the curve change caused by the mathematical process of 
background subtraction compared to the inflection point of the curve itself.  
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Table 5-2. Difference in Tm1 DSF values before and after background correction (40 mg/ml MAb 
with DCVJ). 
 Tm1 DSF [°C] Tm,onset [°C] 
 
first derivative analysis Boltzmann fit Onset temperature  
40 mg/ml  
with DCVJ 
no 
surf 
PX 
188 
PS 
80 
PS 
20 
no 
surf 
PX 
188 
PS 
80 
PS 
20 
no 
surf 
PX 
188 
PS 
80 
PS 
20 
His 7.7 0 0.3 0 0.3 0.1 -0.1 0.2 0.1 0 1.0 1.7 1.1 
His 7.2 -0.1 -0.3 0 0 0 -0.3 0.2 0.1 -0.1 0.5 2.1 1.7 
His 5.0 0 n.a. -0.1 0 0 n.a. 0.2 0.2 -0.3 n.a. 1.9 2.3 
Phos 5.0 
+ NaCl 
0 n.a. 0 0.2 -0.1 n.a. 0.1 0.3 -0.2 n.a. 1.4 2.4 
Phos 7.2 
+ NaCl 
0 -0.2 0.1 0.2 0 0.1 0.1 0.4 -0.3 0.9 1.5 2.3 
Phos 5.0 
+ mannitol 
0 n.a. 0.1 0.3 0 n.a. 0.2 0.3 -0.3 n.a. 1.4 3.1 
Phos 7.2 
+ mannitol 
0.1 -0.8 0 -0.1 -0.2 -0.7 0.1 0.2 0.1 2.5 1.8 3.2 
Phos 5 0 n.a. 0 -0.2 -0.1 n.a. 0.1 0.5 -0.4 n.a. 1.3 4.6 
Phos 7.2 0 -0.4 0 0.1 0 -0.2 0.1 0.2 -0.3 0.6 0.9 2.3 
A positive result indicates that Tm1 DSF was shifted to lower temperature placebo subtraction. 
Because no Tm1 DSF could be obtained without background correction for the samples with 
PX 188 at pH 5.0, a comparison is not available (n.a.) in this case. His, histidine buffer; Phos, 
phosphate buffer with and without additional sodium chloride or mannitol; PX, poloxamer; PS, 
polysorbate; Surf, surfactant. 
As presented in Table 5-2, Tm,onset was shifted substantially up to 4.6 °C indicating a 
significant overestimation without background correction. This effect is illustrated in 
Figure 5-6, which exemplarily compares the original melting trace of 40 mg/ml MAb in 
histidine at pH 7.2 with DCVJ in the presence of PS 80 with the resulting trace after 
background correction. Although Tm,onset is significantly reduced by 2 °C from 61.9 °C 
to 59.9 °C after background subtraction, the inflection point of the Boltzmann fit shifts 
insignificantly from 68.2 °C to 68.0 °C. The analysis of the first derivative is even less 
affected by the background correction procedure delivering a Tm1 DSF of 68.4 °C 
before and after subtraction of the placebo trace. 
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Figure 5-6. Illustration of the Tm values of 40 mg/ml MAb in histidine buffer pH 7.2 in the 
presence of PS 80. Open and closed squares resemble the raw data and background corrected 
melting trace, respectively. Tm1 DSF and Tm2 DSF values determined as the maxima of the first 
derivative are marked with a black “+”. The black line displays the result of the Boltzmann fit to 
the first transition. A grey “x” marks the inflection point (T’m) of the sigmoidal function, while 
Tm,onset is calculated based on the parameters of the fit. Tm1 DSF and T’m are usually in good 
agreement. Although the process of background correction had a minor influence Tm1 DSF, 
Tm,onset was significantly lower because the slope is affected because of the subtraction of the 
signal caused by the surfactant. 
5.5 Discussion 
5.5.1 DSF in presence of surfactant 
In this study, Tm values of a mAb in three concentrations between 0.8 and 40 mg/ml 
were determined in nine different formulations with and without PS 20, PS 80, and 
PX 188 both by DSF and DSC. At the higher pH values tested (pH 7.2 and 7.7), the 
mAb typically showed two distinct transitions; whereas at pH 5.0, a third transition 
occurred at rather high temperatures. In case of mAbs the Fab fragment, the CH2 
and the CH3 domain of the Fc fragment unfolded individually resulting in particular 
endothermic melting transitions in DSC. The order in which these segments unfold is 
determined by their independent stability. Ionescu et al. and Garber et al. used the 
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melting enthalpy to identify the fragments and propose that the Fab fragment is 
responsible for the largest peak.32,33 The CH2 domain, especially in the aglycosylated 
form, is strongly destabilized at low pH (chapter 4.3.3).34 Although the CH3 domain 
and the Fab fragment are likely to unfold simultaneously at higher pH values (7.2, 
7.7), three distinct transitions at lower temperatures result at pH 5.0. The transitions 
could be clearly detected in DSC experiments, whereas the appearance of a second 
or third transition was not consistent in DSF because the increase in fluorescence 
intensity was frequently rather small and thus difficult to resolve. Multiple transitions 
of a mAb with DSF were also reported by Li et al. and He et al., but they focused only 
on the first transition, which resembles the domain with the lowest thermal 
stability.23,24 Goldberg et al. also reported two clearly separated transitions in DSC 
and DSF for one mAb, and for a second mAb, they found up to three transitions, 
depending on pH similar to our results.22 Because of the linear correlation of Tm1 
between DSC and DSF as presented in Figure 5-2 A, Tm1 DSF is most likely caused by 
unfolding of CH2. Experiments with isolated Fab and Fc fragments are necessary to 
ultimately assign a certain MAb segment to Tm2 DSF and Tm3 DSF (chapter 4.3.2). 
As a common trend found by both methods, Tm1 of the mAb at a pH of 5.0 was lower 
than that at pH 7.2 and 7.7 denoting a protein destabilization presumably due to a 
reduction of stabilizing attractive intramolecular electrostatic interactions. The addition 
of mannitol resulted in a slight increase of the Tm1 value corresponding to the 
stabilizing effect of the sugar alcohol presumably by preferential exclusion. The 
addition of sodium chloride increased the ionic strength of the solution and led to a 
reduced Tm1, destabilizing the mAb, which is likely due to shielding of stabilizing 
attractive electrostatic interactions. Low pH and high salt concentrations also turned 
out to be unfavorable for mAb stability in a study by He et al.24 Goldberg 
demonstrated a concentration dependent stabilization by trehalose, whereas a 
destabilization by sodium chloride was observed.22 The effects of sodium chloride 
and mannitol on Tm2 were less pronounced. Interestingly, the effect of pH was 
inversed with respect to Tm2 DSF, resulting in higher values at pH 5.0. 
Excipients interacting with the protein influence Tm by either stabilizing the native or 
the unfolded state. Surfactants occupy interfaces preventing protein aggregation at 
these very interfaces and only marginally influence the conformational stability of the 
protein molecules.36 The results from DSF suggest that the presence of a surfactant 
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potentially stabilized the mAb as can be seen by the increase in Tm1 DSF by approx. 1 - 
2 °C (Figure 5-3 A). In contrast, with DSC (Figure 5-3 B), surfactant containing 
samples showed slightly lower Tm1 DSC values, predominately at pH 5.0. Similar 
results were reported by Bam et al. studying the effect of polysorbates on the stability 
of recombinant human growth hormone.36 They also found a reduced Tm by DSC 
suggesting binding of polysorbate to hydrophobic patches, wheras FTIR and CD 
analysis revealed no change in secondary structure.36 DSC reveals all thermal events 
during unfolding of the secondary and tertiary structure, wheras DSF is sensitive only 
to changes of hydrophobic exposure or the microenvironment at the surface (chapter 
4.3.6). The transitions determined by DSF are in good agreement with DSC data and 
as presented in Figure 5-2 A, a linear correlation exists, although Tm1 DSC is typically 
slightly higher than the Tm1 DSF
 (compare chapter 4.3.5), which was also found by He 
et al.,20 Goldberg et al.,22 and King et al.26 The absolute Tm values depend on the 
heating rate in DSF and DSC because unfolding is not at equilibrium. Therefore, the 
analyzed Tm should be treated as apparent values. Although the heating rate was 
1 °C/min in DSF and DSC, the heat transfer into the different sample volumes is likely 
to be different. The systematic difference between Tm DSC and Tm DSF may also be due 
to preferred binding of the dye to the unfolded protein. In a simple two-state model, 
the unfolded state is consequently preferred, the native state destabilized and the 
apparent Tm shifted to lower temperatures by the dyes. Assuming a competitive 
binding of the nonionic surfactant with the dye for hydrophobic patches at the surface 
of the unfolded protein, the slight apparent increase of Tm1 DSF observed in presence 
of a surfactant can be explained. However, in HTS a threshold, e.g., set to a thermal 
shift > 1 °C21 suggesting stabilizing or destabilizing conditions should be carefully 
evaluated to avoid misinterpretations when comparing surfactant containing and free 
formulations. 
The precise determination of the apparent Tm via DSF is based upon a significant 
increase of the fluorescence intensity while the protein unfolds. Beside factors of the 
protein itself, e.g., hydrophobic nature and folding, the method also depends on 
experimental factors like concentrations (protein, dye, and excipients), sensitivity of 
the dye, instrumental features, and others. Based on the assumption that the 
recorded fluorescence intensity resembles the sum of the dye’s fluorescence caused 
by interaction with the protein and the surfactant or other excipients, a discrimination 
of the protein related signal and the unwanted background signal should always be 
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possible. In practice, no linear dependence was found and the background 
fluorescence conceals the protein transition at lower protein concentrations. 
Background correction by subtraction of placebo samples is essential to enable a 
precise analysis of the melting transition of the protein. By this means, it was possible 
to determine Tm DSF of lower concentrated MAb solutions (4 mg/ml), even with the 
polarity-sensitive dye SYPRO® Orange in presence of a surfactant. The molecular 
rotor DCVJ rendered melting curves of superior quality and also enabled Tm DSF 
determination in case of PS 80, where SYPRO® Orange failed. The characteristics of 
DCVJ and its correlation with SYPRO® Orange, background signals of the 
surfactants, the process of background correction, and further Tm analysis will be 
discussed in the sections below. 
5.5.2 Comparison of the fluorescent dyes SYPRO® Orange and DCVJ 
DSF is based on the environmental sensitive property of a fluorescent dye. Typically 
polarity sensitive dyes are used, which are quenched in aqueous polar media and 
show low fluorescence intensity. Upon protein thermal unfolding, hydrophobic 
residues typically resting within the core of the native protein get exposed to the 
solvent. SYPRO® Orange and other polarity sensitive dyes bind to hydrophobic 
patches and the fluorescence intensity increases. The transition from low intensity of 
the native, folded protein and the high intensity after unfolding is analyzed to 
determine the temperature at which 50 % of the protein is in its unfolded state. The 
highest fluorescence intensity does not necessarily indicate the state at which the 
protein is completely unfolded. The hydrophobic patches, which are responsible for 
the interaction with SYPRO® Orange, also favor protein aggregation and may be 
capped by intermolecular interactions.17 Additionally, multiple domains and binding 
sites per protein molecule with different dye affinity and also the depletion of unbound 
dye at high protein concentration might add to the effect that the transition observed 
in DSF occurs at lower temperature compared to the Tm DSC (Figure 5-2). To 
distinguish DSF from calorimetric methods, other authors suggest a different 
nomenclature, such as “apparent melting (point) temperature”23 or “temperature of 
hydrophobic exposure”.24,25 The different affinity of the presented dyes even 
complicates the interpretation of the thermal events and consequently in simple 
analogy the term “Tm DSF” was chosen. Free rotation of the dicyanovinyl moiety of 
DCVJ allows TICT and the molecule leaves the excited state predominately by 
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radiationless deactivation.29 Instead, fluorescence is favored when intramolecular 
rotation is limited, e.g., in highly viscous media or the rigid microenvironment of 
unfolded or aggregated protein.30 Hawe and coworker used DCVJ and the related 
CCVJ to detect heat induced aggregates in IgG formulations. They found molecular 
rotor dyes superior in comparison to polarity-sensitive dyes like ANS, Bis-ANS, and 
Nile Red especially in formulations containing polysorbate.31 In surfactant-free 
environments, DCVJ was successfully used for DSF by Li et al. recently.23 They 
claimed a good correlation between the Tm values determined with both dyes, but no 
data was presented.23 The results of this study also support the reported linear 
correlation, even in presence of surfactants (Figure 5-2 B). This suggests that both 
dyes show a similar sensitivity to structural changes upon thermal unfolding of the 
mAb. As presented in Figure 5-4 and described by other authors for SYPRO® 
Orange, the fluorescence intensity of both dyes typically drops after the final 
transition of the unfolded protein. This decrease was, on the one hand, supposed to 
be due to protein aggregation by hydrophobic protein-protein interactions reducing 
the hydrophobic surface available for dye binding17,22 and, on the other hand, 
assumed to be caused by common temperature quenching which was shown by He 
et al. for SYPRO® Orange in a hydrophobic environment (Isopropanol and 
chemically unfolded protein by guanidine hydrochloride).24 Yet et al. additionally 
attributed a second exponential decay to the disassociation of the dye from the 
micelles with increasing temperature.16 In case of DCVJ, higher temperatures lead to 
an accelerated TICT and lower viscosity of the solution, which both favor nonradiative 
solvent relaxation. Aside from temperature, excipients, pH, protein concentration, 
aggregation, and other protein-protein interactions strongly influence the viscosity of 
the solution.25,37,38 In preceding experiments, it was shown for this mAb via turbidity 
measurements that strong aggregation of the protein occurred exactly at Tm2 DSF.
39 
Protein aggregation might therefore explain the different sensitivities of both dyes 
towards Tm2 DSF. Although the fluorescence intensity is decreased in case of 
SYPRO® Orange by depletion from the hydrophobic patches that are prone to 
aggregate, a resulting change in microviscosity by aggregation might be responsible 
for the clear Tm2 DSF with DCVJ. Further investigation on the mechanism of interaction 
between the fluorescent dye, the protein, and the solution especially with respect to 
viscosity at elevated temperatures is necessary but is beyond the aim of this article. 
In addition, weaker fluorescence intensities of DCVJ compared to SYPRO® Orange 
5. High-throughput Tm analysis of a mAb by DSF in the presence of surfactants 
113 
in the same samples were detected, which Li and coworkers related to the 
suboptimal excitation and emission filters for DCVJ used by the RT-PCR machine.23 
RT-PCR optics is usually optimized for intercalating dyes to track the amplification of 
nucleotides. Excitation and emission filters are conveniently limited to a certain set of 
wavelength. In this study, a RT 7300 RT-PCR equipped with the standard excitation 
and emission filters was used. Excitation wavelength is fixed to about 490 nm and 
four emission wavelengths are available, of which the lowest of 530 nm was chosen 
for the detection of DCVJ and 578 nm were selected for SYPRO® Orange because 
of the strongest signal. Whereas the emission maximum of SYPRO® Orange fits 
well, higher fluorescence intensity could be achieved with more appropriate filter sets 
for DCVJ. The resulting higher sensitivity would enable a further reduction of the 
necessary protein concentration. Furthermore, other dyes like the related CCVJ can 
be applied with customized filters as recently presented by Ablinger et al. with G-CSF 
in presence of surfactants.40 But such a hardware change requires careful evaluation. 
5.5.3 The surfactant background signal 
SYPRO® Orange is known to show a bright fluorescence in presence of micelles,41 
which results in a high initial fluorescence intensity. This problem was already 
reported in literature, especially in the field of membrane protein science.16,42-44 To 
overcome this problem, Kean and coworker carefully titrated the free surfactant 
concentration to a level with a sufficient signal-to-noise ratio, at which the 
determination of melting event was possible.43 After this, Senisterra et al. 
demonstrated that DSLS is a suitable alternative to DSF with respect to the 
applicability of high throughput thermal stability screenings in the presence of 
surfactants or notably hydrophobic proteins, such as membrane proteins, because no 
fluorescent probe is needed.42 Mezzasalma and coworker name surfactants 
(including polysorbate) as a parameter of their protein stability profiling, a 
ThermoFluor® assay with customized instrumentation based on ANS, but did not 
present any surfactant-related data.45 As exemplarily presented in Figure 5-4, pure 
buffer systems exhibit marginal fluorescence, whereas surfactants and potentially 
other components lead to a significant background signal as a function of the 
temperature. Calculating the apparent Tm based on the original data without 
subtraction of the background would lead to false results. By using background 
correction, the unique trace of the fluorescent dye response to only protein unfolding 
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is obtained, which is the key for the accurate determination of apparent Tm by DSF. 
By comparing the four placebo formulations, a different behavior of the surfactants 
can be derived. PX 188 shows a sharp and intense fluorescence increase with the 
inflection at about 48 - 50 °C. DSC measurement of the PX 188 containing placebo 
confirms an endothermic transition at similar temperatures (Figure 5-5). The CMC of 
PX 188 and other Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) 
block polymers depends strongly on the temperature. The CMC as a function of 
polymer concentration and temperature decreases with increasing temperature.46 By 
means of light-scattering, Zhou and Chu investigated the transition from the unimer to 
the formation of micelles and found micellar structures above about 50 °C for 1.25 % 
PX 188.47 The additional DLS measurements show an increase of the apparent 
hydrodynamic radius from 2.4 nm to about 8 nm starting at approx. 52 °C, as 
presented in Figure 5-5 for the histidine system at pH 7.2, reflecting the transition 
from single polymer coils to micelles. Hydrodynamic radii as well as the critical 
micellization temperature (CMT) are in excellent agreement with the results found by 
Zhou and Chu47 and the theoretical CMT of an aqueous solution of 0.84 % PX 188, 
which can be calculated as 50.49 °C based on the empirical correlation presented by 
Alexandridis et al.48 This temperature induced micelle formation can be explained by 
enhanced dehydration of PX 188 with increasing temperature, which results in an 
increasing aggregation number.47 This process can be clearly traced with DSF with 
both fluorescent dyes. Poloxamers were already investigated by means of a 
fluorescent environmental probe (DPH) by Alexandridis et al. in a common cuvette 
spectrofluorimeter but not in HTS using RT-PCR machines.49  
Both PS 20 and PS 80 show similar background traces. Starting at very high initial 
fluorescence intensity, the value decreases with increasing temperature. This holds 
true for both dyes although the decline by temperature dependent quenching is much 
more pronounced with SYPRO® Orange. Surfactant concentrations of the PS 20 and 
PS 80 were chosen to be approx. 25 times above the corresponding CMC at room 
temperature.50 It is reported that the CMC is decreased in buffered solutions due to 
the ionic strength of the salts,51 also for nonionic surfactants.52 Because of the 
binding of surfactant molecules to the protein surface, the CMC can also be 
increased, although hydrophobic interactions of nonionic surfactants are likely to be 
weak compared to the electrostatic interactions of charged detergents like SDS.53,54 
Surfactant concentrations were chosen in the range of marketed products. Referring 
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to literature, concentrations of PS 20 and PS 80 in biopharmaceutical products are 
usually between 0.0003 - 0.3 % (w/v).27 PX 188 is stated to be preferably used in 
amounts of 0.001 – 1 % (w/v).55 
5.5.4 Background correction and Tm analysis 
The Boltzmann function was reported by many authors to be an adequate tool to 
determine the apparent Tm from the melting curves obtained by DSF.
13,15,17,18 The 
Boltzmann function describes a two stage one-step reaction (folded ↔ unfolded). The 
equation is valid only for reversible reactions. The results reported in literature 
demonstrate that it is applicable in most cases, although protein unfolding is typically 
an irreversible or multistep reaction. Other authors used more complex models to 
describe the underlying thermodynamic processes, and thus, by fitting the data to 
these equations, additional information on the enthalpy of unfolding or binding 
constants can be derived in addition to the melting temperature.9,12,19,45,56 Other 
groups determine the apparent Tm by analysis of the first
14,16,24,25,57 or second22,23 
derivative of the obtained melting curves. Describing the slope of the melting curves, 
the peak centers of the first derivative reflect the steepest ascensions of the raw 
melting curve. Preceding experiments showed that the first derivative is typically in 
very good agreement with the inflection point of the fitted Boltzmann function. In case 
of the surfactant containing solutions, it also turned out that the first derivative 
method is more robust. Especially in situations wherein the data resulted in a poor fit 
because of small transitions, analysis of the first derivative resulted in closer and 
more reproducible results. Data analysis is a major aspect of successful DSF 
experiments with common RT-PCR machines, because further processing of the 
fluorescence intensity readings has to be performed by the user. A user-friendly 
solution would push the application of DSF. Just recently, Wang and coworker 
proposed a Java-based application to simplify data analysis of DSF experiments.58 
Niesen also provided a free Microsoft Excel® template to facilitate Tm analysis for a 
set of RT-PCR machines.59 The advantage of using scientific graphing and analysis 
software like Origin® in combination with scripting languages (LabTalk) is the control 
of every single parameter and the analysis can be adapted to the experimental needs 
like subtraction of background data, nonlinear fitting, or triplicate handling. 
Particularly, the feature to automatically process placebo samples and subtract the 
fluorescence from the corresponding protein signals is a key feature to analyze Tm DSF 
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in the presence of a surfactant in high-throughput fashion. However, a reasonable 
effort has to be taken initially to implement such an algorithm (see Appendix for the 
OpenTM LabTalk script). 
Using a different algorithm based on the area of a Gaussian fit, King et al. calculated 
the onset temperature at which 1 % of the protein is unfolded (T1%).
26 The authors 
found that T1% is a more powerful predictor for protein stability than the common 
midpoint values. Additionally, T1% as low as body temperature was found, meaning 
that a small amount of the protein is likely to be unfolded in vivo while Tm was well in 
an acceptable range. Thus, Tm,onset should be monitored on a routine basis in addition 
to Tm. The presented empiric equation to calculate the onset temperature is based on 
the fitted parameters of the Boltzmann equation (T’m, dT, AL, and AU) (chapter 3.3.2). 
Depending on the slope factor of the transition, Tm,onset is affected by the process of 
background correction as exemplarily illustrated in Figure 5-6. Although the analysis 
of the first derivative is less affected by the background correction procedure, in case 
of excipients with significant influence on the fluorescence intensity, the Tm of the 
protein might be overestimated. Although Tm1 DSF did not change markedly, Tm,onset 
might be shifted significantly making careful background correction particularly 
important. 
5.6 Summary and outlook 
Surfactants are challenging in DSF because the fluorescent dye can interact with 
micellar structures, and the resulting background fluorescence disturbs the analysis 
of the unfolding protein. With careful background correction by subtraction of the 
background fluorescence of placebo formulations from the protein melting curves, the 
apparent Tm of the protein can be analyzed even in the presence of PS 20, PS 80, 
and PX 188. The obtained Tm DSF values were in good agreement with DSC 
measurements, and a linear correlation for Tm1 with and without surfactant was 
presented. Thermal shifts of Tm1 due to formulation parameters followed common 
trends with destabilization of the mAb at low pH with and without sodium chloride, 
whereas mannitol was found to be slightly stabilizing. Tm DSF analysis in the presence 
of PX 188 was notably difficult, because the temperature dependent micellization of 
PX 188 resulted in a misleading and disturbing signal in DSF, which was confirmed 
by additional DSC and DLS measurements. DCVJ enabled the determination of 
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Tm DSF in the presence of surfactants in many cases where SYPRO® Orange failed 
and showed superior melting curves in higher protein concentrations. Its fluorescence 
as a molecular rotor is predominantly depending on the viscosity and spatial 
restriction, whereas the commonly used SYPRO® Orange and other polarity 
sensitive dyes show fluorescence in nonpolar environment also present in micelles. 
This benefit is limited by a lower sensitivity of DCVJ than that of SYPRO® Orange 
regarding the protein concentration.  
5.7 Conclusion 
We recommend using DCVJ for Tm DSF analysis if surfactants are present and the 
protein concentration is high enough to achieve an adequate fluorescence signal. 
This protein concentration also depends on the used RT-PCR machine. SYPRO® 
Orange is necessary for low protein concentrations in the absence of surfactants and 
possibly at a lower surfactant content. The occurring background fluorescence should 
be corrected by subtraction of a placebo sample in all cases with both dyes. 
Background correction had minor influence on the inflection point but enabled the 
determination of correct Tm onset values. Furthermore, the empiric equation for Tm onset 
calculation based on the common Boltzmann fit is beneficial for automatized data 
analysis enabling an easy routine analysis of Tm onset. The high-throughput fashion of 
DSF with low consumption of time and material is now adaptable to a more flexible 
and comprehensive screening including surfactants that are typically used as 
stabilizing agents. Therefore, this method may find its application during the 
development of therapeutic biologics in either surfactant containing formulations or 
inherently hydrophobic proteins. 
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6 Temperature-ramped studies on the aggregation, unfolding, and 
interaction of a therapeutic mAb 
This chapter has been published as Tim Menzen and Wolfgang Friess, 2014, 
Temperature-ramped studies on the aggregation, unfolding, and interaction of a 
therapeutic monoclonal antibody, J Pharm Sci 103(2): 445-455. 
6.1 Abstract 
Investigations on thermal behavior are essential during the development of 
therapeutic proteins. Understanding the link between thermal unfolding and 
aggregation might help to minimize conformational and colloidal instabilities. In this 
study, a therapeutic monoclonal antibody and its Fab and Fc fragments were 
investigated. The apparent melting temperature of a protein and its onset were 
determined by differential scanning fluorimetry. Temperature-ramped turbidity 
measurements were performed to assess the temperature of aggregation, where 
large protein particles occurred. The formation of small aggregates was monitored 
and the interaction parameter kD at low, ambient, and high temperature was 
calculated by temperature-ramped dynamic light scattering. Transformation of kD into 
A2
* based on literature findings allowed the interpretation of net repulsive or attractive 
conditions. Repulsive net charges at low pH increased the colloidal stability, although 
a reduction of the conformational stability was observed. At neutral conditions and in 
the presence of salt, unfolding was followed by precipitation of the protein. A sharp 
decrease of kD and negative A2
* values suggest that the aggregation was driven by 
hydrophobic interactions. Thus, the presented methods described and explained the 
thermal behavior of the protein and demonstrated their value for the development of 
pharmaceutical protein products. 
6.2 Introduction 
The therapeutic and commercial success of protein drugs, especially monoclonal 
antibodies (mAbs), is well known today. The development of new drugs, biosimilars 
of marketed products, or other forms such as antibody drug conjugates (ADCs), is 
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still challenging because of the outstanding complexity of the stability and function of 
the protein molecule.1 mAbs commonly face different types of instability reactions, 
including chemically altered material, changed conformational structures, or the 
formation of native or nonnative protein aggregates.2-5 All of these instabilities can 
reduce the efficiency and safety of the product. For example, immunogenic reactions 
in patients are assumed to be caused by “altered protein,” although clear evidence is 
still lacking and the topic is in hot discussion.6,7 It is reasonable to minimize the 
occurrence of unwanted altered protein during the development of a protein drug. 
Spectroscopic methods such as fluorescence, ultraviolet-visible (UV-Vis), circular 
dichroism, and Fourier-transform infrared spectroscopy are typically applied to 
characterize the conformational structure of the protein.8 Additionally, a thermal 
analysis by differential scanning calorimetry (DSC) or differential scanning fluorimetry 
(DSF) reveals the apparent melting temperature (Tm) of a protein, which is commonly 
linked to the overall thermal stability of the protein.9-12 Because of the vast distribution 
of particle size, many methods are necessary to describe protein aggregates 
comprehensively. Typically, high performance size exclusion chromatography (HP-
SEC) and light scattering techniques are applied for small, soluble aggregates; 
nanoparticle tracking analysis, light obscuration, and microflow imaging are applied 
for subvisible particles; and visual inspection is applied for large particles, to name 
some prominent examples.5,13 
A net attraction between protein molecules leads to aggregation although multiple 
individual forces are involved. The interaction potential is composed of long 
(Coulomb) and short range forces (van-der-Waals, solvation and hydrogen-bonds, 
hard-sphere repulsion/excluded volume, and other specific interactions).14,15 Instead 
of assessing each single force, a common approach is the determination of the 
osmotic second virial coefficient A2 from the parametric expansion of the osmotic 
pressure (also referred to as B22). A2 describes the deviation from the ideal solution 
due to overall pairwise molecular interactions between the particles.16 Although 
crystallization and solubility were thoroughly investigated in relation to A2 for many 
proteins,17-25 research on mAbs focused mainly on the effect of intermolecular 
interactions at the low concentration on the viscosity of highly concentrated mAb 
solutions. Saito and coworker demonstrated that A2 is dependent on the surface 
properties of mAbs, and a high negative A2 value correlated with a high viscosity of 
concentrated mAb solutions, and an increased tendency of the mAb for aggregation 
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due to the attractive interactions.26 Also, a strong correlation between A2 and the 
viscosity of highly concentrated mAb solutions was found by Connolly et al.27 They 
concluded that weak interactions are responsible because the net charge of the mAb 
was in no correlation.27 In their work, the assessment of A2 via static light scattering 
(SLS) or analytical ultracentrifugation (AUC) is of low throughput and other methods 
such as self-interaction chromatography (SIC) have been proposed to reduce time 
and material consumption.24,28-31 Yadav and coworkers recently published a different 
approach to determine A2 based on measurements only using a dynamic light 
scattering (DLS) instrument.32 With careful consideration of the attenuation factor, the 
recorded scatter intensity signal is used to create Debye plots to calculate A2. 
Although this elegant approach enables A2 measurements in a single machine, it is 
limited by a low throughput and cannot be adopted to well plate readers. On the 
contrary, the diffusion interaction parameter kD, which is easily accessible via DLS, is 
used as an alternative screening parameter. The kD value can be expressed as 
33 
         (       ) (6-1) 
where A2 is the osmotic second virial coefficient, M is the molar mass of the protein, 
ζ1 is the coefficient from the linear term of the virial expansion of the concentration 
dependent friction coefficient, and υsp is the partial specific volume of the protein. 
Thus, the kD value consist of a first, thermodynamic part expressed by A2 and a 
second, hydrodynamic part. To determine kD, the mutual diffusion coefficient D is 
determined for several dilutions of the protein sample. From the slope of the linear fit 
to the data points, kD can be determined based on the following equation 
     (     ) (6-2) 
where D is the mutual diffusion coefficient, D0 is the diffusion coefficient at infinite 
dilution, and c is the protein concentration. 
Yadav and coworkers investigated the interactions of mAbs at low ionic strength and 
suggest that close to the isoelectric point (pI), specific attractive forces are 
responsible for self-association and also lead to high viscosity in high mAb 
concentrations, although a correlation to kD was not found under these latter 
conditions.34 Chari et al. involved kD measurements to demonstrate that at high mAb 
concentrations and low ionic strength, both long-range and short-range electrostatic 
interactions are responsible for viscosity effects.35 Although long-range electrostatic 
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interactions were responsible for mAb aggregation at low concentration, Kumar and 
coworker found that at high mAb concentrations, short-range hydrophobic 
interactions predominate the aggregation kinetics.36 Although Arzenšek and coworker 
intensively investigated the effects of pH and ionic strength on kD by the addition of 
sodium chloride,37 Rubin et al. recently studied the aggregation of a mAb with respect 
to the ionic strength from salts of the Hofmeister series.38 They found that a lower kD 
value is suggestive for a lower relative colloidal stability of the mAb.38 However, 
because of the hydrodynamic component, the sign of kD does not indicate net 
attractive or net repulsive intermolecular interaction.26 Lehermayr et al. and also 
Connolly et al. present a linear fit of the data to transform kD into A2.
27,39 In this article, 
a linear fit was performed on the united data set of A2 and kD values published in 
literature on mAbs to obtain an equation to transform the interaction parameters. This 
equation was used to estimate the thermodynamic interaction parameter (A2
*) and 
thus the net attraction or net repulsion. 
To understand the role of intermolecular interactions during the process of thermal 
unfolding and aggregation of mAbs, kD and A2
* values were investigated at low, 
ambient, and elevated temperature by DLS. The absolute values and their change 
upon heating were used to interpret the results from DSF regarding the 
conformational stability and the exposure of hydrophobic patches upon unfolding. 
The results from the DLS and temperature-ramped turbidity experiments were linked 
to characterize and interpret the aggregation behavior. Additionally, the Fab and the 
Fc domain were isolated to study the influence of the individual domains on the 
overall stability of the mAb. A strong effect of pH and ionic strength was observed. At 
the low pH of 5.0 and low ionic strength, a high kD value was observed suggesting 
strong electrostatic repulsion, which prevented the protein from precipitation. Despite 
this colloidal stabilization, a reduced conformational stability was found with respect 
to the negative shift of the Tm value compared with the neutral pH. At pH 7.2 and 5.0 
in the presence of salt, lower kD values were found. Furthermore, different 
aggregation behaviors for Fab and Fc or the full mAb were observed. In the case of 
Fab, kD values did not change with increasing temperatures until presumably minimal 
perturbation of the structure below the onset temperature of unfolding resulted in 
substantial aggregation. In the case of Fc and the full mAb, unfolding and 
aggregation coincided at similar temperatures and were associated with a reduction 
of kD suggesting that the conformational change induced new interaction spots. At the 
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neutral pH or when the charges were shielded in the presence of a salt at the low pH, 
precipitation of the protein occurred. 
6.3 Materials and methods 
6.3.1 mAb fragmentation and protein formulation 
A therapeutic monoclonal antibody of IgG1 type produced in CHO cells (“MAb”) was 
digested with 0.1 % (w/w) of papain from papaya latex (Sigma Aldrich, Steinheim, 
Germany) in a 40 mM histidine buffer containing 10 mM cysteine and 2 mM disodium 
ethylenediaminetetraacetic acid at pH 7.0. The mixture was incubated for 24 h at 
37 °C and the reaction was stopped by the addition of an aqueous iodoacetamide 
solution to reach a concentration of 40 mM iodoacetamide. To isolate the fragments, 
the mixture was purified by chromatography using an ÄKTA purifier 10 system (GE 
Healthcare, Uppsala, Sweden) and ultrafiltration steps. First, all Fc carrying species 
were retained by protein A affinity chromatography using a 5 ml Pierce protein A 
cartridge (Thermo Fisher Scientific, Bonn, Germany). Second, size exclusion 
chromatography (SEC) using a Sephacryl® 16/60 column (GE Healthcare) was 
performed to separate Fc from residual full MAb or partly fragmented MAb. Finally, 
the protein was dialyzed by means of Vivaspin® 20 tubes with a 10 kDa molecular 
weight cut-off PES membrane (Sartorius Stedim Biotech, Göttingen, Germany) to 
remove all low molecular weight species with the target formulation buffer (10 mM 
phosphate at pH 5.0 and pH 7.2, with or without 140 mM sodium chloride (NaCl) and 
280 mM mannitol). The pH of the samples was adjusted and filtration was performed 
using 0.2 µm syringe filter (Pall, Port Washington, New York, USA). The protein 
concentration was determined using an extinction coefficient of 1.49 ml g-1 cm-1. 
Isoelectric focusing using a Servalyt Precotes® gel (Serva Electrophoresis, 
Heidelberg, Germany) resulted in isoelectric points (pI) between 8.3 - 9.5 for the full 
MAb, 9.5 - 10.7 for Fab, and 6.9 - 7.8 for Fc. The purity of the isolated Fab and Fc 
fragments was confirmed by hydrophobic interaction chromatography using a 
TSKgel® Phenyl-5PW column (Tosoh Bioscience, Stuttgart, Germany) on an Agilent 
1200 series HPLC system (Agilent Technologies, Santa Clara, California, USA) as 
described by Wakankar et al.40 
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6.3.2 Differential scanning fluorimetry (DSF) 
DSF was performed using a RT7300 Real-Time PCR machine (Applied Biosystems, 
Foster City, California, USA) as recently described (chapter 5).41 In short, 20 µl of the 
sample (0.8 mg/ml MAb, 2.6 mg/ml Fab, and 1.3 mg/ml Fc) was pipetted into a 96-
well plate (Applied Biosystems) and 1 µl of an aqueous working solution of SYPRO® 
Orange (Sigma Aldrich) was added to a final dye dilution of 1:5000 in relation to the 
supplied stock solution by the manufacturer. The temperature was increased from 
20 °C to 96 °C at 1 °C/min in steps of 1 °C. The fluorescence intensity at 578 nm was 
analyzed with Origin® 8.0 SR6 (Originlab Corporation, Northampton, Massachusetts, 
USA) regarding the temperature at the inflection point (Tm) and the onset temperature 
of unfolding (Tm,onset) using a nonlinear Boltzmann fit to the melting transitions (see 
also chapter 3.3).41 A placebo sample was used for background correction, and the 
presented values are mean values of three wells. A negative impact of the dye on Tm 
was ruled out as the Tm value of the MAb in 10 mM phosphate buffer pH 7.2 obtained 
by DSC was not significantly changed (ΔTm < 0.1 °C) by either the presence of 1x 
SYPRO® Orange or 0.1 % dimethyl sulfoxide (DMSO) (chapter 4.3.6.2). 
6.3.3 Temperature-ramped turbidity measurements 
Turbidity measurements were performed with an Agilent 8453 UV-Vis 
Spectrophotometer equipped with a Peltier temperature controller (Agilent 
Technologies) in a 500 µl glass micro cuvette with PTFE stopper (Hellma Analytics, 
Müllheim, Germany). Samples of 0.8 mg/ml MAb, 2.6 mg/ml Fab, and 1.3 mg/ml Fc 
were used. The temperature was gradually increased by 1 °C from 20 °C to 97 °C. 
The absorption values at 350 nm were exported and the first derivative of the data 
was calculated and splined with Origin® LabTalk 8.0 SR6. The maximum and the 
onset (10% of maximum) of the interpolated first derivative curve resemble the 
temperature of aggregation (Tagg) and the onset temperature of aggregation 
(Tagg,onset), respectively. 
6.3.4 Dynamic light scattering (DLS) 
DLS measurements were performed in 384-well plates (Corning Incorporated, 
Corning, New York, USA) using a DynaPro plate reader (Wyatt Technologies, Santa 
Barbara, California, USA). A triplicate of three wells was measured for every sample 
with 20 acquisitions of 2 s for every well. The machine was cooled with gaseous 
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nitrogen, and a temperature protocol was applied starting with 4 °C, 8 °C, and 10 °C, 
followed by a stepwise increase by +5 °C up to 85 °C. The DYNAMICS® software 
version 7.1.7.16 (Wyatt Technologies) was used to analyze the recorded 
autocorrelation function by means of cumulants analysis to determine the diffusion 
coefficient (D) and the derived hydrodynamic radius (Rh) via the Stokes-Einstein 
equation. For phosphate buffers with and without NaCl, a viscosity of 1.019 mPa s at 
20 °C and a refractive index of 1.333 were used. The viscosity of the 280 mM 
mannitol containing buffers was calculated as 1.017 mPa s at 25 °C according to Liu 
et al.42 and a refractive index of 1.340 as typical for 280 mM sugar solutions was 
applied in the DYNAMICS® software. The effect of the temperature dependent 
reduction of the refractive index was tested based on the findings of Schiebener et al. 
for water.43 The deviation of kD was found to be below 0.1 ml/g when considering a 
heating induced reduction of the refractive index from 1.333 to 1.320. Because of the 
insignificance of this difference, no temperature corrections of the refractive index 
were made. The presented results of Rh are mean values with standard error 
determined from the triplicate sample with a protein concentration in a comparable 
range between 1.2 – 2.5 mg/ml. The measurements were repeated at 4 °C of all 
samples and at 25 °C for the samples at pH 5.0. 
6.3.5 Calculation of the interaction parameter kD and A2 
The diffusion coefficients D of a series of at least seven samples with protein 
concentrations ranging from about 0.4 mg/ml to about 12 mg/ml were determined as 
triplicates by DLS. A linear fit was performed on the D versus protein concentration 
data to obtain the diffusion coefficient at infinite dilution D0. By normalizing D by D0, 
the slope of the linear fit resembles the interaction parameter kD.
38  
6.3.6 Transformation of the interaction parameters of mAbs 
As an alternative to the direct determination of A2, Lehermayr et al. described a linear 
correlation of kD and A2 for several mAbs and suggested using this empiric 
correlation for A2 assessment based on kD from DLS measurements to save time and 
material.39 Connolly et al. confirmed this common linear correlation, although a 
different method for A2 determination was used.
27 As presented in Figure 6-1, the 
combination of the published kD and A2 results for mAbs supports the hypothesis of a 
common linearity between both parameters. 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
130 
 
Figure 6-1. Graphical illustration of the equation for the transformation of the interaction 
parameters of MAbs (TIM). The data points with closed symbols were omitted after DFFITS 
outlier analysis to result in a linear fit (R
2
 = 0.858) across the remaining 93 data points (open 
symbols). The TIM equation (eq. (6-3)) allows the estimation of the thermodynamic interaction 
parameter A2
*
 from kD values from DLS measurements. By this means, estimation of net 
attractive or net repulsive interaction is possible without the experimental determination of A2. 
Thus, based on the published data described in Table 6-1, an equation for the 
transformation of the interaction parameters of mAbs (short “TIM”) was calculated as 
   
  
       
     
 (6-3) 
where A2
* is the estimated osmotic second virial coefficient and M is the molar mass 
of the mAb. As summarized in Table 6-1, a multitude of mAb molecules, buffer types, 
pH, excipient, and analytical methods are included.  
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Table 6-1. Summary of the experimental conditions from literature where kD and A2 of mAbs 
were described.  
Reference 
Number and type of 
mAbs investigated 
Number and type of 
formulations investigated 
A2 deter-
min. by 
Saluja et al. 
(2007) [Pfizer] 44 
1 IgG2 
(pI 8.5..9.25) 
4 
(pH 4 - 9; I=4 - 300 mM) 
SLS 
Saluja et al 
(2010) [Amgen] 45 
1 IgG2 
(pI 8.8) 
10 
(pH 5.5, I=10 - 110mM) 
DLS/ 
AUC 
Lehermayr et al. 
(2011) [Roche] 39 
7 IgG1 (pIs 7.5..10), 
1 IgG4 (pI 6.3-7.8) 
2 
(pH 6; I=20 - 170 mM) 
SLS 
Kumar et al. 
(2011) [Abbott] 36 
1 IgG1 
6 
(pH 4.5, 6; I=1 - 100 mM) 
SLS 
Connolly et al. 
(2012) [Genentech] 27 
6 IgG1, 1 IgG4 
1 
(pH 5.5, I=20 mM) 
DLS/ 
AUC 
Arzenšek et al. 
(2012) [Sandoz] 37 
1 IgG1 
(pI 8.46) 
48 
(pH 3 - 10; I=15 – 175 mM) 
SLS 
Saito et al. (2012) 
[Daiichi Sankyo] 26 
3 IgG1 
(pIs 6.7, 8.8, 8.9) 
4 
(pH 5 - 8; I=150 mM) 
AUC 
The published data is the basis for the transformation of the interaction parameters of mAbs 
(TIM) equation (eq. (6-3)) to estimate A2
*
 from kD measurements. The TIM equation is illustrated 
in Figure 6-1 after the DFFITS outlier test was performed and single measurements were 
omitted from the linear fit as discussed in the text. Experiments were performed at room 
temperature and kD values were obtained by dynamic light scattering (DLS). IgG, 
Immunoglobulin G; pI, isoelectric point; I, ionic strength; SLS, static light scattering; AUC, 
analytical ultracentrifugation. 
Two exceptions are also presented. The results published by Kumar et al. and Saluja 
et al. in their early works exhibit a good linearity but are not in agreement with other 
data.36,44 In the latter case, the A2 values are exactly one order of magnitude too high 
to fit into the correlation but the calculations presented in their article are plausible. 
Because of the large impact of samples, which do not seem to follow the typical 
trend, the DFFITS outlier test was performed on the complete data set (compare 
chapter 4.2.11). In an iterative approach, the sample with the highest absolute 
DFFITS value suggesting a high influence on the linear regression was eliminated 
until all cases were within the outlier threshold of 1.46 By this statistical test, all values 
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of Kumar et al.,36 two values with the lowest ionic strength at pH 3 of Arzenšek et al,37 
and all values but the sample at pH 9 from Saluja et. al. (2007),44 were omitted 
(Figure 6-1). Thus, the data set was reduced from 103 to 92 different constellations, 
which are represented in the TIM equation (eq. (6-3)). Interestingly, extreme cases of 
low pH and low ionic strength seem to be responsible for the observed outliers. 
These cases may show a deviating ζ1 value. This could be due to differences in level 
and distribution of hydration, potential slight changes in protein conformation at 
extreme pH values, or specific salt interaction affecting the overall size and shape of 
the antibody molecules.47 Therefore, the TIM equation is suggested to be only valid in 
the case of moderate pH and ionic strength conditions. The TIM equation should 
allow a quick estimation of the quality of the important net attractive or net repulsive 
interaction based on the thermodynamic parameter A2
* without the experimental 
efforts. It has to be noted that some authors26,27,35,39,45 used the equation postulated 
by Harding and Johnson which contains υsp without the factor of 2 as presented in 
eq. (1-1).48 It is described by Teraoka that this factor corrects for the backflow of 
solvent molecules by diffusion into the voids left by protein molecules.33 However, in 
the context of the presented conversion with respect to the relatively small value of 
the partial specific volume of about 0.730 - 0.739 ml/g for mAbs,26,27,37,49 the 
difference is assumed to be of minor influence on the overall fit. Moreover, Cheng 
and coworker just recently investigated the partial specific volume of an IgG2 at two 
different pH values.50 They found similar values for a citrate-phosphate formulation 
buffer at pH 7.0 and pH 4.0.50 Furthermore, they observed a linear temperature 
dependence of υsp and found that a temperature increase from 10 °C to 50 °C 
resulted in an increase of υsp by about 2 %.
50 These findings suggest that the solution 
conditions show only a minor effect on the partial specific volume of a MAb molecule. 
As expected, the value of 1.19 for the slope of the linear fit (eq. (6-3)) from the TIM 
equation is well within the range of the slope factors reported by Lehermayr et al. and 
Connolly et al. of 1.06 and 1.33, respectively, whose data sets are both included 
(Table 6-1).27,39 This value of 1.19 is lower than expected from the definition in eq. 1. 
This deviation was suggested to reflect a protein shape factor as the antibodies 
deviate from a perfect sphere.39 According to eq. (6-3), the sign of A2
* changes from 
negative (net attraction) to positive (net repulsion) at a kD value of -6.29 ml/g. 
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6.4 Results and Discussion 
6.4.1 Aggregation, unfolding, and interaction of the mAb in 10 mM phosphate 
buffer pH 7.2 
Table 6-2 contains a comprehensive summary of the results of the thermal stability 
analysis. On the example of the MAb formulation in 10 mM phosphate buffer at 
pH 7.2, the results should be explained and discussed in detail. The hydrodynamic 
radius Rh, based on the diffusion coefficient D obtained from the DLS measurements 
at increasing temperatures, and the kD values is presented in Figure 6-2 A. At a MAb 
concentration of 2.2 mg/ml, the Rh was nearly unchanged with increasing 
temperatures from 5.23 nm at 4 °C to 5.15 nm at 60 °C. Starting at 65 °C, the radius 
sharply increased and exceeded 10 nm indicating the formation of small aggregates. 
On the basis of the diffusion coefficients of a dilution series of seven MAb solutions 
between 0.4 and 12 mg/ml, the D0 and kD values were calculated. The diffusion 
parameter at infinite dilution D0 is derived from the intercept of the linear fit of D 
versus protein concentration. At ambient temperature (20 - 25 °C) the D0 results 
between 4.3*10-7 and 4.8*10-7 cm2 s-1 are in good agreement with data published for 
mAbs (compare Table 6-2).34,37,39,44,45,51,52 As illustrated in Figure 6-2 A, D0 increased 
with increasing temperature until it reached a maximum value at 60 °C (T@D0max). 
The observed drop of D0 when exceeding this temperature is linked to the 
aggregation of the mAb resulting in smaller diffusion coefficients due to the increase 
in size as can be seen from the Rh in Figure 6-2 A. This finding suggests that at 
temperatures below T@D0max, the calculated kD value can be assigned to the MAb 
monomer. Above T@D0max, the calculation is spoiled by MAb aggregates, and 
mathematically obtained kD values are incorrect and must not be further interpreted 
or compared with the ones obtained for the monomeric form. As can be seen in 
Figure 6-2 A, the kD value at the initial temperature of 4 °C was about zero 
(0.8±1.2 ml/g). With increasing temperature, the kD value was found to be constant 
until a first small drop occurred at 25 °C (-5.7 ml/g) followed by another plateau up to 
60 °C (-8.6 ml/g) with little changes. Exceeding 60 °C, the kD value dropped sharply 
to about -70 ml/g at 70 °C. With respect to the TIM equation (eq. 3), the A2
* values 
indicate that at the elevated temperatures, the thermodynamic interaction switched 
from net repulsion to net attraction (compare Table 6-2). Furthermore, the melting 
profiles from DSF analysis of the mAb and its Fab and Fc fragment are presented in 
Figure 6-2 B. The graphs demonstrate that at the neutral pH, two prominent unfolding 
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transitions are observed, which can be linked to and identified by the fragments. The 
first transition resembles the CH2 domain of the Fc fragment. The second transition 
of the full mAb is caused by simultaneous unfolding of the Fab and CH3 domain.41 
From the midpoint of the fluorescence transitions tracing the presentation of the 
hydrophobic patches upon unfolding of the protein, the apparent Tm of the protein is 
obtained where half of the accessible hydrophobic patches are exposed. With an 
onset value of 59.3 °C (Tm,onset) and a Tm1 of 68.4 °C, the DSF data suggest that the 
decrease of kD at 60 °C is linked to the unfolding of the protein. The exposed 
hydrophobic patches are assumed to face hydrophobic interactions, which will lead to 
a more attractive net interaction represented by a smaller, i.e., more negative kD and 
negative A2
* value. Moreover, the aggregation of the MAb molecules via the exposed 
hydrophobic patches can explain the decrease in fluorescence intensity after a 
maximum has been passed in DSF. The participation of the hydrophobic surface 
regions in intermolecular interactions results in less interaction with the extrinsic 
fluorescent dye as was originally postulated by Niesen et al.53 Unfolding of the Fab 
domain at about 80 °C (Tm2 = 81.5 °C) is followed by precipitation of the mAb, which 
is confirmed by an increase in turbidity (Tagg = 79.5 °C) and a decrease in 
fluorescence intensity (Figure 6-2 B). After filtration through a 0.2 µm PVDF filter, a 
clear solution was obtained with baseline value for A350nm and 96±1 % of the protein 
was removed as calculated from A280nm. Thus, the MAb precipitate after heating to 
97 °C consisted predominately of large particles. 
A 
 
 B 
 
Figure 6-2. Hydrodynamic radius Rh (circles), interaction parameter kD (black squares), and 
diffusion coefficient at infinite dilution D0 (open triangles) as a function of temperature on the 
example of the mAb in 10 mM phosphate buffer at pH 7.2. The lines should guide the eye. (A). 
Exemplary melting profiles obtained by DSF of the full MAb, its isolated Fab and Fc fragments, 
and a 2:1 mixture of Fab and Fc in 10 mM phosphate buffer at pH 7.2. The Tm values obtained 
by first derivative analysis are marked with crossed circles (B). 
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6.4.2 Aggregation, unfolding, and interaction of the mAb at other pH and ionic 
strength conditions 
The results for the mAb in the other formulations are in good agreement (Table 6-2 
and supplementary Figure 6-4 in chapter 6.8). The addition of 140 mM NaCl or 
280 mM mannitol to the 10 mM phosphate buffer at pH 7.2 showed the same trend. 
For all the three formulations at the neutral pH the Rh values were below 10 nm up to 
the T@D0max of 65 °C. With the Tm1 values closely settled between 67.3 and 69.4 °C, 
the excipients showed only a minor influence on the conformational stability at 
pH  .2. Mannitol was found to be slightly stabilizing with ΔTm1 of about +1.0 °C, 
whereas the addition of NaCl destabilized the mAb with ΔTm1 of -1.1 °C. As can be 
seen in Figure 6-3 A, at the neutral pH, the kD value decreased dramatically when the 
protein started to aggregate and negative A2
* occurred. Precipitation of the mAb 
occurred at approx. 80 °C, which coincides with the second melting transition of the 
mAb. This finding suggests that aggregation driven by attractive hydrophobic 
interactions of the full mAb is linked to the unfolding of the Fab and the CH3 domain. 
As the pH value is lowered to 5.0 and the mAb net charge becomes positive, the 
outcome is different. In 10 mM phosphate buffer at pH 5.0 without any excipient, the 
kD value was calculated as 37.1±2.1 ml/g at 4 °C. This strong net repulsion prevented 
the mAb from forming large aggregates as indicated by an Rh value still below 10 nm 
at 80 °C and by an absent increase in turbidity. The same results were obtained after 
the addition of mannitol. The neutral sugar alcohol did only slightly reduce the kD 
value (34.6±2.1 ml/mg) and had a minor stabilizing effect on the conformational 
stability (ΔTm1 = 1.6 °C) but did not change the aggregation behavior. Similar to the 
findings at pH 7.2, the kD values decreased with the onset of unfolding but A2
* values 
were always positive (Table 6-2 and Figure 6-3 A). These findings suggest that the 
hydrophobic patches, which are exposed upon unfolding, mediated attractive 
intermolecular hydrophobic interactions and reduced the overall net repulsion but the 
electrostatic interaction still dominated. In contrast, the presence of 140 mM NaCl 
dramatically reduced the kD value to -1.5±1.0 ml/g already at 4 °C suggesting 
interaction forces similar to the conditions at neutral pH. Additionally, strong 
precipitation was observed by turbidity measurements. These findings suggest that 
the repulsive positive net charges that prevented the aggregation were shielded by 
the addition of the salt. Saluja et al. observed that already above an ionic strength of 
40 mM, kD values were leveled independent of the pH of the solution.
44 At pH 5.0, 
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Arzenšek and coworker presented kD values of 36 ml/g and -4 ml/g for 15 mM and 
175 mM, respectively, and kD values between -3 ml/g and -10 ml/g at neutral pH,
37 
which is in good agreement with our results. This confirms that at the applied ionic 
strength of 150 mM of the NaCl containing buffer mimicking physiological conditions, 
repulsive electrostatic forces are effectively shielded. Furthermore, the low pH 
significantly affected the conformational stability of the mAb. The apparent Tm values 
were several degrees lower at pH 5.0 compared with pH 7.2 (Table 6-2). The addition 
of NaCl to the MAb formulation at pH 5.0 resulted in a negative shift of Tm1 (ΔTm1 
= -3.3 °C) with Tm,onset as low as 48.6 °C. He and coworkers also observed a 
destabilizing effect of low pH and the addition of NaCl in their Tm screening of 
mAbs.10 
6.4.3 Investigation of the isolated Fab and Fc fragments 
Especially for the CH2 domain of the Fc fragment, a strong pH dependence of the 
thermal stability is known54-57 and the apparent Tm value of the Fc decreased by 
6.7 °C when the pH value was changed from pH 7.2 to pH 5.0 (Table 6-2 and 
supplementary Figure 6-5 and 6-6 in chapter 6.8). In contrast, the apparent Tm of the 
Fab fragment was increased by 1 °C at the low pH, and the overall high apparent Tm 
values of about 80 °C suggest that the conformation of the Fab part is rather robust 
against heat and charge effects. Interestingly, a marked change in Rh of the Fab 
fragment was already observed at 55 °C and 60 °C at neutral pH and in the presence 
of salt. This indicates that aggregation occurred at temperatures considerably below 
the onset of unfolding of the Fab fragment. Additionally, the kD values of the Fab 
monomer were constant and close to zero (Table 6-2 and Figure 6-3 B). Thus, the 
aggregation of Fab was initiated presumably by minimal structural perturbation. At the 
low pH of 5.0 without the shielding effect of NaCl, no Fab precipitation was observed, 
and Rh was still below 10 nm at 80 °C, although the kD value decreased at higher 
temperatures and negative A2
* values occurred. This might be a hint that the TIM 
equation is valid only for the full mAbs and cannot be transferred to individual Fab 
fragments. In contrast to the Fab part, the Fc fragment showed similar behavior as 
the full mAb. The CH3 transition was not observed by DSF in the case of the isolated 
fragment but was confirmed by DSC experiments (chapter 4.3.2). The formation of Fc 
aggregates started at the same temperature as the midpoint of protein unfolding (Tm 
≈ T@Rh < 10 nm; Table 6-2). Accompanied by the onset of unfolding of Fc, the kD 
6. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic mAb 
137 
value dropped sharply and negative A2
* values occurred at T@D0max, which suggests 
attractive forces favoring the aggregation that are presumably induced by the 
conformational change. Therefore, it is likely that the exposed hydrophobic patches 
of the lower melting CH2 domain are responsible for triggering the aggregation upon 
heating. As aggregation proceeds above T@D0max, the kD value cannot be discussed 
beyond this point. 
A 
 
 B 
 
Figure 6-3. Interaction parameter kD at selected low, ambient, and high temperatures of the 
mAb (A) and the Fab and Fc fragments (B) in various 10 mM phosphate buffer formulations at 
pH 7.2 and pH 5.0 with or without 140 mM sodium chloride. 
Because of the homology of the Fc part for all human or humanized mAbs, one might 
assume that changes in thermal stability of the full mAb can be related to the Fab 
part. As was demonstrated for the mAb in this study, the thermal stability of the full 
protein is not reflected by simply summing up the behavior of the two separated 
fragments (compare Figure 6-2 B and also Table 6-2). The higher Tm1 and Tm,onset 
values of the first transition suggest a mutual stabilization of the Fc domain in the full 
mAb. Furthermore, the influence of hydrophobic interactions upon unfolding on Fab 
and Fc differed. With the exception of the strong repulsive conditions at pH 5.0 and 
low ionic strength, all samples finally precipitated at high temperature. The Tagg value 
corresponded to Tm2, which points to the fact that precipitation occurs after unfolding 
of the Fab and or the CH3 domain. 
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6.4.4 Interpretation of kD at elevated temperatures 
The kD value was also investigated by Rubin and coworkers at 25 °C, 35 °C, and 
45 °C in a study on the influence of Hofmeister salts on mAb aggregation.38 They 
observed that the formulation induced differences of kD diminished at the elevated 
temperatures and therefore suggested that kD measurements are supposed to be 
performed at ambient temperatures.38 As was demonstrated in this study, the 
analysis of kD at even higher temperatures allowed the interpretation of aggregation 
and interaction in combination with conformational stability. A similar temperature-
ramped DLS experiment was performed by Kenrick and Some, recently.58 They also 
observed a drop of kD at temperatures where Rh of the protein increased.
58 Because 
of the increased Rh due to aggregation, we emphasize the interpretation of kD values 
only up to T@D0max where the protein is still in its monomeric form. It would be 
interesting to investigate kD at temperatures beyond T@D0max to analyze the 
interaction between the aggregates. But the inhomogeneity of the aggregate 
population and a nonlinearity of D, e.g., due to concentration dependent aggregation 
kinetics even in the diluted state create major hurdles. One option to investigate the 
interaction parameter of oligomers was presented by Printz et al. using HP-SEC in 
combination with subsequent online SLS/UV detection but this method is only 
suitable for small soluble aggregates.59 Interestingly, they found A2 values of induced 
dimers and small oligomers that were close to the value of the monomer. 
6.4.5 Temperature-ramped analysis for pharmaceutical protein formulation 
development 
During formulation development of a therapeutic protein, material and time 
consumption are important factors of any analytical method. Table 6-3 compares the 
investigated methods with respect to these parameters and suggests a value for 
pharmaceutical formulation development. The analysis of Tm is essential for the 
assessment of the conformational stability of the protein. It also allows the 
investigation of mAb domains, which can unfold individually or show a cooperative 
unfolding. The advantages of DSF compared with conventional DSC are the high-
throughput design with small sample volumes and short analysis times, which 
renders this method essential for formulation development. DSC is needed for the 
detailed thermodynamic characterization based on heat capacity data with high 
resolution of all unfolding events or when excipients like surfactants challenge the 
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application of DSF, although the gaps for application are closing.41,60,61 Furthermore, 
DSF in combination with kD and A2
* analysis at higher temperatures helps to 
understand the link between unfolding, intermolecular interactions, and aggregation 
upon heating. 
Table 6-3. Overview of the thermal stability parameters assessed in this study.  
Analytical 
method 
Outcome 
parameter 
Outcome 
Material and time 
consumption 
(on the example 
of this study) 
Value for 
pharm. 
formulation 
develop. 
DSF 
Tm, Tm,onset 
Conformational stability; 
exposure of hydrophobic sites 
upon thermal unfolding 
3x 20 µl = 
48 µg 
Time: low 
Essential 
DLS 
kD 
Net intermolecular interactions; 
prediction of aggregation 
tendency,26,36,47,62 viscosity at 
higher concentration,26,34,44,52 
crystallizability17,18,21,22,25 
7x (3x 30 µl) = 
8.5 mg 
Time: medium 
Essential 
DLS 
(Temp.-ramped) 
kD (T) 
Interaction tendency at higher 
temperature and upon thermal 
unfolding 
7x (3x 30 µl) = 
8.5 mg 
Time: high 
Remarkable 
DLS 
(Temp.-ramped) 
Rh (T) 
Conformational stability; small 
aggregates upon thermal 
unfolding; association of native 
protein at higher temperature in 
combination with DSF 
3x 30 µl = 
108 - 225µg 
Time: 
medium/high 
Essential 
UV-Vis 
(Temp.-ramped) 
Tagg, Tagg,onset 
Conformational stability; small 
aggregates upon thermal 
unfolding 
1x 500 µl = 
400 µg 
Time: high 
Beneficial 
Material and time consumption is based on the methods as used. The value for pharmaceutical 
formulation development is discussed in detail in the text. 
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Additionally, this temperature-ramped DLS measurement enables to observe the 
formation of small aggregates. In combination with the conformational stability data,12 
and HP-SEC data for small aggregates from stress tests at elevated temperatures, a 
detailed understanding of the aggregation behavior can be achieved. Although the 
importance of the interaction parameters with respect to aggregation,26,36,45,62 
viscosity at higher concentration,26,34,44,52 and crystallization17,18,21,22,25 prediction was 
demonstrated many times, the use of kD at higher temperatures for the prediction of 
storage stability needs to be evaluated in future studies. Another aspect is the 
occurrence of large aggregates, which can be addressed by temperature-ramped 
turbidity measurements. The absence of large aggregates is a critical quality attribute 
of a protein product as demanded by the pharmacopoeias. Preliminary tests showed 
that the sample volume can be strongly reduced with the use of a 50 µl submicro 
glass cuvette (Hellma Analytics, Müllheim, Germany) compared with a standard 
cuvette (Tagg (500 µl, n=3) = 79.5±0.1 °C, Tagg (50 µl, n=3) = 79.3±0.1 °C; 0.8 mg/ml 
MAb in 10 mM phosphate buffer pH 7.2). High-throughput screenings of Tagg with 
small volumes can be performed with a temperature-ramp-controlled multiwell plate 
reader. 
6.5 Summary 
To investigate the intermolecular interactions during thermal unfolding and 
aggregation of a mAb and additionally its Fab and Fc fragments, several protein 
stability parameters were investigated and compared. First, the Tm and Tm,onset values 
were determined by DSF to obtain the information of the process of unfolding. An 
analysis of the cleaved mAb allowed a clear assignment of the unfolding events of 
the Fab and the Fc domain. Second, the Tagg was assessed by temperature-ramped 
light absorption measurements at 350 nm detecting the formation of large protein 
aggregates upon heating. Finally, by performing temperature-ramped DLS 
measurements, the formation of small aggregates was monitored by the increase in 
the hydrodynamic radius Rh and additionally, the interaction parameter kD at 
refrigerated, ambient, and high temperature was calculated as long as the monomer 
was observed. On the basis of literature results, an equation for the transformation of 
the interaction parameters of mAbs (“TIM”) was determined, which allows an 
empirical translation from kD into A2
* for the interpretation of net attraction or 
repulsion. At the low pH of 5.0 and low ionic strength, electrostatic repulsion reflected 
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in a high kD and positive A2
* values prevented both the full mAb and the fragments 
from precipitation at high temperatures, despite substantial exposure of hydrophobic 
patches upon unfolding as demonstrated by DSF. At pH 7.2 as well as at pH 5.0 with 
charge shielding effect by 150 mM NaCl, MAb, Fab, and Fc showed a different 
behavior. Already at about 55 - 60 °C, below the onset temperature of unfolding, the 
Fab fragment started to aggregate. The kD values of the Fab monomer were constant 
over the observed temperature range and close to zero, suggesting that the 
aggregation of Fab was triggered already by a minimal perturbation of the native 
structure. In contrast, at temperatures where the Fc fragment started to unfold, the kD 
dropped strongly to negative kD and negative A2
* values. Therefore, the newly 
exposed hydrophobic patches upon unfolding, which facilitate the interaction with the 
fluorescent dye, mediated hydrophobic interactions that led to the aggregation of the 
protein. Finally, all proteins in case of neutral pH or charge shielding by NaCl addition 
formed a precipitate after CH3 domain and Fab unfolded upon heating. Similar 
results were observed for the full mAb, although a mutual conformational stabilization 
in relation to the isolated fragments is suggested by the Tm values. At the same time, 
a low apparent Tm value was found at the low pH of 5.0, suggesting a conformational 
destabilization. The addition of excipients such as salt or mannitol was found to be of 
minor influence on the Tm value compared with the effect of pH. The new and 
beneficial information from interaction parameter analysis at elevated and high 
temperatures helped to understand the link between unfolding and aggregation of the 
MAb as well as the role of the individual Fab and Fc fragments. We emphasize the 
integration of temperature-ramped screenings for the analysis of unfolding, 
aggregation, and interaction during formulation development of therapeutic protein 
drugs. 
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6.8 Supplementary information 
The graphs in Figure 6-4 till 6-6 have not been published with the main article and 
additionally illustrate the data of Table 6-2 to highlight the described effects. 
MAb (pH 7.2)  MAb (pH 5.0) 
A 
 
 B 
 
C 
 
 D 
 
E 
 
 F 
 
Figure 6-4. Hydrodynamic radius Rh, interaction parameter kD, and diffusion coefficient at 
infinite dilution D0 as a function of temperature of the mAb in 10 mM phosphate buffers (A + B) 
and with mannitol (C + D) or NaCl (E + F). The onset of unfolding is illustrated by diagonal 
shades with apparent Tm values in the center as observed by DSF. The occurrence of turbidity 
is marked by horizontal shades. 
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Fc (pH 7.2)  Fc (pH 5.0) 
A 
 
 B 
 
C 
 
 D 
 
Figure 6-5. Hydrodynamic radius Rh, interaction parameter kD, and diffusion coefficient at 
infinite dilution D0 as a function of temperature of the Fc fragment in 10 mM phosphate buffers 
(A + B) and with NaCl (C + D). The onset of unfolding is illustrated by diagonal shades with 
apparent Tm values in the center as observed by DSF. The occurrence of turbidity is marked by 
horizontal shades. 
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Fab (pH 7.2)  Fab (pH 5.0) 
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 B 
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 D 
 
Figure 6-6. Hydrodynamic radius Rh, interaction parameter kD, and diffusion coefficient at 
infinite dilution D0 as a function of temperature of the Fab fragment in 10 mM phosphate buffers 
(A + B) and with NaCl (C + D). The onset of unfolding is illustrated by diagonal shades with 
apparent Tm values in the center as observed by DSF. The occurrence of turbidity is marked by 
horizontal shades. 
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7 Aggregate growth analyzed by fluorescence (cross-) correlation 
spectroscopy 
7.1 Introduction 
The interaction between protein molecules is responsible for protein aggregation, and 
involves both short- (hard sphere, van der Waals, hydrophobic interactions, etc.) and 
long range (electrostatic) forces.1 The interaction parameters kD or A2, which are 
closely related (see TIM equation, chapter 6.3.6), therefore should be investigated 
routinely during development of therapeutic proteins.1-5 Negative, i.e., attractive 
interaction parameters were observed between mAb monomers upon thermal 
unfolding, leading to irreversible nonnative protein aggregates supposedly due to 
hydrophobic interactions (chapter 6). Consequently, the analysis of intermolecular 
interactions between aggregates and monomers is highly appreciated to investigate 
potential nucleation-driven aggregation as a process for aggregate propagation,6 as 
heterogeneous nucleation by sheds from glass and pumps has been reported in 
literature for other proteins,7 and mAbs in particular.8 In contrast, Kiese et al. spiked 
native-like mAb aggregates from shaking and denatured mAb particles from heat 
stress to unstressed mAb formulations, and found no indication for homogenous 
nucleation upon storage.9 But both kD and A2 describe the net effects arising from 
protein-protein interactions between the same (monomeric) molecules. Printz et al. 
determined A2 between small mAb higher molecular weight species after separation 
by HP-SEC and found preferential interaction between the higher molecular weight 
species as compared with the interaction between monomeric species.10 Hence, the 
interaction parameters between the same (aggregated) species are obtained, but the 
question regarding the interaction between monomer and aggregates is not 
addressed. The interaction parameter between two different protein molecules A23, 
can be analyzed, e.g., by cross-interaction chromatography.11 Furthermore, surface 
plasmon resonance and the quartz crystal microbalance are sensitive to interactions 
between molecules, and can be adapted to investigate cross-species effects.12-14 The 
similarity of these methods is the immobilization of one species to a resin or surface 
while the interaction of the analyte molecule is measured. For the analysis of two 
different species in solution, a method is necessary that can distinguish both 
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molecules and subsequently records a change upon interaction. A promising 
approach is the single particle analysis of fluorescently labeled molecules, which is 
presented in this chapter. 
Fluorescence correlation spectroscopy (FCS) analyzes physicochemical properties of 
single fluorescent labeled molecules. A laser beam is focused to form a tiny confocal 
volume in the sample solution. At nanomolar concentrations of the labeled sample, 
single molecules get excited while diffusing through this illuminated volume, leading 
to fluctuations of the collected fluorescence intensity over time. By mathematically 
correlating the fluorescence intensity to itself after increasing lag time τ, an 
autocorrelation function can be derived. It describes the self-similarity of the signal 
over time. Thus, short residence in the confocal volume leads to a fast decay of the 
autocorrelation function. Whereas the diffusion time is related to the Brownian 
motion, either the viscosity of the solvent or the radius of (spherical) molecules can 
be calculated by the Stokes-Einstein equation, if the corresponding parameter is 
known. By extending the setup with a second laser and detector, two spectrally 
different dyes can be analyzed at the same time. This enables fluorescence cross-
correlation spectroscopy (FCCS) in which fluctuations of both signals are correlated 
with each other. The resulting cross-correlation (CC) function describes the similarity 
between both colors. A high CC amplitude is observed when both dyes move 
uniformly. In case of molecules labeled with one distinct dye, a CC signal results from 
some strong interaction between both molecules, forcing them to move together 
through the confocal volume. For a fundamental introduction and applications of both 
FCS and FCCS, the reader is referred to the excellent reviews in literature.15-17  
Protein aggregation is indicated via FCS by slower diffusion of the molecules due to 
their increased size. But large differences in molecular weight are necessary for a 
significant change in diffusion time so that the addition of single monomers to existing 
aggregates cannot be detected. Therefore, FCCS is used to detect a CC signal when 
molecules labeled with one dye are bound to aggregates which contain the other 
label, independent of their size. Consequently, the existing labeled aggregates have 
grown when CC is observed after addition of differently labeled monomers. A model 
IgG1 monoclonal antibody “MAb” was labeled with Alexa Fluor® 488 and 647, 
respectively. Labeled MAb aggregates are obtained by spiking of labeled MAb 
monomer to 2 mg/ml of the unlabeled MAb and applying thermal stress. FCS and 
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FCCS measurements are performed before and after the aggregates are formed, and 
furthermore upon addition of the differently labeled MAb to detect aggregate growth. 
In this case, the existing aggregates are either exposed to unstressed MAb monomer 
or a stressed sample. 
7.2 Materials and methods 
7.2.1 Preparation and purification of labeled protein 
An IgG1 type monoclonal antibody MAb was dialyzed into 1 mM sodium phosphate 
buffer pH 6.0 using Vivaspin® 20 tubes with 30 kDa MWCO (Sartorius Stedim 
Biotech, Göttingen, Germany) and adjusted to 2 mg/ml using the NanoDrop 2000 
photometer (Thermo Scientific, Wilmington, Delaware, USA) based on an extinction 
coefficient of 1.49 ml g-1 cm-1. For covalent linking of the N-hydroxysuccinimide 
(NHS) ester of the fluorescent dye, the pH value of the solution was adjusted to 8.3 
with 1 M sodium hydrogen carbonate. Alexa Fluor® 488 or Alexa Fluor® 647 (Life 
Technologies, Paisley, United Kingdom) dissolved in dimethyl sulfoxide (DMSO) was 
added to the MAb solution at a 1.2:1 ratio. The reaction was gently shaken and 
protected from light for one hour at room temperature. Subsequently, a 10-fold 
excess of a 1.5 M hydroxylamine solution at pH 8.5 was added. After 1 h of 
incubation the reaction mix was semi-quantitatively purified by HP-SEC using an 
Agilent 1100 HPLC system (Agilent Technologies, Santa Clara, California, USA) and 
a Tosoh TSKgel® G3000SWXL column (7.8x300 mm) (Tosoh Bioscience, Stuttgart, 
Germany). Fractions of the reaction mix were injected using a mobile phase of 
100 mM sodium phosphate buffer with additional 100 mM sodium sulfate pH 6.8 at a 
flow rate of 0.8 ml/min. The eluate containing the monomer fraction was collected 
after UV-detection at 280 nm, pooled, concentrated, and dialyzed into a 1 mM 
phosphate buffer pH 6.0 using a Vivaspin® 6 tube with 30 kDa MWCO. After 
purification, the degree of labeling (DOL) was determined photometrically using the 
NanoDrop 2000 photometer via the extinction coefficients and correction factors 
given by the manufacturer. 
7.2.2 Thermal stress for the preparation of protein aggregate 
Two formulations of 2 mg/ml MAb in 10 mM sodium phosphate buffer at pH 5.0, 
140 mM sodium chloride (NaCl) and at pH 7.2, 280 mM mannitol were prepared. 
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Furthermore, 2 mg/ml MAb in phosphate buffered saline (PBS) solution pH 7.4 
according to Dulbecco’s formula containing sodium, potassium, magnesium, calcium, 
and chloride was used.18 Labeled MAb (see chapter 7.2.1) was spiked into the 
samples to obtain the necessary nanomolar concentrations for FCS. Samples were 
heat stressed at 76 °C in Eppendorf Safe-Lock® tubes (Eppendorf, Hamburg, 
Germany) using an Eppendorf Thermomixer. 
7.2.3 Fluorescence correlation spectroscopy (FCS) and fluorescence cross-
correlation spectroscopy (FCCS) 
FCS and FFCS were performed with a ConfoCor 3 (Carl Zeiss, Jena, Germany). 
Prior to the experiments, the z-plane and the x,y-position of the pinhole were 
adjusted to optimize the confocal volume with a Alexa Fluor® 488 solution. The 
optimal concentrations of the labeled MAb were evaluated based on the obtained 
count rates in the corresponding detector channels. A concentration of approx. 60 nM 
MAbAF488 and 350 nM MAbAF647 was consequently used throughout all FCS and 
FCCS measurements. Measurements were performed with unstressed (native) 
protein and samples after thermal stress (see chapter 7.2.2). 
The fluorescence microscope was equipped with two laser light sources at 488 and 
633 nm. The detector channels Ch1 and Ch2 were adjusted for the detection of the 
fluorescence signal from Alexa Fluor 488 and 647, respectively. One measurement 
run consisted of ten sequences of each 10 s acquisition time. Each sample 
measurement was replicated at least three times (usually five times) to gain statistical 
significance. Occasionally, large particles (typically observed with the stressed 
samples) generated a short massive increase (“spike”) in the fluorescence count rate. 
A data set with such a spike is not suitable for autocorrelation analysis and was 
rejected. Data analysis was performed using an in-house MATLAB program 
(MathWorks, Natick, Massachusetts, USA) using a one component fit, which allowed 
corrections for triplet-blinking of the dye. Furthermore, background fluorescence of 
the solutions and cross-talk was taken into account. The results of the fits of each 
measurement run were averaged to obtain mean values with standard deviation. 
The molecular weight of the aggregated species was estimated from reference 
measurements of green fluorescent protein (eGFP) with a known molecular mass of 
28 kDa in the corresponding buffers. The diffusion time τD obtained by autocorrelation 
analysis was calculated using the following formula 
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 (7-1) 
with M the molar mass of the MAb and the reference eGFP. 
7.3 Results and discussion 
7.3.1 Autocorrelation (AC) analysis for the detection of protein aggregation 
Diffusion times (τD) of MAbAF488 were obtained from AC analysis of the fluorescence 
signal in Ch1 (Figure 7-1 A). The native, unstressed labeled MAb molecule showed 
τD values of about 220 µs in the saline buffers. In the mannitol containing buffer, a 
higher τD value of 275 µs was observed as the viscosity is slightly higher due to the 
sugar alcohol (see DLS results in chapter 6). After thermal stress at 76 °C for 1 h, the 
increased diffusion times indicate the formation of aggregates containing the labeled 
MAbAF488. At this temperature, the CH2 domain of the MAb but neither the Fab region 
nor the CH3 domain unfolded as indicated by DSF experiments (Table 6-2). 
Furthermore, the stress temperature was below Tagg,onset where the formation of large 
aggregates was observed by turbidity measurements (chapter 6). This finding is in 
agreement with the formation of aggregates of rituximab at 60 °C that is initiated by at 
least partial unfolding of CH2 as described by Anderson et al.19  
A 
 
 B 
 
Figure 7-1. Diffusion times obtained by autocorrelation analysis of the samples before and after 
thermal stress (76 °C, 1 h) (A). The estimated molecular weight of the species obtained from 
extrapolation of the experimental diffusion time from eGFP (B). 
The significantly slower diffusion indicates the formation of large aggregates. To 
estimate the average molecular weight of the aggregated species, the obtained τD 
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values were extrapolated from τD of eGFP with known molecular mass (Figure 7-1 B). 
In PBS pH 7.4 and pH 7.2 + mannitol, τD values of 114 and 152 µs were obtained for 
eGFP, respectively. eGFP showed a high amount of triplet-blinking at the low pH of 
5.0 leading to false τD values, and thus a value of 114 µs was assumed for the NaCl 
containing buffer at pH 5.0. For the unstressed MAb, the estimated molar mass 
ranged between 185 – 225 kDa, which is a good indicator for the monomer within the 
precision of this approximation. The smallest aggregates of about 0.6 MDa were 
detected in physiological PBS, whereas particles in the range of 550 MDa formed in 
the mannitol containing buffer at pH 7.2. The repulsive positive net charges of the 
MAb at the low pH of 5.0 were substantially shielded as aggregates of about 4 MDa 
were observed (compare chapter 6). The approx. 1:200 ratio of labeled molecules 
suggests that the aggregates consisted predominately of unlabeled MAb. 
7.3.2 Cross-correlation (CC) analysis for the detection of protein aggregation 
and aggregate growth 
Additionally, samples containing both MAbAF488 and MAbAF647 and 2 mg/ml unlabeled 
MAb were stressed and analyzed. The results from CC analysis are presented in 
Figure 7-2 A. Before stressing the sample, no significant CC was observed 
suggesting that MAbAF488 and MAbAF647 diffuse freely in solution. After thermal stress 
at 76 °C for 1 h, a significant CC was obtained for all three formulations. Especially 
for the 10 mM phosphate buffer at pH 7.2 with 280 mM mannitol, a very high amount 
of about 15.5 % CC was observed. This indicates that significant amounts of both 
labeled molecules were incorporated in protein aggregates. Furthermore, these 
results confirm the AC analysis where the longest diffusion time, i.e. the largest 
aggregates, was observed for the same sample (see Figure 7-1).  
Next, samples containing MAbAF488 and 2 mg/ml unlabeled MAb were stressed for 1 h 
at 76 °C. As presented in Figure 7-1 A, aggregates consisting of labeled and 
predominately unlabeled protein were formed. Subsequently, MAbAF647 was spiked 
into the solution of AF488-carrying MAb aggregates and the CC signal was analyzed 
after 30 min. A significant CC was observed for all three formulations (Figure 7-2 B). 
This result suggests that MAbAF647 attached or absorbed onto the aggregates which 
were previously formed by heat stress. Although less likely, a replacement of MAb 
molecules in the aggregates by new MAb molecules could also explain the increased 
CC. Interestingly, a different result was obtained when the MAbAF647 molecules were 
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stressed for 30 min at 76 °C. No significant CC was detected in this case (Figure 
7-2 B). Thus, already formed MAb aggregates did not interact with other heat stress 
molecules or aggregates. 
A 
 
 B 
 
Figure 7-2. Results from cross-correlation (CC) analysis of the samples containing both labeled 
species before and after thermal stress (76 °C, 1 h) (A). Obtained CC signal when unstressed or 
stressed (76 °C, 30 min) MAbAF647 was added to a stressed sample (76 °C, 1 h) containing 
MAbAF488 (B). 
It was reported that heat stress can induce conformational changes to mAb 
monomers.20,21 Especially Hawe and coworkers showed that heat stress damaged 
the mAb structure at similar temperatures, below the critical temperature of 
aggregation at which the monomers are lost.21 Thus, one can speculate that 
structurally perturbed MAbs evaded the interaction with the existing aggregates. This 
would suggest that structural changes upon heat stress were responsible for the 
different behavior of stressed and unstressed MAb. Finally, although only up to one 
dye molecule was conjugated to the MAb (DOL(MAbAF488) = 1.1; DOL(MAbAF647) = 
0.4), and both attached dye moieties are negatively charged,22-24 an artificial effect 
induced by the label cannot be ruled out. 
7.4 Summary and outlook 
The confocal setup of FCS allows the detection of single fluorescently labeled 
species. By means of AC analysis, the diffusion times of the labeled species can be 
derived. The application of heat stress to MAb formulations containing a small 
amount of labeled MAb induced the formation of aggregates, which were detected by 
an increased diffusion time in FCS. Large aggregates of several MDa were observed. 
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In addition, FCCS measurements confirmed the aggregate formation, because a 
significant CC signal was observed when aggregates were formed in the presence of 
two MAbs carrying two different fluorescent labels. Furthermore, FCCS allowed for 
the detection of aggregate growth. Significant CC was obtained when MAb monomer 
was added to preformed MAb aggregates. In contrast, no CC was observed when 
aggregated and supposedly structurally perturbed MAb was added to already existing 
MAb aggregates. But further detailed studies appear necessary to substantiate this 
highly interesting finding. The ability to follow individual entities of both monomeric or 
aggregated character and the possibility to watch interactions between two species, 
are a valuable and outstanding chance to gain a comprehensive understanding of the 
processes involved in aggregation and interaction of proteins. 
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8 Laser-induced breakdown detection of temperature-ramp 
generated aggregates of a therapeutic mAb 
This chapter is intended for publication. A manuscript is in preparation by Tim 
Menzen, Wolfgang Friess, and Christoph Haisch. 
8.1 Abstract 
The detection and characterization of protein aggregation is essential during 
development and quality control of therapeutic proteins, as aggregates are typically 
inactive and may trigger anti-drug-antibody formation in patients. Especially large 
multi-domain molecules, such as the important class of therapeutic monoclonal 
antibodies (mAbs), can form various aggregates that differ in size and morphology. 
Although particle analysis advanced over the recent years, new techniques and 
orthogonal methods are highly valued. To our knowledge, the physical principle of 
laser-induced breakdown detection (LIBD) was not yet applied to sense aggregates 
in therapeutic protein formulations. We established a LIBD setup to monitor the 
temperature-induced aggregation of a mAb. The obtained temperature of aggregation 
was in good agreement with the results from previously published temperature-
ramped turbidity and dynamic light scattering measurements. This study 
demonstrates the promising applicability of LIBD to investigate aggregates from 
therapeutic proteins. The technique is also adaptive to online detection and size 
determination, and offers interesting opportunities for morphologic characterization of 
protein particles and impurities, which will be part of future studies. 
8.2 Introduction 
Protein aggregation is a major hurdle for therapeutic proteins as the aggregated 
species typically lack activity and are potentially more immunogenic than protein 
monomers in patients.1 The complex pathways of protein aggregation, especially in 
case of large multi-domain proteins, such as monoclonal antibodies (mAbs), lead to 
aggregates of various size and morphology.2,3 To cover the full size range from 
several nanometers to micrometers, an arsenal of analytical tools is needed and 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
162 
employed to investigate aggregates of protein drugs during development and in 
quality control.3-5 Not only the size, but also morphology and structure of protein 
aggregates as well as nonproteinaceous impurities are in the focus of the 
pharmaceutical scientist and drive the development of new analytical techniques.6,7 
Progress was achieved, especially in the challenging range of micron (1 – 100 µm) 
and submicron (100 nm – 1 µm) particles, e.g., by micro-flow imaging (MFI) and 
resonant mass measurement.8,9 As the obtained size information is always linked to 
the measurement principle and technique, orthogonal methods are highly valued and 
also appreciated by the regulatory agencies.10 
Laser-induced breakdown detection (LIBD) of particles in solution relies on the effect 
that the energy threshold to induce a plasma breakdown in the focus of an intense 
pulsed laser is dependent on the dielectric properties (atom number density and 
refractive index) and is lower for solids than liquids (and gases).11 The detection and 
counting of breakdown events induced by micron- and submicron particles by means 
of acoustic and optical detectors has been exploited mainly in the area of 
environmental analysis. A minimum detectable diameter of about 19 nm was 
demonstrated with polystyrene standard particles, while theoretical calculations even 
suggest a minimum size range of about 1 nm.12 The probability to induce a 
breakdown by the laser pulse is increasing with both higher particle concentration 
and larger particle size,13 thus complicating size distribution analysis of real-world 
samples where both parameters are unknown. Although LIBD is not established as 
routine technique, it was shown to be integrated as mobile, robust field measuring 
system.14 To our best knowledge, LIBD has not been used for detection of protein 
aggregates in protein solutions before. 
Consequently, the application of LIBD for the analysis of protein aggregates is highly 
intriguing. We therefore built a LIBD setup and tried to study the formation of mAb 
aggregates upon thermal unfolding. Using a temperature-ramped setup to induce 
aggregation, the breakdown incidence, i.e. the ratio of observed breakdowns to the 
number of laser pulses within 30 seconds, was monitored. A significant increase in 
breakdown incidences was observed after protein aggregation demonstrating that 
LIBD in principle can be used for characterization of protein formulations and the high 
potential of the method has to be further exploited in future studies. 
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8.3 Materials and methods 
8.3.1 Sample preparation 
Stock solutions of an IgG1 monoclonal antibody (“MAb”) in 10 mM sodium phosphate 
buffer at pH 7.2 or 5.0 with or without 140 mM sodium chloride (NaCl) and 280 mM 
mannitol were used.15 Samples of 0.2 mg/ml MAb were prepared by dilution with the 
corresponding buffer and filtered through a 0.2 µm PVDF membrane syringe filter 
(Pall Life Sciences, Port Washington, New York, USA) immediately before the 
experiments. 
8.3.2 Temperature-ramped LIBD setup 
A schematic illustration of the temperature-ramped LIBD setup is illustrated in Figure 
8-1. A pulsed (10 Hz) Surelite Nd:YAG laser (Continuum, San Jose, California, USA) 
was frequency-doubled to 532 nm. A lens with 20 mm was used to focus the beam 
into a quartz glass cuvette (Hellma Analytics, Müllheim, Germany). The center of the 
focus was positioned 1 mm from the cuvette inner wall to reduce loss of laser light in 
case of turbid solutions. The laser energy was recorded using a beam splitter and 
laser energy sensor (Ophir Optronics, Jerusalem, Israel). The cuvette was placed in a 
cell holder that was connected to a Thermo Haake C25P temperature controlled 
water bath (Thermo Electron, Karlsruhe, Germany). Using a lens of f = 40 mm, the 
emitted light from a LIBD event passed a long-pass filter and was detected by a 
photodiode. The electrical signal of the photodiode was amplified and collected using 
a Tektronix TDS 620A oscilloscope (Tektronix, Wilsonville, Oregon, USA). The 
oscilloscope also received the trigger signal from the laser source for timing. The 
LIBD signal was observed after about 300 nanoseconds and the electronic signal 
was transferred via a GPIB-to-USB converter (National Instruments, Austin, Texas, 
USA) to a personal computer (PC). The data from the photodiode and the laser 
energy sensor were recorded and processed using LabVIEW® 2010 (National 
Instruments Corporation, Austin, Texas, USA). The software logged the laser energy 
and signal amplitude of the photodiode for every individual pulse. 
Before every measurement, the laser was turned on for at least one hour for internal 
thermal equilibration ensuring laser pulse stability. With a laser pulse energy of 
39±4 µJ, the breakdown incidence of highly purified water (MilliQ Plus 185, Merck 
Millipore, Billerica, Massachusetts, USA) and the filtrated formulation buffers were 0.1 
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and 0.7 breakdowns/30 s, respectively (5000 laser pulses). The cuvette was filled 
with 2 ml of the sample and sealed by a rubber stopper equipped with a 
thermocouple. A linear temperature ramp from 20 °C to 95 °C in 75 min (1 °C/min) 
was adjusted at the water bath. The temperature in the solution was recorded using a 
HH147U thermo logger (Omega Engineering, Stamford, Connecticut, USA) 
connected to the PC. 
The signal amplitudes were analyzed in order to identify LIBD events using a 
threshold value above the background signal amplitude with Origin® 8 SR6 
(Originlab, Northampton, Massachusetts, USA). The breakdown incidence was 
calculated in time bins of 30 s. Using the recorded temperature data over time, the 
temperature where the breakdown incidence suddenly increased (Tagg,LIBD), was 
determined at the intersection of two tangents fitted to the cumulated breakdown 
incidence at the baseline and the slope. 
 
Figure 8-1. Schematic illustration of the temperature-ramped LIBD setup including data 
acquisition using a LabVIEW® virtual instrument (VI). 
8.3.3 Differential scanning calorimetry (DSC) 
DSC thermograms from 20 °C to 96 °C at 1 °C/min were obtained from the MAb 
samples at a concentration of 0.8 mg/ml using a VP-DSC MicroCalorimeter 
(MicroCal, Northampton, Massachusetts, USA; now Malvern Instruments) as 
described previously.16 The apparent melting temperatures (Tm values) of the CH2 
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and the CH3 domains as well as the Fab part were obtained from the peak maxima of 
the melting transitions. 
8.4 Results 
The breakdown incidence represents the number of LIBD events per time bin of 30 s. 
At the starting temperature of 20 °C, a breakdown incidence of 0 to 
5 breakdowns/30 s was observed for all 0.2 mg/ml MAb samples in 10 mM 
phosphate buffer at pH 7.2 (Figure 8-2). Subsequently, the temperature of the 
sample was linearly increased with a heating rate of 1 °C/min. The breakdown 
incidence was constant at the initial level until a sudden onset of breakdown events 
occurred. This onset was observed for all three MAb formulations at the neutral pH 
but the Tagg,LIBD was slightly lower for the sample without NaCl or with mannitol (Table 
8-1). Followed by the strong and sudden onset of breakdown events at a given 
temperature, the breakdown incidence typically decreased slightly with further 
increasing temperature. 
Table 8-1. Summary of the results from DSC, temperature-ramped turbidity and DLS 
measurements,* and LIBD measurements of 0.2 mg/ml MAb in 10 mM phosphate buffers at 
pH 7.2 and 5.0 with or without NaCl and mannitol. 
 Tm by DSC  
[°C] 
Tagg,onset  
[°C] 
Tagg  
[°C] 
Tagg LIBD  
[°C] 
TRh > 10nm  
[°C] 
 CH2 CH3 Fab Turbidity LIBD DLS 
pH 7.2 72.1 82.2 77.1±0.1 79.5±0.1 78.2±0.8 65 – 70 
+ mannitol 73.0 83.0 78.1 80.5 81.7 65 – 70 
+ NaCl 71.4 82.6 78.2 80.5 82.5 65 – 70 
pH 5.0 61.0 80.9 87.4 - - - 80 – 85 
+ mannitol 65.5 83.1 88.6 - - - 80 – 85 
+ NaCl 63.2 81.8 87.4 82.7 85.2 87.5 70 – 75 
* previously published by Menzen and Friess.
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Figure 8-2. Results from experiments with 0.2 mg/ml MAb at pH 7.2 (A + B), with additional 
280 mM mannitol (C + D), and with additional 140 mM NaCl (E + F). The LIBD signal was 
counted in time bins of 30 s while the temperature in solution increased linearly from 20 to 
90 °C with a rate of 1 °C/min. The Tagg LIBD value was analyzed via two intersecting tangents from 
the accumulated breakdown incidence. 
The DSC measurements revealed two melting transitions of the MAb at pH 7.2 (Table 
8-1). The first melting transition is caused by the CH2 domain, whereas the larger, 
second transition at higher temperature reflects simultaneous unfolding of the CH3 
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domain and the Fab fragment.15 Aggregation occurred upon heating in all 
formulations at pH 7.2, and the temperature of aggregation (Tagg) and its onset value 
(Tagg,onset) from temperature-ramped turbidity measurements were previously 
reported.15 In the same study, also the hydrodynamic radius (Rh) was monitored by 
dynamic light scattering (DLS) upon heating to 85 °C in steps of 5 °C. The 
temperature range in which Rh exceeded 10 nm, indicating the formation of small 
aggregates, is provided in Table 8-1.15 
In case of the 0.2 mg/ml MAb samples at pH 5.0, a sudden breakdown onset was 
observed only for the formulation containing 140 mM NaCl (Figure 8-3). In contrast, 
no increase in breakdown incidences and consequently no Tagg,LIBD values were 
determined in case of the other two formulations at the low pH and low ionic strength 
(Table 8-1). 
Similarly, only the NaCl containing sample became turbid upon heating, whereas the 
MAb solutions remained clear in case of the 10 mM phosphate buffer and with 
additional mannitol.15 The formation of small aggregates was detected by DLS. In 
addition, unfolding of the CH2 and CH3 domain and the Fab fragment was observed 
as three distinct DSC melting transitions at pH 5.0 (Table 8-1). 
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Figure 8-3. Results from experiments with 0.2 mg/ml MAb at pH 5.0 (A), with additional 280 mM 
mannitol (B), and with additional 140 mM NaCl (C + D). A jump in LIBD incidence was observed 
only for the NaCl containing sample and its Tagg,LIBD value was analyzed via two intersecting 
tangents from the accumulated breakdown incidence. 
8.5 Discussion 
At the applied laser energy, the breakdown incidence of the background formulation 
buffers was below 0.7 breakdowns/30 s. In contrast, the samples at pH 7.2 and 5.0 
with NaCl showed a clear sudden onset of breakdown events with rising temperature 
(Figure 8-2 and Figure 8-3). Breakdown incidences above 10 breakdowns/30 s were 
detected. This increase is explained by the formation of MAb aggregates, which were 
induced by thermal unfolding of the protein. Almost identical Tagg values were 
obtained from turbidity measurements (Table 8-1). The same temperature-ramp of 
1 °C/min was used during DSC, turbidity, and LIBD measurements. The observed 
aggregation temperatures from LIBD and turbidity measurements were in the range 
of the apparent Tm values of the CH3 domain and Fab, which suggests that the 
process of aggregation is mediated by at least partial unfolding of these regions 
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(Table 8-1). Although attractive hydrophobic interactions increase upon unfolding due 
to the exposure of hydrophobic surfaces, the overall positive net charge prevented 
the MAb from precipitation at the low pH value and at low ionic strength.15 This 
electrostatic repulsion is shielded in the presence of 140 mM NaCl, which leads to 
precipitation of the protein also at pH 5.0, similar to the formulations at pH 7.2.  
DLS, although performed with a slower heating rate and in steps of 5 °C, 
demonstrated an increase in Rh at temperatures below the Tagg values identified by 
the other methods (Table 8-1). This suggests that small MAb oligomers form first. 
Under conditions that shield repulsive charge interactions, subsequently larger 
aggregates build up which are detected by an increase in turbidity and LIBD. 
Consequently, the current LIBD setup allows for the detection of larger protein 
aggregates, most likely in the low micrometer range. Thus, sedimentation might the 
reason for the observed reduction in breakdown incidence after the breakdown onset 
at Tagg (Figure 8-2 and Figure 8-3). 
Scattered laser light from protein aggregates that are out of the focus may disturb the 
optical detection of the plasma breakdowns. This interference was suppressed by the 
confocal breakdown detection geometry and by a long-pass light filter (>600 nm) in 
front of the photodiode, which blocks the scattered laser light. Furthermore, the focus 
of the beam was adjusted in close proximity to the inner wall of the cuvette and a low 
MAb concentration of 0.2 mg/ml was applied to reduce the total amount of protein 
aggregates in the cell. Thereby, the risk of the laser intensity falling below the 
breakdown threshold was reduced. 
The current method allows reliable detection of the heat-induced protein aggregates 
in a straight-forward setup. But many more detailed studies have to follow to establish 
the full strength of LIBD for a comprehensive particle analysis. Since the breakdown 
incidence depends on both particle size and concentration, it is not possible to 
determine one of these parameters from a simple counting experiment. One option to 
obtain the size information is to increase the laser power during the experiment, 
record the breakdown incidence as a function of the laser energy, and correlate the 
results to a calibration generated with standard particles.17,18 Another approach 
derives the size information from the precise spatial position and dimension of the 
breakdown within the energy profile of the focused laser beam using a camera.19-21 In 
both cases, a rather high number of breakdowns is necessary for statistical analysis, 
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which requires for a high-repetition laser source, at least in case of low particle 
concentrations. Furthermore, careful calibration with standard particles is necessary. 
Moreover, the current sample volume can be easily reduced by glass cuvettes with 
smaller volume, leading to reduced sample consumption.  
The LIBD technique can be combined with symmetrical,22 and asymmetrical,23 flow 
field-flow fractionation for particle separation, revealing improved sensitivity for 
polystyrene particles below a size of 70 nm compared to static light scattering (SLS). 
For LIBD, a linear relationship between signal and particle size was observed at low 
breakdown propensities.19 The LIBD technique is more sensitive than SLS regarding 
the detection of small particles.23,24 Hence, the use of the flow-through cell connected 
to a size-separation system may enable detailed analysis of small protein aggregates 
or impurities such as silicone oil droplets, and other foreign particles. Again, a high 
repetition rate pulsed laser would then be beneficial in order to improve statistics. 
Thus, the presented setup is a first approach to highlight the promising application of 
LIBD to investigate foreign (extrinsic), process-related (intrinsic), and proteinaceous 
(inherent) particles in pharmaceutical protein formulations. 
8.6 Summary and outlook 
In this study, LIBD was applied for the first time to detect MAb aggregates that were 
intentially formed by heat stress. Protein aggregation upon heating and the 
corresponding Tagg,LIBD values were determined based on the breakdown incidence. 
Tagg,LIBD was in good agreement with the results from temperature-ramped turbidity 
measurements. Differences in MAb aggregation corresponded to pH and charge 
shielding effects by salts as previously described.15 
The presented temperature-ramped setup induced considerable amounts of protein 
aggregates in short times from relevant therapeutic formulations, which allowed a 
comparison with previously published data using orthogonal techniques. Turbidity 
and DLS measurements suggested that only large particulate MAb aggregates were 
detected with the current LIBD setup. 
In upcoming studies, the power of LIBD for sizing and counting of protein particles 
has to be investigated. The current setup has potential for further improvement, e.g., 
by using a smaller volume flow-through cell, a laser featuring a higher pulse repetition 
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rate, and it can be connected to size-separation techniques. Furthermore, information 
about particle size could be obtained from spatial and intensity characteristics of the 
breakdown event using a camera instead of a photodiode.19-21 LIBD was shown to be 
applicable over a wide particle size range (nanometer to micrometer), 25 and could be 
a highly valuable new technique for the challenging analysis of subvisible particles. In 
future studies, protein particles with well characterized size and morphology, e.g., by 
means of flow-imaging and resonant mass techniques,8,9 need to be studied to 
evaluate potential effects of density, shape, and refractive index of the protein 
aggregates on the plasma formation. In summary, LIBD is a new and promising, 
orthogonal approach to investigate protein aggregates or impurities such as silicone 
oil and nonproteinaceous particles in pharmaceutical samples. It is based on a 
physical principle different from all other methods utilized in the field of protein 
formulation development and characterization. 
8.7 Acknowledgements 
The LIBD experiments were performed in collaboration with Prof. Dr. Christoph 
Haisch from the Institute of Hydrochemistry of the Technische Universität München, 
Germany. Prof. Dr. Christoph Haisch and Prof. Dr. Reinhard Niessner, leader of the 
chair, are gratefully acknowledged for this opportunity. 
8.8 References 
1. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S 2012. Immunogenicity of protein 
aggregates—Concerns and realities. Int J Pharm  431(1–2):1-11. 
2. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D 2012. Classification of protein aggregates. J 
Pharm Sci  101(2):493-498. 
3. Mahler H-C, Friess W, Grauschopf U, Kiese S 2009. Protein aggregation: Pathways, induction 
factors and analysis. J Pharm Sci  98(9):2909-2934. 
4. Zölls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A 2012. 
Particles in therapeutic protein formulations, Part 1: Overview of analytical methods. J Pharm Sci  
101(3):914-935. 
5. den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, 
Jiskoot W 2011. Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech 
Product Development. Pharm Res  28(4):920-933. 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
172 
6. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan Y-X, 
Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B 2009. 
Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product 
quality. J Pharm Sci  98(4):1201-1205. 
7. Carpenter J, Cherney B, Lubinecki A, Ma S, Marszal E, Mire-Sluis A, Nikolai T, Novak J, 
Ragheb J, Simak J 2010. Meeting report on protein particles and immunogenicity of therapeutic 
proteins: Filling in the gaps in risk evaluation and mitigation. Biologicals  38(5):602-611. 
8. Weinbuch D, Zölls S, Wiggenhorn M, Friess W, Winter G, Jiskoot W, Hawe A 2013. Micro–
flow imaging and resonant mass measurement (archimedes) – complementary methods to 
quantitatively differentiate protein particles and silicone oil droplets. J Pharm Sci  102(7):2152-2165. 
9. Zölls S, Weinbuch D, Wiggenhorn M, Winter G, Friess W, Jiskoot W, Hawe A 2013. Flow 
Imaging Microscopy for Protein Particle Analysis—A Comparative Evaluation of Four Different 
Analytical Instruments. The AAPS Journal  15(4):1200-1211. 
10. Weinberg WC, Ha L, Kirshner SL, Verthelyi DI. 2010. Regulatory Perspective on Aggregates 
as a Product Quality Attribute. In Wei Wang CJR, editor Aggregation of Therapeutic Proteins, ed., 
Hoboken, New Jersey: John Wiley & Sons, Inc. p 435-451. 
11. Bettis JR 1992. Correlation among the laser-induced breakdown thresholds in solids, liquids, 
and gases. Appl Opt  31(18):3448-3452. 
12. Bundschuh T, Knopp R, Kim JI 2001. Laser-induced breakdown detection (LIBD) of aquatic 
colloids with different laser systems. Colloids Surf, A  177(1):47-55. 
13. Scherbaum FJ, Knopp R, Kim JI 1996. Counting of particles in aqueous solutions by laser-
induced photoacoustic breakdown detection. Applied Physics B Laser and Optics  63(3):299-306. 
14. Latkoczy C, Kagi R, Fierz M, Ritzmann M, Gunther D, Boller M 2010. Development of a mobile 
fast-screening laser-induced breakdown detection (LIBD) system for field-based measurements of 
nanometre sized particles in aqueous solutions. Journal of Environmental Monitoring  12(7):1422-
1429. 
15. Menzen T, Friess W 2014. Temperature-Ramped Studies on the Aggregation, Unfolding, and 
Interaction of a Therapeutic Monoclonal Antibody. J Pharm Sci  103(2):445-455. 
16. Menzen T, Friess W 2013. High-throughput melting-temperature analysis of a monoclonal 
antibody by differential scanning fluorimetry in the presence of surfactants. J Pharm Sci  102(2):415-
428. 
17. Bitea C, Walther C, Kim JI, Geckeis H, Rabung T, Scherbaum FJ, Cacuci DG 2003. Time-
resolved observation of ZrO2-colloid agglomeration. Colloids and Surfaces A: Physicochemical and 
Engineering Aspects  215(1–3):55-66. 
8. LIBD of temperature-ramp generated aggregates of a therapeutic mAb 
173 
18. Bitea C, Müller R, Neck V, Walther C, Kim JI 2003. Study of the generation and stability of 
thorium(IV) colloids by LIBD combined with ultrafiltration. Colloids and Surfaces A: Physicochemical 
and Engineering Aspects  217(1–3):63-70. 
19. Bundschuh T, Hauser W, Kim JI, Knopp R, Scherbaum FJ 2001. Determination of colloid size 
by 2-D optical detection of laser induced plasma. Colloids and Surfaces A: Physicochemical and 
Engineering Aspects  180(3):285-293. 
20. Kim JW, Son JA, Yun JI, Jung EC, Park SH, Choi JG 2008. Analysis of laser-induced 
breakdown images measuring the sizes of mixed aquatic nanoparticles. Chem Phys Lett  462(1–3):75-
77. 
21. Jung EC, Yun JI, Kim JI, Park YJ, Park KK, Fanghänel T, Kim WH 2006. Size measurement of 
nanoparticles using the emission intensity distribution of laser-induced plasma. Applied Physics B  
85(4):625-629. 
22. Thang NM, Knopp R, Geckeis H, Kim JI, Beck HP 1999. Detection of Nanocolloids with Flow-
Field Flow Fractionation and Laser-Induced Breakdown Detection. Anal Chem  72(1):1-5. 
23. Bouby M, Geckeis H, Manh TN, Yun JI, Dardenne K, Schafer T, Walther C, Kim JI 2004. 
Laser-induced breakdown detection combined with asymmetrical flow field-flow fractionation: 
application to iron oxi/hydroxide colloid characterization. J Chromatogr A  18(1):97-104. 
24. Bundschuh T, Wagner TU, Köster R 2005. Laser-induced Breakdown Detection (LIBD) for the 
Highly Sensitive Quantification of Aquatic Colloids. Part I: Principle of LIBD and Mathematical Model. 
Particle & Particle Systems Characterization  22(3):172-180. 
25. Bundschuh T, Wagner TU, Köster R 2005. Laser-induced Breakdown Detection (LIBD) for the 
Highly Sensitive Quantification of Aquatic Colloids. Part II: Experimental Setup of LIBD and 
Applications. Particle & Particle Systems Characterization  22(3):181-191. 
 
Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies 
174 
Summary of the thesis 
Protein instabilities are one major obstacle during R&D of therapeutic protein drugs 
and mAbs in particular. These instabilities arising from the complex protein structure 
are determined by the chemical nature of the amino acid residues and the physical 
nature of stabilizing and destabilizing inter- and intramolecular interactions. As a 
result, proteins are susceptible to chemical degradation and aggregation processes. 
Both are typically linked to a diminution of the native conformation, a reduced activity 
or complete loss of function, and unwanted side effects. Monitoring the thermal 
unfolding is an integral part of assessing the conformational stability of proteins. A 
high thermal stability reduces the probability of the protein to populate unfolded 
states at physiological and storage temperatures, and subsequent instability 
reactions are less likely. Therefore, the Tm value is routinely analyzed and also 
Tm,onset is very interesting as it marks first structural perturbation. Commonly, DSC is 
applied for thermal analysis but suffers from long analysis times and considerable 
material consumption. In contrast, DSF is a high-throughput technique for Tm analysis 
using RT-PCR machines in a multi-well plate format. It utilizes an extrinsic fluorescent 
dye which monitors protein unfolding by adsorption to hydrophobic structures 
exposed upon heating. But a DSF method was not yet established in the research 
group. During DSF method development, sample dilution and effects from the organic 
solvent were evaluated. The DSF method was applied to mAb concentrations from 
40 µg/ml to 175 mg/ml. For data analysis, an Origin® LabTalk script was developed 
which automatically processes and analyzes the fluorescence raw data and presents 
Tm and Tm,onset values based on first derivative analysis and Boltzmann fitting for 
individual transitions of multi-domain proteins (OpenTM, see Appendix). A robust 
DSF method with two RT-PCR machines was established. 
The melting profiles of two mAb molecules were comprehensively studied by DSF 
and DSC. By means of enzymatic cleavage, Fab and Fc fragments were prepared 
and enabled thorough characterization of the unfolding sequence and thermal 
sensitivity of the mAbs domains. This fundamental understanding allowed for the 
specific investigation of intrinsic and extrinsic factors which affect the thermal stability 
of the mAbs. First, the effect of deglycosylation was studied on the interesting case of 
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Cetuximab (CX) which carries an additional glycan moiety at the Fab part in 
comparison to the other mAb. In contrast to the common glycosylation site at Fc that 
significantly contributes to the thermal stability of the CH2 domain, deglycosylation of 
the Fab-glycans did not change the Tm values. This effect indicated that these 
glycans are not involved in conformational stabilization of CX. Next, various buffers, 
excipients, ionic strength, and pH conditions were investigated as the environment of 
the protein strongly affects the thermal stability, and thus formulation development is 
essential for stable and active products. An overall strong effect of the pH value was 
observed with considerably lower Tm values of the CH2 domain at pH 5.0 compared 
to pH 7.2, especially in the presence of arginine and histidine. Interestingly, a 
significant effect of the counterion partner to both basic amino acids was observed. 
Synergistic stabilizing effects were obtained for arginine and histidine in combination 
with aspartate and glutamate by reducing the formation of aggregates upon thermal 
unfolding of the Fab part. Especially DSF was highly valuable for Tm screenings 
where the high-throughput design was beneficial. A good correlation was found for 
DSC and DSF with respect to the Tm and Tm,onset values although consistently lower 
values were obtained by DSF. During intensive studies, both methods revealed 
outstanding benefits but also individual drawbacks which highlight their 
complementary and orthogonal application (Table I). 
Table I. Comparison of DSC and DSF for thermal analysis of proteins. 
 DSC DSF 
Unfolding 
monitored by 
Heat capacity (direct) Fluorescence intensity (indirect) 
Benefits 
Robust, precise 
Label-/marker free 
Provides thermodynamic 
parameters 
High-throughput design 
Small sample volumes 
Broader concentration range 
Drawbacks Time and material consuming Extrinsic fluorescent dye 
Limitations High protein concentrations 
Resolution of multiple transitions 
(Presence of surfactant) 
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The popular extrinsic dye SYPRO® Orange, which is routinely used for DSF, shows 
high background fluorescence in the presence of surfactants. Thus, protein 
formulations containing surfactants, which are typically used as stabilizing agents, are 
challenging in DSF. A high mAb concentration was necessary to monitor protein 
unfolding above the background signal of the surfactants with SYPRO® Orange. 
Furthermore, the molecular rotor dye DCVJ, which is less sensitive towards micelles, 
was used for the first time for DSF to analyze Tm in the presence of surfactants. The 
Tm values obtained with both dyes were in excellent agreement. The application of 
DCVJ allowed Tm analysis at a 10-fold lower mAb concentration. It was shown that 
careful background subtraction is necessary to obtain good results, especially when 
Tm,onset values are investigated. Automatic background correction by subtraction of a 
placebo sample is also supported by the OpenTM Origin® LabTalk script. With 
successful Tm analysis by DSF in the presence of surfactants, a gap for its application 
to the challenging high-throughput formulation development is closing. 
Temperature-ramped studies including DSF, DSC, DLS, and turbidity measurements 
allowed for interesting insights into the conformational and colloidal stabilities of the 
mAbs. At pH 5.0, below the pI of the mAb, positive net charges resulted in a strong 
repulsion of the molecules in solution indicated by large, positive kD values. In this 
case, no precipitation was observed upon heating. When 140 mM NaCl was added, 
the charge shielding effects of the salt reduced the kD value and aggregation 
occurred. Similar effects were obtained at pH 7.2 when net charges are neutral. 
Thus, a high kD value was indicative for colloidal stability due to repulsive electrostatic 
interactions. On the other hand, the conformational stability, especially of the 
sensitive CH2 domain, was significantly reduced at the low pH and by addition of salt. 
Higher Tm values were found when 280 mM mannitol instead of salt was used to 
achieve isotonicity. The opposing results underline the indispensability of 
comprehensive stability studies which include both conformational and colloidal 
analysis. Based on literature reports, the TIM empiric equation was derived for the 
transformation of the interaction parameters kD and A2 for mAbs for a better 
estimation of net attraction or repulsion. Moreover, the kD value was determined upon 
heating. As long as the monomer was present, a reduction of kD upon thermal 
unfolding indicated increasingly attractive interaction due to the exposing 
hydrophobic structures which lead to aggregation and precipitation of the mAb. While 
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the isolated Fc fragment behaved similar to the full mAb, the Fab fragment started to 
aggregate already below its Tm,onset value. 
Unfortunately, interaction parameters like kD or A2 are not transferable to 
intermolecular interactions between aggregates and monomers which might drive the 
nucleation of aggregates. An FCS and FCCS approach was chosen to investigate the 
adsorption of mAb monomers to existing aggregates formed by heat stress. The 
interesting results suggest that native mAb molecules were adsorbed onto the 
preformed aggregates while a stressed solution of aggregates and structurally 
perturbed monomers did not interact. Although detailed studies are necessary, FCCS 
in particular rendered a powerful technique for the analysis of homogeneous 
nucleation processes and the observation of interactions between monomeric and 
aggregated species in solution. 
Finally, a LIBD setup was used for the first time to detect protein aggregation. A 
strong laser was focused into a glass cuvette containing the mAb formulation, and 
the incidence of breakdown events was monitored upon heating of the cell. Protein 
aggregation was indicated by a sharp onset of breakdown events at temperatures 
that were in good agreement with the results from previous temperature-ramped 
studies. Potential improvements of the setup include a smaller sample volume, 
connection to size based separation techniques, and advanced breakdown analysis 
which facilitates particle sizing. Thus, LIBD is a promising orthogonal technique for 
the investigation of protein aggregates and nonproteinaceous impurities in 
pharmaceutical samples. 
In conclusion, the fundamental understanding of unfolding, aggregation, and 
interaction processes of mAbs upon heating was deepened. For this purpose, 
established analytical techniques were challenged, and substantial methodical 
improvements were achieved. Furthermore, promising results were obtained with 
novel techniques which expand the current set of protein analytics. Therefore, this 
work may support scientists working on formulation development of mAbs and 
encourages the development of more advanced hard- and software to improve 
rational and successful R&D of therapeutic protein drugs. 
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Appendix 
List of abbreviations 
A  Absorption 
A2  Second osmotic virial coefficient, also B22 
AC  Autocorrelation 
ADC  Antibody-drug conjugate 
ANS  1-Anilinonaphthalene-8-sulfonic acid 
Asn  Asparagine 
AUC  Analytical ultracentrifugation / area under the curve 
Bis-ANS 4,4'-Dianilino-1,1'-binaphthyl-5,5'-disulfonic acid 
c  Concentration 
CC  Cross-correlation 
CCD  Charge-coupled device 
CCVJ  9-(2-Carboxy-2-cyanovinyl)julolidine 
CD  Circular dichroism 
CDR  Complementarity-determining region 
CHO  Chinese hamster ovary 
CMC  Critical micellization concentration 
CMT  Critical micellization temperature 
Cp  Heat capacity 
CV  Column volume 
CX  Cetuximab 
D  Difusion coefficient 
DCVJ  9-(Dicyanovinyl)julolidine 
DFFITS Difference in fits, standardized 
DLS  Dynamic light scattering 
DMSO Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DOE  Design of experiment 
DOL  Degree of labeling 
DSC  Differential scanning calorimetry, also microcalorimetry (µDSC) 
DSF  Differential scanning fluorimetry 
DSLS  Differential static light scattering 
ε280nm  Extinction coefficient at 280 nm 
EDTA  Ethylenediaminetetraacetate 
eGFP  Enhanced green fluorescent protein 
Em  Emission (wavelength) 
Ex  Excitation (wavelength) 
f  Focal length 
Fab  Fragment, antigen binding 
FBDD  Fragment-based drug discovery, also fragment based lead discovery 
Fc  Fragment, crystallizable 
FCCS  Fluorescence cross-correlation spectroscopy 
FCS  Fluorescence correlation spectroscopy 
FTIR  Fourier transform infrared spectroscopy 
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GdnHCl Guanidinium hydrochloride 
GPIB  General purpose interface bus 
HIC  Hydrophobic interaction chromatography 
His  Histidine 
HPLC  High performance liquid chromatography 
HP-SEC High performance size exclusion chromatography 
HTS  High-throughput screening 
IgG  Immunoglobulin G 
IEF  Isoelectric focusing 
kD  Diffusion interaction parameter 
LED  Light emitting diode 
LIBD  Laser-induced breakdown detection 
mAb  Monoclonal antibody 
MAb  A therapeutic IgG1 model mAb 
MFI  Micro-flow imaging 
MWCO Molecular weight cut-off 
MS  Mass spectrometry 
NaCl  Sodium chloride 
Nd:YAG Neodymium-doped yttrium aluminium garnet 
NHS  N-hydroxysuccinimide 
PBS  Phosphate buffered saline 
PC  Personal computer 
PDB  Protein Data Bank (RCSB PDB) 
PES  Polyethersulfone 
Phos  Phosphate buffer 
pI  Isoelectric point 
PMT  Photomultiplier tube 
PP  Polypropylene 
PS  Polysorbate 
PTFE  Polytetrafluoroethylene 
PX  Poloxamer 
PVDF  Polyvinylidene fluoride 
RC  Regenerated cellulose 
R&D  Research and development 
Rh  Hydrodynamic radius 
RT-PCR Real-time polymerase chain reaction 
SEC  Size exclusion chromatography (see also HP-SEC) 
SIC  Self-interaction chromatography 
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SLS  Static light scattering 
S/N  Signal to noise 
Tagg  Temperature of aggregation 
Tagg,onset Onset temperature of aggregation 
TICT  Twisted intramolecular charge transfer 
TIM  Transformation of the interaction parameters of mAbs 
Tm  Protein melting temperature 
Tm,onset Onset temperature of protein melting / unfolding 
USB  Universal serial bus 
UV-Vis Ultraviolet-visible light 
VI  Virtual instrument 
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OpenTM Origin® LabTalk script for the analysis of DSF experiments 
type "Running openTM version 6.1 R1\nTm analyis script for RT7300 & qTower2 RT-PCR 
CSV-files\ndone 2010-2014 by Tim Menzen at the LMU, Munich, Germany"; 
type "Usage: If necessary create a new workbook and feel free to type in sample 
names in 96-well plate scheme (12x8)\nEnter required parameters in the dialog box 
(passing arguments via command line is obsolete)."; 
/* 
Recommended sample scheme for 96-well plates and Tm analysis with openTM: 
Triplicate sample (S) + one placebo (P) as blank. Start with A1. Fill up column by 
column. 
  1  2  3  4 .. 
A S1 S3 S5 .. 
B S1 S3 S5 
C S1 S3 S5 
D P1 P3 S5 
E S2 S4 P5 
F S2 S4 .. 
G S2 S4 
H P2 P4 
--> 24 samples per well plate 
cave: In case of enabled Background subtraction and Signal averaging, this scheme 
is essential. 
 
Tested and supported systems: 
- Origin 8 SR6 (!) 
- Origin 8.5 
- RT7300 (Applied Biosystems) 
- qTower 2 & 2.2 (Analytik Jena) 
 
Brief history of the openTM script: 
The script was started from the scratch in 2010 with the need to analyze the 
protein melting temperature (Tm) from DSF experiments with the RT7300 RT-PCR 
machine. 
Tm analysis was performed by fitting of the sigmoidal Boltzmann function to the 
melting curve. 
It was designed to investigate monoclonal antibodies (mAbs) which often show 
multiple melting transitions (typically 2-3) due to their distinct domains. 
Thus, different procedures were included to define the range of the Boltzmann fit 
dependent on the shape of the melting profile. 
A robust procedure to calculate the Onset temperature of unfolding was introduced 
based on the Boltzmann fit.  
Optional Background subtraction of blank samples was included (the script expects 
every 4th sample to be a blank starting with A1, B1, C1, etc.). 
Next, Tm values were additionally obtained by analysis of the first derivative of 
the melting curves. Both values are displayed in the graphs for visual inspection. 
Signal averaging was added to generate mean melting curves from the triplicates 
(allows easy reporting and manual fitting). 
Data import for the qTower 2 RT-PCR was implemented. 
Command line usage was replaced by a dialog box for better ease of use and several 
smaller fixes and tweaks... 
 
note: 
Origin handles CSV files dependent on the regional settings of the operating 
system. Thus, dot "." and comma "," mismatches can occur. 
 
why "openTM"? 
open = feel free to use the code + TM = melting temperature & Tim Menzen ;-) 
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For beginners of LabTalk scripting, the excellent official online wiki is highly 
recommended.  
*/ 
 
// SECTION: SCRIPT INITIALIZATION 
 
// record time point for script runtime 
string date1$=%[%[$(@D, D13),>" "], 4:5]; 
int min1=%(date1$); 
string date1$=%[%[$(@D, D13),>" "], 7:8]; 
int sec1=%(date1$); 
 
// global 96-well plate definition 
StringArray AF = {"A","B","C","D","E","F","G","H"}; 
 
// grab the open workbook and use it as sample book 
SampleBook$="SampleBook"; 
win -r %H %(SampleBook$); //%H system variable for current active window title 
range SampleBookSheet1R=[SampleBook$]1!; 
range SampleBookR = [SampleBook$]1!1; 
 
 
// SUBSECTION: USER INTERFACE 
 
// Check for arguments from User. Arguments are obsolete with version 5.9 due to 
getn dialog 
int numArgs = macro.narg; 
type "$(numArgs) argument(s) has (have) been passed."; 
if (numArgs>0) { 
 type -n "Command line arguments have been passed. Passing arguments is 
obsolete since version 5.9. Ignore arguments?"; 
} 
// initialize variables and open parameter input dialog 
int Device=1, StartCol=1, StopCol = 12, StartFitFilter = 1, PerformBlankedFit 
= 0, StartTemp=20; 
double deltaT = 1; 
GetN (Device 1=RT7300, 2=qTower) Device 
 (Sart with col #) StartCol 
 (Stop with col #) StopCol 
 (Start Fit with Filter #) StartFitFilter 
 (Start temperature / °C) StartTemp 
 (Temperature increase / °C) deltaT 
 (Background / blanking) PerformBlankedFit 
 (Initialize parameters); 
// I/O 
type "Device %(DeviceName.GetAt(Device)$) has been selected\nStart with column 
$(StartCol) and stop with column $(StopCol)\nStart Fit with Filter no. 
$(StartFitFilter)\nStart at $(StartTemp) °C with temperature steps of $(deltaT) 
°C"; 
if (PerformBlankedFit==0) { 
 type "Perform Fit on all samples (no blanking / background subtraction)"; 
} else { 
 type "Perform Fit for BLANKED samples (subtract placebo spectrum)"; 
} 
 
// Temperature conversion. cave: temperature ramps different than 1°C/min (i.e. 1 
row = 1 °C) are experimental 
RowToTemp(x) = StartTemp+x*deltaT-deltaT; 
TempToRow(x) = (x+deltaT-StartTemp)/deltaT; 
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// SECTION: DATA IMPORT AND PROCESSING 
 
switch (Device) { 
 
case 1: 
// SUBSECTION: RT7300  
 
// Device specific script adjustments 
StringArray Filter = {"Filter A","Filter B","Filter C","Filter D"}; 
StringArray WL = {"530nm", "554nm", "578nm", "610nm"}; 
dataset DetectorLimit = {1100000,2500000,3500000,2900000}; //empiric values 
derived from initial fluorescence of tenside solutions 
// SampleBook protection (will be overridden otherwise, although firstmode=3 
SampleBookR[9]$="RT7300 well plate"; // row 9 not used in 8by12 style 96 well 
plates 
// open Import dialog 
impCSV options.decimal:=0 options.firstmode:=3; // see 
http://wiki.originlab.com/~originla/wiki2/index.php?title=X-
Function:Details_of_TreeNodes_in_Import_CSV 
string ImpBook$ = %H; 
string FileName$=page.longname$; 
SampleBookSheet1R.name$=FileName$;//rename SampleBook's worksheet 
// create book for processed data 
newbook name:="Data RT7300 raw data" result:=ResBook$ sheet:=0; 
string tempResBookName$=page.name$; 
loop (ii,StartCol,StopCol) { 
 loop (jj,0,7) { 
  fsample = ($(jj)*12)+$(ii); 
  range outputR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii); 
  wxt test:=col(2)=$(fsample) iw:=[ImpBook$]1 ow:=outputR sel:=0 c1:=1; 
  loop(bb,1,4) { 
   range outputColR=%(outputR)!wcol(bb+2); 
   outputColR[L]$="%(AF.GetAt(bb)$), %(WL.GetAt(bb)$)"; 
  } 
  range outputColR=%(outputR)!col(1); 
  outputColR[L]$="Temperature"; 
  outputColR[C]$="Temperature"; 
  outputColR[U]$="°C"; 
  outputColR=RowToTemp(outputColR); 
 }  
} 
// get final temperature from data and input parameter 
range DataR = [ResBook$]1!col(1); 
double finalTemp = StartTemp+deltaT*(DataR.nrows-1); // 20 + (76-1)*1  = 96 
// rename workbook 
string ResBook$="Wellplate"; 
win -r %(tempResBookName$) %(ResBook$); 
// I/O 
type "Data import from RT7300... done.";  
break; 
 
 
case 2: 
// SUBSECTION. qTower 
 
// Device specific script adjustments 
StringArray Filter = {"FAM", "SYPRO Orange", "TAMRA", "ROX"}; //edit filter names 
dependent on your system 
StringArray WL = {"520nm", "580nm", "580nm", "605nm"}; 
dataset DetectorLimit = {100000,100000,100000,100000}; //empiric values derived 
from saturation warning 
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// SampleBook protection (will be overridden otherwise, although firstmode=3 
SampleBookR[9]$="qTower well plate"; // row 9 not used in 8by12 style 96 well 
plates 
// open Import dialog 
impCSV options.decimal:=2 options.firstmode:=3; // see 
http://wiki.originlab.com/~originla/wiki2/index.php?title=X-
Function:Details_of_TreeNodes_in_Import_CSV 
string DataSheet$ = wks.name$; 
string DataBook$ = %H; 
string FileName$=page.longname$; 
SampleBookSheet1R.name$=FileName$;//rename SampleBook's worksheet 
stringarray WellID; 
// log number of samples 
range IDrow = [DataBook$]1!col(1); 
int nExp = IDrow.nrows; 
int nFilters = nExp/96; 
range DataR = [DataBook$]1!; 
int nSteps = DataR.ncols-1; 
double finalTemp = StartTemp+deltaT*(nSteps-1); // 20 + (76-1)*1  = 96 
// create intermediate data books 
loop (aa,1,nFilters) { 
 range DataR = [DataBook$]1!1[1]:end[96]; 
 wtranspose iw:=DataR ow:=[DataF$(aa)]; 
 del DataR; 
 // add Well ID to longname 
 loop (bb,1,96) { 
  range SampleR=[DataF$(aa)]1!$(bb); 
  SampleR[L]$=SampleR[1]$; 
  int CFerror = WellID.add(SampleR[1]$); 
 } 
 range firstrow=[DataF$(aa)]1![1]; 
 del firstrow; 
 range firstcol = [DataF$(aa)]1!col(1); 
 firstcol.type = 1; 
} 
// create book for processed data 
newbook name:="Data qTower raw data" result:=ResBook$ sheet:=0; 
string tempResBookName$=page.name$; 
loop(i,1,96) { 
 newsheet name:=WellID.GetAt(i)$; 
 // create x-axis 
 range TempR=[ResBook$]$(i)!1; 
 TempR = {StartTemp:deltaT:finalTemp}; 
 TempR[L]$ = "Temperature"; 
 TempR[U]$ = "°C"; 
 // set column 2 to well plate position 
 range SampleR=[ResBook$]$(i)!2;  
 SampleR = {i:0:nSteps}; 
 // copy data from DataFBooks to WellplateBook 
 loop (j,1,nFilters) { 
  range DataFromR = [DataF$(j)]1!$(i); 
  range DataToR = [ResBook$]$(i)!$(j+2); 
  DataToR = DataFromR; 
  DataToR[L]$ = Filter.GetAt(j)$; 
 } 
} 
string ResBook$="Wellplate"; 
win -r %(tempResBookName$) %(ResBook$); //rename 
// delete intermediate data books 
loop (aa,1,nFilters) { 
 range DataFR = [DataF$(aa)]; 
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 del DataFR; 
} 
// I/O 
type "Data import from qTower... done."; 
break; 
 
} // terminate switch 
 
 
// SECTION: WORKBOOK CREATION 
 
// create new book with well plate sample scheme for the readings 
StringArray Plotbookorder = {"JustCurves", "BlankedCurves", "DiffCurves", 
"SplinedCurves"}; 
newbook name:="Graphic results (inserted plot book)" result:=PlotBook$; 
wks.autoaddrows=0; 
wks.nCols=12; 
wks.nRows=8; 
wks1.name$=%(Plotbookorder.GetAt(1)$); 
loop (aa,2,4) { 
 newsheet name:=%(Plotbookorder.GetAt(aa)$); 
 wks.autoaddrows=0; 
 wks.nCols=12; 
 wks.nRows=8; 
} 
string tempPlotBookName$=page.name$; 
 
// create new book with well plate sample scheme for the processed data (peaks, 
etc) 
newbook name:="Data process data" result:=PDBook$ sheet:=1; 
wks.autoaddrows=0; 
wks.nCols=12; 
wks.nRows=8; 
wks.col1.label$="Sample"; 
wks.col1.comment$=FileName$; 
PDBook$!wks1.name$="Table"; //declare sheet order*/ 
loop(i,1,Filter.GetSize()) { 
 newsheet name:=Filter.GetAt(i)$;// cols:=12 rows:=8; not working since 
autoaddrows 
} 
newsheet name:="DiffData"; 
string tempPDBookName$=page.name$; 
 
// create new book for S/N data 
newbook name:="Results S/N data" result:=SNBook$ sheet:=0; 
loop(i,1,Filter.GetSize()) { 
 newsheet name:=Filter.GetAt(i)$; 
} 
string tempSNBookName$=page.name$; 
 
// create new book for signal averaging data 
newbook name:="Data averaged signals" result:=AverageBook$ sheet:=0; 
string tempAverageBookName$=page.name$; 
 
// create new book with well plate sample scheme for the readings 
newbook name:="Graphic average results (inserted averaged plot book)" 
result:=AveragedPlotBook$; 
wks.autoaddrows=0; 
wks.nCols=12; 
wks.nRows=2; 
wks1.name$=%(Plotbookorder.GetAt(1)$); 
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loop (aa,2,4) { 
 newsheet name:=%(Plotbookorder.GetAt(aa)$); 
 wks.autoaddrows=0; 
 wks.nCols=12; 
 wks.nRows=2; 
} 
string tempAveragedPlotBookName$=page.name$; 
 
// I/O 
type "Initializing workbooks... done."; 
 
 
// SECTION: PLOT THE RAW DATA 
 
// global x-axis range calculation 
int plotxto = finalTemp+10-MOD(finalTemp,10); // bring up to next 10-digit 
loop (ii,StartCol,StopCol) { 
 loop (jj,0,7) { 
  fsample = ($(jj)*12)+$(ii); 
  range outputR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii); 
     
  // PLOT 
  plotxy iy:=%(outputR)!(1,3:end) plot:=202 
ogl:=[SinglePlot%(AF.GetAt(jj+1)$)$(ii)]; 
  //change graph style 
  yl.text$="Fluorescence intensity [a.u.]"; 
  layer.x.from=StartTemp; // x-axis start from 
  layer.x.to=plotxto; // smart x-scale 
  layer.y.label.divideBy=1000; 
  layer.y.label.suf$="k"; 
  //move legend 
  legend.y = layer1.y.to - legend.dy / 2; 
  legend.x = layer1.x.from + legend.dx / 2; 
  //add title label 
  label -j 1 -s -sa -n title Position %(AF.GetAt(jj+1)$)$(ii), 
%(FileName$)\n%([SampleBook$]1!wcol(ii)[jj+1]$); 
  title.fsize=28; 
  title.y = layer.y.to + title.dy / 2; 
  //change line style 
  set %C -z 3; // set symbol size 
  // insert graph window into 8by12 worksheet 
  insertGraph gname:=SinglePlot%(AF.GetAt(jj+1)$)$(ii) 
cell:=[PlotBook$]1!wcol(ii)[jj+1] resizecell:=1; 
 } 
 // Change sheet style 
 range PlotBookCol=[PlotBook$]JustCurves!col($(ii)); 
 PlotBookCol[L]$="Well plate column #$(ii)";  
 PlotBookCol.type=2; //disregard col type 
} 
PlotBook$="PlotBook"; 
win -r %(tempPlotBookName$) %(PlotBook$); // rename Books 
// I/O 
type "%(PlotBook$)... done."; 
 
 
// SECTION: SIGNAL AVERAGING  
// included with 5.1, 20120613 
 
// summary plots (with and without blanking) of all averaged melting curves 
StringArray SumPlot = {"SumAvPlot", "SumAvPlotBlanked"}; 
// determine the number of sample from the arguments 
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nSamples = (StopCol-StartCol+1)*2; 
// average wells 1-3 & 5-7 of every column (omit blanks) 
loop (ii,1,nSamples) { 
  // define wells to be averaged 
  int AVtoggle = 2-mod(ii,2); // (1..2) toggle 
  int AVcounter = round(ii/2,0); // (1,1..2,2..) 
  AverageName$ = "%(AF.GetAt(AVtoggle*4-
3)$)$(AVcounter)%(AF.GetAt(AVtoggle*4-2)$)$(AVcounter)%(AF.GetAt(AVtoggle*4-
1)$)$(AVcounter)"; 
  newsheet book:=%(AverageBook$) name:=AverageName$; 
  // prepare X column of averaged data 
  range AveragedXR = [%(AverageBook$)]$(ii)!col(1); 
  range RawXR = [%(ResBook$)]1!col(1); 
  AveragedXR = RawXR; 
  AveragedXR[L]$="Temperature"; 
  AveragedXR[C]$="Temperature"; 
  AveragedXR[U]$="°C"; 
  // average the 3 wells over all filters 
  loop (gg,StartFitFilter,Filter.GetSize()) { 
   // prepare mean values 
   range RawWellY1R = [%(ResBook$)]%(AF.GetAt(AVtoggle*4-
3)$)$(AVcounter)!wcol(gg+2); // 1st well.. Filter A starts in col(3) 
   range RawWellY2R = [%(ResBook$)]%(AF.GetAt(AVtoggle*4-
2)$)$(AVcounter)!wcol(gg+2); // 2nd well 
   range RawWellY3R = [%(ResBook$)]%(AF.GetAt(AVtoggle*4-
1)$)$(AVcounter)!wcol(gg+2); // 3rd well 
   range AveragedYR = [%(AverageBook$)]$(ii)!wcol(gg+1); // 
destination for averaged signals. Filter A will be in col(2) 
   AveragedYR = (RawWellY1R + RawWellY2R + RawWellY3R)/3; 
   AveragedYR[C]$="%(Filter.GetAt(gg)$)"; 
   AveragedYR[U]$="a.u."; 
   AveragedYR[L]$="Average of 
%(RawWell1R.name$)+%(RawWell2R.name$)+%(RawWell3R.name$)"; 
   // blank averaged signals 
   range RawPlaceboR = 
[%(ResBook$)]%(AF.GetAt(AVtoggle*4)$)$(AVcounter)!wcol(gg+2); // Placebo is the 
4th well 
   range BlankedAveragedYR = [%(AverageBook$)]$(ii)!wcol(gg+5); 
// Filter A will be in col(6) 
   BlankedAveragedYR = AveragedYR - RawPlaceboR; 
   BlankedAveragedYR[C]$="Blanked %(Filter.GetAt(gg)$)"; 
   BlankedAveragedYR[U]$="a.u."; 
   BlankedAveragedYR[L]$="Blanked Average of 
%(RawWell1R.name$)+%(RawWell2R.name$)+%(RawWell3R.name$)"; 
   // for further data processing decide if BLANKED or NON-
BLANKED 
   if (PerformBlankedFit==1) { 
    InputAveragedYR=BlankedAveragedYR; 
   } else { 
    InputAveragedYR=AveragedYR; 
   } 
   // derive (differentiate) (do not smooth the average curves) 
   range DerivedBlankedAveragedYR = 
[%(AverageBook$)]$(ii)!wcol(gg+9); // Filter A will be in col(10) 
   differentiate iy:=InputAveragedYR smooth:=0 
oy:=DerivedBlankedAveragedYR; 
   DerivedBlankedAveragedYR[C]$="Blanked 1st derivative 
%(Filter.GetAt(gg)$)"; 
   DerivedBlankedAveragedYR[U]$="a.u."; 
   DerivedBlankedAveragedYR[L]$="Derived Blanked Average of 
%(RawWell1R.name$)+%(RawWell2R.name$)+%(RawWell3R.name$)"; 
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   // spline 
   xmaxforspline = RowToTemp(DerivedBlankedAveragedYR.nrows); 
   noip = (xmaxforspline-StartTemp)*10+1; 
   interp1xy iy:=DerivedBlankedAveragedYR method:=spline 
npts:=$(noip) xmin:=$(StartTemp) xmax:=$(xmaxforspline) boundary:= notaknot 
oy:=[%(AverageBook$)]$(ii)!(14,$(gg+14)); 
   range SplinedDerBlaAveXR = [%(AverageBook$)]$(ii)!wcol(14); // 
new splined x-axis will be in col(14) 
   SplinedDerBlaAveXR[L]$="Temperature"; 
   SplinedDerBlaAveXR[U]$="°C"; 
   SplinedDerBlaAveXR[C]$="Blanked+splined 1st derivative"; 
   range SplinedDerBlaAveYR = [%(AverageBook$)]$(ii)!wcol(gg+14); 
// Filter A will be in col(15) 
   SplinedDerBlaAveYR[C]$="Blanked+splined 1st derivative 
%(Filter.GetAt(gg)$)"; 
   SplinedDerBlaAveYR[U]$="a.u."; 
   SplinedDerBlaAveYR[L]$="Splined Derived Blanked Average of 
%(RawWell1R.name$)+%(RawWell2R.name$)+%(RawWell3R.name$)"; 
   // peak find 
   range 
SplinedDiffPeakCenters=[%(AverageBook$)]$(ii)!wcol(gg*2+17); 
   range SplinedDiffPeakY=[%(AverageBook$)]$(ii)!wcol(gg*2+18); 
   SplinedDiffPeakCenters[C]$="Temperature"; 
   SplinedDiffPeakCenters[U]$="°C"; 
   SplinedDiffPeakCenters[L]$="Peaks %(Filter.GetAt(gg)$)"; 
   pkFind -se iy:=SplinedDerBlaAveYR method:=first dir:=both 
ocenter:=SplinedDiffPeakCenters; // -se to ignore "Keine Peaks gefunden.." 
   NoFoundPeaks=SplinedDiffPeakCenters.nrows; 
   if (0 != xf_get_last_error_code()) { 
    strError$ = "pkFind failed: " + 
xf_get_last_error_message()$; 
    type strError$; 
    SplinedDiffPeakCenters[1]=StartTemp;  
    SplinedDiffPeakY[1]=0; // set first row = 0 
    SplinedDiffPeakY[C]$="no peak found"; 
    type 
"[%(SplineBook$)]%(AF.GetAt(jj+1)$)$(ii)!col($(gg*2+4)) skipping peakfind"; 
   } else {     
    SplinedDiffPeakY[C]$="Peaks %(Filter.GetAt(gg)$)"; 
    SplinedDiffPeakY[U]$="a.u."; 
    SplinedDiffPeakY[L]$=""; 
    loop (uu,1,$(NoFoundPeaks)) { 
     SplinedDiffPeakY[uu] = 
SplinedDerBlaAveYR[$(SplinedDiffPeakCenters[uu])]; 
    
 SplinedDiffPeakCenters[uu]=SplinedDerBlaAveXR[SplinedDiffPeakCenters[uu]]; 
    } 
   } 
   SplinedDiffPeakCenters.type=4; //set as X 
  } 
  // sort graphs in new 12by2 order 
  int helpx = round(ii/2,0)+StartCol-1; 
  int helpy = -1*mod(ii,2)+2; //awesome! 
  // change graph layouts 
  loop (kk,1,4) { //loop through plot book 
  // splined graphs have different x-axis scaling 
  if (kk==4) { 
   colx = 14; 
   colystart = 15; 
   colystop = 18; 
   plottype = 200; 
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   // plot peak dots 
   loop (yy,1,4) { 
    plotxy 
iy:=[%(AverageBook$)]$(ii)!($(yy*2+17):$(yy*2+18)) plot:=201 color:=6 
ogl:=[Av%(Plotbookorder.GetAt(kk)$)%(AverageName$)]; 
   } 
   loop (xx,1,4) { 
    range 
graphPeak=[Av%(Plotbookorder.GetAt(kk)$)%(AverageName$)]1!$(xx);  
    win -o Av%(Plotbookorder.GetAt(kk)$)%(AverageName$) { 
     layer -ilx graphPeak; 
    } 
   } 
  } else { 
   colx = 1; 
   colystart = kk*4-2; 
   colystop = kk*4+1; 
   plottype = 202; 
  } 
  // PLOT 
  plotxy iy:=[%(AverageBook$)]$(ii)!($(colx),$(colystart):$(colystop)) 
plot:=plottype ogl:=[Av%(Plotbookorder.GetAt(kk)$)%(AverageName$)]; 
  //change Graph style 
  yl.text$="Mean fluorescence intensity (n=3) [a.u.]"; 
  layer.x.from=StartTemp; // x-axis start from 
  layer.x.to=plotxto; // smart x-scale 
  layer.y.label.divideBy=1000; 
  layer.y.label.suf$="k"; 
  //move legend 
  legend.y = layer1.y.to - legend.dy / 2; 
  legend.x = layer1.x.from + legend.dx / 2; 
  //add title label 
  label -j 1 -s -sa -n title Position %(AverageName$), 
%(FileName$);//\n%([SampleBook$]1!wcol(ii)[jj+1]$); 
  title.fsize=28; 
  title.y = layer.y.to + title.dy / 2; 
  //change line style 
  set %C -z 3; // set symbol size 
  //insert plots 
  range AveragedPlotsR = [AveragedPlotBook$]$(kk)!wcol(helpx)[helpy]; 
  insertGraph gname:=Av%(Plotbookorder.GetAt(kk)$)%(AverageName$) 
cell:=AveragedPlotsR resizecell:=1; 
 } 
  // SUMMARY PLOT 
  filterno = 3; // 1=A, 2=B, 3=C, 4=D 
  coly=5+filterno; 
  plotxy iy:=[%(AverageBook$)]$(ii)!(1,$(coly)) plot:=plottype 
color:=$(ii) ogl:=[%(SumPlot.GetAt(2)$)]; 
  coly=1+filterno; 
  plotxy iy:=[%(AverageBook$)]$(ii)!(1,$(coly)) plot:=plottype 
color:=$(ii) ogl:=[%(SumPlot.GetAt(1)$)]; 
} 
// rename Books 
AveragedPlotBook$="AveragePltBk"; 
win -r %(tempAveragedPlotBookName$) %(AveragedPlotBook$); 
AverageBook$="AverageBook"; 
win -r %(tempAverageBookName$) %(AverageBook$);  
// change summary plot style 
loop (ll, 1, 2) { 
 win -o %(SumPlot.GetAt(ll)$) { 
  //change graph style 
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  yl.text$="Mean fluorescence intensity (n=3) [a.u.]"; 
  layer.x.from=StartTemp; // x-axis start from 
  layer.x.to=plotxto; // smart x-scale 
  layer.y.label.divideBy=1000; 
  layer.y.label.suf$="k"; 
  //move legend 
  legend.y = layer1.y.to - legend.dy / 2; 
  legend.x = layer1.x.from + legend.dx / 2; 
  // Update legend of summary plot 
  legend.fsize=12; 
  legendupdate mode:=custom custom:="@WS"; 
 } 
} 
// I/O 
type "%(AverageBook$)... done."; 
type "%(AveragedPlotBook$)... done."; 
  
 
// SECTION: BLANKS SUBTRACTION  
// Blank samples are in wells 4 & 8 of every column 
 
// create new workbook and start subtraction 
newbook name:="Data blanked data" result:=BlankedBook$ sheet:=0; 
string tempBlankedBookName$=page.name$; 
int BlankDist=4; //every 4th sample is a blank 
loop(ii,StartCol,StopCol) { 
 loop(jj,0,7) { 
  fsample = ($(jj)*12)+$(ii); 
  range BlankedR=[BlankedBook$]%(AF.GetAt(jj+1)$)$(ii)!1; 
  range SampleR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!1; 
  BlankedR=SampleR; //fill in the temperature 
  BlankedR.name$="Temp"; 
  BlankedR[L]$="Temperature"; 
  BlankedR[U]$="°C"; 
  int fblank=fsample+BlankDist; 
  loop(kk,StartFitFilter,Filter.GetSize()) {//loop over all 4 filters 
   range SampleR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!$(kk+2); 
   range 
BlankR=[ResBook$]%(AF.GetAt(jj+BlankDist)$)$(ii)!$(kk+2); 
   range BlankedR=[BlankedBook$]%(AF.GetAt(jj+1)$)$(ii)!$(kk+2); 
//vorher kk+1 aber da gleicher style notwendig für PerformBlankedFit 
   BlankedR=SampleR-BlankR; 
   BlankedR[L]$="%(AF.GetAt(jj+1)$)$(ii)-
%(AF.GetAt(jj+BlankDist)$)$(ii)="; 
   BlankedR[C]$="Blanked Filter %(AF.GetAt(kk)$)"; 
  }   
  // PLOT 
  plotxy iy:=[BlankedBook$]%(AF.GetAt(jj+1)$)$(ii)!(1,3:end) plot:=202 
ogl:=[SingleBlankedPlot%(AF.GetAt(jj+1)$)$(ii)]; //vorher (1,2:end) aber da 
gleicher style notwendig für PerformBlankedFit 
  //change Graph style 
  yl.text$="Fluorescence intensity [a.u.]"; 
  layer.y.label.divideBy=1000; 
  layer.y.label.suf$="k"; 
  //move legend 
  legend.y = layer1.y.to - legend.dy / 2; 
  legend.x = layer1.x.from + legend.dx / 2; 
  layer.x.from=StartTemp; // x-axis start from 
  layer.x.to=plotxto; // smart x-scale 
  //add title label 
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  label -j 1 -s -sa -n title Position %(AF.GetAt(jj+1)$)$(ii), 
%(FileName$)\n%([SampleBook$]1!wcol(ii)[jj+1]$); 
  title.fsize=28; 
  title.y = layer.y.to + title.dy / 2; 
  //change line style 
  set %C -z 3; // set symbol size 
  // insert graphs     
  insertGraph gname:=SingleBlankedPlot%(AF.GetAt(jj+1)$)$(ii) 
cell:=[PlotBook$]BlankedCurves!wcol(ii)[jj+1] resizecell:=1; 
  // adjust BlankDist 
  if (BlankDist==1) { 
   BlankDist=4; 
  } else { 
   BlankDist-=1; 
  } 
 } 
} 
// rename Books 
string BlankedBook$="BlankedWell"; 
win -r %(tempBlankedBookName$) %(BlankedBook$); 
// I/O 
type "%(BlankedBook$)... done."; 
 
 
// SECTION: DATA PROCESSING 
 
// Decide if BLANKED or NON-BLANKED samples are to be analyzed 
if (PerformBlankedFit==1) { 
 ResBook$=%(BlankedBook$); 
 type "Using %(BlankedBook$) for fitting!"; 
} 
 
// Find min, max, peaks, S/N values 
loop (ii,StartCol,StopCol) { 
 loop (jj,0,7) { 
  fsample = ($(jj)*12)+$(ii); 
  range outputR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii); 
  loop(hh,StartFitFilter,Filter.GetSize()) { 
   range InputR=%(outputR)!wcol(hh+2);//filter A starts in col 3 
   int minPeakHeight = round(max(InputR)/100); // 40: empirical 
value. 
   dataset PeakD=peaks(InputR, 4, minPeakHeight);//tweak value 
between 4 and 10000 
   loop (ee,1,2) { 
    range DataR=[PDBook$]%(Filter.GetAt(hh)$)!wcol(ee+1); 
    DataR[fsample]=RowToTemp(PeakD[ee]); 
    DataR[L]$="Peak $(ee)"; 
   } 
   range TableR=[PDBook$]%(Filter.GetAt(hh)$)!col(1); 
   TableR[fsample]$="%(AF.GetAt(jj+1)$)$(ii)"; 
   //table peaks 
   range TableR=[PDBook$]"Table"!wcol(hh+1);//col 1 samples 
   TableR[C]$=Filter.GetAt(hh)$; 
   TableR[U]$="°C"; 
   TableR[L]$="Peaks"; 
   TableR[fsample]=RowToTemp(PeakD[1]); 
   //table min-max 
   range TableMinR=[PDBook$]"Table"!wcol(hh+5);//col 5 sample, 
peaks 
   TableMinR[C]$=Filter.GetAt(hh)$; 
   TableMinR[U]$="°C"; 
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   TableMinR[L]$="Min"; 
   range TableMaxR=[PDBook$]"Table"!wcol(hh+9);//col 9 sample, 
peaks, min 
   TableMaxR[C]$=Filter.GetAt(hh)$; 
   TableMaxR[U]$="°C"; 
   TableMaxR[L]$="Max"; 
   // find MINUMUM and MAXIMUM 
   mi = min(InputR); // important: variable has to be at least 
double (no int), because qTower produces rational numbers 
   mx = max(InputR); 
   for (int gg=1; gg<=InputR.GetSize(); gg++) { 
    if (mi==InputR[gg]) { 
     TableMinR[fsample]=RowToTemp(gg); 
    }  
    if (mx==InputR[gg]) { 
     TableMaxR[fsample]=RowToTemp(gg); 
    }  
   } 
   // S/N Ratio 
   range PDPeak1R=[PDBook$]%(Filter.GetAt(hh)$)!wcol(2); 
   range PDPeak2R=[PDBook$]%(Filter.GetAt(hh)$)!wcol(3); 
   range SNPeakR=[SNBook$]%(Filter.GetAt(hh)$)!col(2); 
   SNPeakR[L]$="Peak"; 
   SNPeakR[U]$="°C"; 
   range PDFilterC_yR=%(OutputR)!wcol(5); // Filter C in col 5 
   range SNPeak_yR=[SNBook$]%(Filter.GetAt(hh)$)!col(3); 
   SNPeak_yR[L]$="Peak_y=S"; 
   SNPeak_yR[U]$="a.u.";    
   range PDMinR=[PDBook$]"Table"!col(8); // Min Filter C 
   range SNMinR=[SNBook$]%(Filter.GetAt(hh)$)!col(4); 
   SNMinR[L]$="Min"; 
   SNMinR[U]$="°C";    
   range SNMin_yR=[SNBook$]%(Filter.GetAt(hh)$)!col(5); 
   SNMin_yR[L]$="Min_y=N"; 
   SNMin_yR[U]$="a.u."; 
   range SNInit_yR=[SNBook$]%(Filter.GetAt(hh)$)!col(6); 
   SNInit_yR[L]$="Init_y=N"; 
   SNInit_yR[U]$="a.u."; 
    
   // get peak 
   if (PDPeak1R[fsample]>PDPeak2R[fsample]) { 
    SNPeakR[fsample]=PDPeak1R[fsample]; 
   } else { 
    SNPeakR[fsample]=PDPeak2R[fsample]; 
   } 
   // get min 
   SNMinR[fsample]=PDMinR[fsample]; 
       
   // set S and N values (e.g., corresponding fluorescence 
intensities) 
   SNPeak_yR[fsample]=PDFilterC_yR[TempToRow(SNPeakR[fsample])]; 
   SNMin_yR[fsample]=PDFilterC_yR[TempToRow(SNMinR[fsample])]; 
   SNInit_yR[fsample]=InputR[1]; 
   range PHR=[SNBook$]%(Filter.GetAt(hh)$)!col(7); // peak height 
   PHR[L]$="Peak Height"; 
   PHR[U]$="a.u."; 
   PHR[fsample]=SNPeak_yR[fsample]-SNMin_yR[fsample]; 
   range IHR=[SNBook$]%(Filter.GetAt(hh)$)!col(8); // peak height 
   IHR[L]$="Init Height"; 
   IHR[U]$="a.u."; 
   IHR[fsample]=SNInit_yR[fsample]-SNMin_yR[fsample]; 
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   range SNRR=[SNBook$]%(Filter.GetAt(hh)$)!col(9); 
   SNRR[L]$="S/N Ratio"; 
   SNRR[fsample]=SNPeak_yR[fsample]/SNMin_yR[fsample]; 
   range WPRR=[SNBook$]%(Filter.GetAt(hh)$)!col(10); 
   WPRR[L]$="Weighted Peak Ratio"; 
  
 WPRR[fsample]=(SNPeak_yR[fsample]+SNMin_yR[fsample])/SNMin_yR[fsample]; 
   range AGGCR=[SNBook$]%(Filter.GetAt(hh)$)!col(11); 
   AGGCR[L]$="Agg. content"; 
   AGGCR[U]$="%"; 
   AGGCR[fsample]=(SNInit_yR[fsample]-
SNMin_yR[fsample])/(SNPeak_yR[fsample]-SNMin_yR[fsample])*100; 
   range TableR=[SNBook$]%(Filter.GetAt(hh)$)!col(1); 
   TableR[fsample]$="%(AF.GetAt(jj+1)$)$(ii)"; 
  } 
  range TableR=[PDBook$]"Table"!col(1); 
  TableR[fsample]$="%(AF.GetAt(jj+1)$)$(ii)"; 
 }   
} 
// rename books 
PDBook$="ProcessData"; 
win -r %(tempPDBookName$) %(PDBook$); 
SNBook$="SNData"; 
win -r %(tempSNBookName$) %(SNBook$); 
// I/O 
type "%(PDBook$), %(SNBook$)... done."; 
 
 
// SECTION: DIFFERENTIATION 
 
// derive the fluorescence melting curves to find the Tm values 
loop(gg,StartFitFilter,Filter.GetSize()) { 
 loop(ii,StartCol,StopCol) { 
  loop(jj,0,7) { 
   fsample = ($(jj)*12)+$(ii); 
   range InputR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!; 
   range DataR=%(InputR)wcol(gg+2); 
   differentiate iy:=DataR smooth:=1 poly:=1 npts:=5; 
   // find peaks in differentiation 
   int diffcol=InputR.ncols; 
   range DiffR=%(InputR)wcol(diffcol); 
  
/*   // new style (experimental) 
   range AllDiffPeakCenters = [DiffTmBook$]$(gg)!wcol(fsample); 
   AllDiffPeakCenters[U]$="°C"; 
   AllDiffPeakCenters[C]$=%(AF.GetAt(jj+1)$)$(ii); 
   //AllDiffPeakCenters[L]$="Peak Center"; 
   pkFind -se iy:=DiffR method:=max dir:=both 
ocenter:=AllDiffPeakCenters; 
   if( 0 != xf_get_last_error_code() ){ 
    strError$ = "XFunction Failed: " + 
xf_get_last_error_message()$; 
    type strError$; 
    AllDiffPeakCenters=0; 
    type "if loop: diffcol=$(diffcol); %(DiffR)"; 
   } else { 
   AllDiffPeakCenters = RowToTemp(AllDiffPeakCenters); 
   type "else loop: diffcol=$(diffcol); %(DiffR)"; 
   } 
*/    
   // old fashion 
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   int minDiffHeight = round(max(DiffR)/5); // 40: empirical 
value. 
   dataset PeakD=peaks(DiffR,5,minDiffHeight); // 
   if (PeakD.getSize()<2) { 
    minDiffHeight = round(minDiffHeight/5); 
    PeakD=peaks(DiffR,10,minDiffHeight); 
   } 
   if (PeakD.getSize()<2) { 
    minDiffHeight = round(minDiffHeight/2); 
    PeakD=peaks(DiffR,10,minDiffHeight); 
   } 
   if ($(PeakD[3])>$(PeakD[2])) { 
    range 
BetweenPeaksR=%(InputR)wcol(diffcol)[$(PeakD[2]):$(PeakD[3])]; 
    mi=min(BetweenPeaksR); 
   } else { 
    range 
BetweenPeaksR=%(InputR)wcol(diffcol)[$(PeakD[1]):$(PeakD[2])]; 
    mi=min(BetweenPeaksR); 
   } 
    
   // find minimum between both peaks -> most negative value = 
descending slope 
   range 
InputDiffR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(diffcol); 
   for (int ff=1; ff<=InputDiffR.GetSize(); ff++) { 
    if (mi==InputDiffR[ff]) { 
     mii=ff;      
    } 
   } 
   DiffR=abs(DiffR); //work with absolute values (necessary for 
further analysis) 
   range 
BetweenMinandPeak2R=%(InputR)wcol(diffcol)[$(mii):$(PeakD[2])]; 
   double miatmeltcurve=min(BetweenMinandPeak2R);   
   if ($(miatmeltcurve)=="--") { //fit will break if 
miatmeltcurve is empty 
    miatmeltcurve=RowToTemp($(PeakD[2])); 
   } 
   range 
InputDiffR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(diffcol); 
   for (int ff=1; ff<=InputDiffR.GetSize(); ff++) { 
    if (miatmeltcurve==InputDiffR[ff]) { 
     miatmeltcurve=RowToTemp(ff); 
    } 
   } 
    
   // empirical evaluation for find the local minimum in front of 
peak by subtracting an empirical temperature value (-> 4p) 
   if ($(PeakD[3])>$(PeakD[2])) { 
    int ULpeak3 = $(PeakD[3])-2; 
    range localMinDiffR=%(InputR)wcol(diffcol)[$(ULpeak3-
15):$(ULpeak3)]; // 15 
    localmin=min(localMinDiffR); 
   } else { 
    if ($(PeakD[2])>$(PeakD[1])) { 
     int ULpeak2 = $(PeakD[2])-2; 
     range 
localMinDiffR=%(InputR)wcol(diffcol)[$(ULpeak2-15):$(ULpeak2)]; // 15 
     localmin=min(localMinDiffR); 
    } else { 
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     int ULpeak1 = $(PeakD[1])-2; 
     range 
localMinDiffR=%(InputR)wcol(diffcol)[$(ULpeak1-15):$(ULpeak1)]; 
     localmin=min(localMinDiffR); 
    } 
   }     
   range 
InputDiffR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(diffcol); 
   for (int ff=1; ff<=InputDiffR.GetSize(); ff++) { 
    if (localmin==InputDiffR[ff]) { 
     localmin=RowToTemp(ff); 
    } 
   } 
   // reporting 
   loop(hh,1,5) { 
    int DiffDataCol = (gg-1)*5+hh+1; 
    range TableR=[PDBook$]"DiffData"!col(DiffDataCol);//col 
1 samples 
    if (hh<4) { 
     TableR[C]$=Filter.GetAt(gg)$; 
     TableR[U]$="°C"; 
     TableR[L]$="Peak $(hh)"; 
     TableR[fsample]=RowToTemp(PeakD[hh]); 
    } else { 
     if (hh==4) { 
     TableR[C]$=Filter.GetAt(gg)$; 
     TableR[U]$="°C"; 
     TableR[L]$="Min tween 1&2"; 
     TableR[fsample]=miatmeltcurve; 
     } else { 
      TableR[C]$=Filter.GetAt(gg)$; 
      TableR[U]$="°C"; 
      TableR[L]$="local Min"; 
      TableR[fsample]=localmin; 
     } 
    } 
   } 
   // create the plots 
   if (gg==4) { 
    //fill first column 
    range TableR=[PDBook$]"DiffData"!col(1); 
    TableR[fsample]$="%(AF.GetAt(jj+1)$)$(ii)"; 
    // PLOT 
    plotxy iy:=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!(1,7:end) 
plot:=202 ogl:=[DiffPlot%(AF.GetAt(jj+1)$)$(ii)]; 
    //change Graph style 
    yl.text$="Fluorescence intensity [a.u.]"; 
    layer.y.label.divideBy=1000; 
    layer.y.label.suf$="k"; 
    //move legend 
    legend.y = layer1.y.to - legend.dy / 2; 
    legend.x = layer1.x.from + legend.dx / 2; 
    layer.x.from=StartTemp; // x-axis start from 
    layer.x.to=plotxto; // smart x-scale 
    //add title label 
    label -j 1 -s -sa -n title Position 
%(AF.GetAt(jj+1)$)$(ii), %(FileName$)\n%([SampleBook$]1!wcol(ii)[jj+1]$); 
    title.fsize=28; 
    title.y = layer.y.to + title.dy / 2; 
    //change line style 
    set %C -z 3; // set symbol size 
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    //insert graphs 
    insertGraph gname:=DiffPlot%(AF.GetAt(jj+1)$)$(ii) 
cell:=[PlotBook$]DiffCurves!wcol(ii)[jj+1] resizecell:=1; 
   } 
  } 
 } 
} 
//DiffTmBook$="DiffTmBook"; 
//win -r %(tempDiffTmBookName$) %(DiffTmBook$); // rename 
// I/O 
type "Differentiation... done."; 
 
 
 
// SECTION: SPLINING 
 
// create new book with interpolated data 
newbook name:="Data splined derived data" result:=SplineBook$ sheet:=0; 
string tempSplineBookName$=page.name$; 
loop(gg,StartFitFilter,Filter.GetSize()) { 
 loop(ii,StartCol,StopCol) { 
  loop(jj,0,7) { 
   fsample = ($(jj)*12)+$(ii); 
   range InputR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!; 
   // interpolate - splining 
   range DiffDataR=%(InputR)wcol(gg+6); 
   xmaxforspline = RowToTemp(DiffDataR.nrows); 
   noip = (xmaxforspline-StartTemp)*100+1; 
   interp1xy iy:=%(InputR)(1,$(gg+6)) method:=spline 
npts:=$(noip) xmin:=$(StartTemp) xmax:=$(xmaxforspline) boundary:= notaknot 
oy:=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!(1,$(gg+1)); 
   range 
SplinedCol1R=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!col(1); 
   SplinedCol1R[U]$="°C"; 
   SplinedCol1R[C]$="Temperature"; 
   range 
SplinedDataR=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(gg+1); 
   SplinedDataR[C]$="Splined %(Filter.GetAt(gg)$)"; 
   range 
SplinedDiffPeakCenters=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(gg*2+4); 
   range 
SplinedDiffPeakY=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(gg*2+5);// 1 col vor 
Peak Center 
   SplinedDiffPeakCenters[C]$="Temperature"; 
   SplinedDiffPeakCenters[U]$="°C"; 
   SplinedDiffPeakCenters[L]$=%(AF.GetAt(jj+1)$)$(ii); 
   pkFind -se iy:=SplinedDataR method:=first dir:=both 
ocenter:=SplinedDiffPeakCenters; // -se to ignore "Keine Peaks gefunden.." 
   NoFoundPeaks=SplinedDiffPeakCenters.nrows; 
   if (0 != xf_get_last_error_code()) { 
    strError$ = "pkFind failed: " + 
xf_get_last_error_message()$; 
    type strError$; 
    SplinedDiffPeakCenters[1]=StartTemp;  
    SplinedDiffPeakY[1]=0; // set first row = 0 
    SplinedDiffPeakY[C]$="no peak found"; 
    type 
"[%(SplineBook$)]%(AF.GetAt(jj+1)$)$(ii)!col($(gg*2+4)) skipping peakfind"; 
   } else {     
    SplinedDiffPeakY[C]$="Peaks %(Filter.GetAt(gg)$)"; 
    SplinedDiffPeakY[U]$="a.u."; 
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    SplinedDiffPeakY[L]$="first derivated fluorescence 
intensity"; 
    loop (uu,1,$(NoFoundPeaks)) { 
     SplinedDiffPeakY[uu] = 
SplinedDataR[$(SplinedDiffPeakCenters[uu])]; 
    
 SplinedDiffPeakCenters[uu]=SplinedCol1R[SplinedDiffPeakCenters[uu]]; 
    } 
   } 
   SplinedDiffPeakCenters.type=4; //set as X 
  } 
 } 
} 
SplineBook$="SplineBook"; 
win -r %(tempSplineBookName$) %(SplineBook$); //rename 
// I/O 
type "Splining... done."; 
 
 
 
// SUBSECTION: PLOT SPLINED DIFF DATA 
 
loop(ii,StartCol,StopCol) { 
 loop(jj,0,7) { 
  loop(gg,1,4) { 
   plotxy 
iy:=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!($(gg*2+4):$(gg*2+5)) plot:=201 color:=6 
ogl:=[SplinedDiffPlot%(AF.GetAt(jj+1)$)$(ii)]; 
  } 
  loop (xx,1,4) { 
   range 
graphPeak=[SplinedDiffPlot%(AF.GetAt(jj+1)$)$(ii)]1!$(xx);  
   win -o SplinedDiffPlot%(AF.GetAt(jj+1)$)$(ii) { 
    layer -ilx graphPeak; 
   } 
  } 
  // PLOT 
  plotxy iy:=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!(1,2:5) plot:=200 
ogl:=[SplinedDiffPlot%(AF.GetAt(jj+1)$)$(ii)]; 
  win -o SplinedDiffPlot%(AF.GetAt(jj+1)$)$(ii) { 
   //change Graph style 
   xb.text$="Temperature [%(?X,@LU)]"; 
   layer.y.label.divideBy=1000;  
   layer.y.label.suf$="k"; 
   //move legend 
   legend.y = layer1.y.to - legend.dy / 2; 
   legend.x = layer1.x.from + legend.dx / 2; 
   layer.x.from=StartTemp; // x-axis start from 
   layer.x.to=plotxto; // smart x-scale 
   //add title label 
   label -j 1 -s -sa -n title Position %(AF.GetAt(jj+1)$)$(ii), 
%(FileName$)\n%([SampleBook$]1!wcol(ii)[jj+1]$); 
   title.fsize=28; 
   title.y = layer.y.to + title.dy / 2; 
  } 
  insertGraph gname:=SplinedDiffPlot%(AF.GetAt(jj+1)$)$(ii) 
cell:=[PlotBook$]SplinedCurves!wcol(ii)[jj+1] resizecell:=1; 
 } 
} 
// I/O 
type "Plotting splined differentiation plots ... done."; 
OpenTM Origin® LabTalk script for the analysis of DSF experiments 
197 
 
 
 
// SECTION: BOLTZMANN FIT --> Tm and Ton 
 
// create new books for the results of the 4 different fit processes (1-4p) 
StringArray MainSA = {"1p","2p","3p","4p"}; 
newbook name:="Results Tm from Boltzmann Fit" result:=FitBook$ sheet:=0; 
string tempFitBookName$=page.name$; 
newbook name:="Results Tmonset (Onset temperature)" result:=TonBook$ sheet:=0; 
string tempTonBookName$=page.name$; 
loop(aa,1,4) { 
 type "... fitting with %(MainSA.GetAt(aa)$) "; 
 // create new sheets in FitBook 
 newsheet book:=FitBook$ name:="%(MainSA.GetAt(aa)$)FitTable";//add a new 
sheet for table like fit results 
 loop (hh,1,4) { 
  newsheet book:=FitBook$ name:="%(MainSA.GetAt(aa)$)Tmelt$(hh)";//add 
a new sheet for wellplate style x0 
  range DataR=[FitBook$]%(MainSA.GetAT(aa)$)Tmelt$(hh)!; 
  DataR.autoaddrows=0; 
  DataR.nCols=12; 
  DataR.nRows=8; 
 } 
 // create new sheets in TonBook 
 newsheet book:=TonBook$ name:="%(MainSA.GetAt(aa)$)TonTable";//add a new 
sheet for table like TON results 
 loop (hh,1,4) { 
  newsheet book:=TonBook$ name:="%(MainSA.GetAt(aa)$)Ton$(hh)";//add a 
new sheet for wellplate style x0 
  range DataR=[TonBook$]%(MainSA.GetAT(aa)$)Ton$(hh)!; 
  DataR.autoaddrows=0; 
  DataR.nCols=12; 
  DataR.nRows=8; 
 } 
 //create new sheets in PlotBook 
 loop(i,StartFitFilter,Filter.GetSize()) { 
  newsheet book:=PlotBook$ name:="%(MainSA.GetAt(aa)$)FitCurves$(i)"; 
  range DataR=[PlotBook$]%(MainSA.GetAT(aa)$)FitCurves$(i)!; 
  DataR.autoaddrows=0; 
  DataR.nCols=12; 
  DataR.nRows=8; 
 } 
 //range notation stay constant and can therefore easily been done before the 
for-loop 
 range rFitSample=[FitBook$]"%(MainSA.GetAt(aa)$)FitTable"!col(1); 
 rFitSample[L]$="Sample"; 
 rFitSample[C]$=FileName$; 
 range rTonSample=[TonBook$]"%(MainSA.GetAt(aa)$)TonTable"!col(1); 
 rTonSample[L]$="Sample"; 
 rTonSample[C]$=FileName$; 
 // start fitting across all filters... 
 loop(gg,StartFitFilter,Filter.GetSize()) { 
  range rFitA1 = [FitBook$]"%(MainSA.GetAt(aa)$)FitTable"!wcol(gg*4-2); 
// formula StartFitFilter*4-4+2 
  rFitA1[L]$="A1 %(Filter.GetAt(gg)$)"; 
  rFitA1[C]$="Boltzmann for %(Filter.GetAt(gg)$)"; 
  rFitA1.width=10; 
  range rFitA2 = [FitBook$]"%(MainSA.GetAt(aa)$)FitTable"!wcol(gg*4-1); 
  rFitA2[L]$="A2 %(Filter.GetAt(gg)$)"; 
  rFitA2[C]$="Boltzmann for %(Filter.GetAt(gg)$)"; 
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  rFitA2.width=10; 
  range rFitx0 = [FitBook$]"%(MainSA.GetAt(aa)$)FitTable"!wcol(gg*4); 
  rFitx0[L]$="x0 %(Filter.GetAt(gg)$)"; 
  rFitx0[C]$="Boltzmann for %(Filter.GetAt(gg)$)"; 
  rFitx0.width=10; 
  range rFitdx = [FitBook$]"%(MainSA.GetAt(aa)$)FitTable"!wcol(gg*4+1); 
  rFitdx[L]$="dx %(Filter.GetAt(gg)$)"; 
  rFitdx[C]$="Boltzmann for %(Filter.GetAt(gg)$)"; 
  rFitdx.width=10; 
  range rTon = [TonBook$]"%(MainSA.GetAt(aa)$)TonTable"!wcol(gg+1); 
  rTon[L]$="Tonset %(Filter.GetAt(gg)$)"; 
  rTon[U]$="°C"; 
  rTon[C]$="Lower interception"; 
  rTon.width=10; 
  range PDPeak1R=[PDBook$]%(Filter.GetAt(gg)$)!col(2); 
  range PDPeak2R=[PDBook$]%(Filter.GetAt(gg)$)!col(3); 
  range DiffPeakR=[PDBook$]"DiffData"!wcol(gg*5);// 5th,starts col 5  
  range DiffLocalMinR=[PDBook$]"DiffData"!wcol(gg*5+1);// 5th, col 6 
  range TableMinR=[PDBook$]"Table"!wcol(gg+5);//col 6=min Filter A 
  loop(ii,StartCol,StopCol) { 
   range 
DataR=[FitBook$]"%(MainSA.GetAt(aa)$)Tmelt$(gg)"!col($(ii)); 
   DataR[L]$="Col #$(ii)"; 
   DataR[U]$="°C"; 
   DataR[C]$="%(Filter.GetAt(gg)$)"; 
   DataR.type=2; 
   range 
DataTonR=[TonBook$]"%(MainSA.GetAt(aa)$)Ton$(gg)"!col($(ii)); 
   DataTonR[L]$="Col #$(ii)"; 
   DataTonR[U]$="°C"; 
   DataTonR[C]$="Tonset %(Filter.GetAt(gg)$)"; 
   DataTonR.type=2; 
   loop(jj,0,7) { 
    fsample = ($(jj)*12)+$(ii); 
    range outputR=[ResBook$]%(AF.GetAt(jj+1)$)$(ii); 
    //fill col 1 with Sample Name 
    rFitSample[fsample]$="%(AF.GetAt(jj+1)$)$(ii)"; 
    rTonSample[fsample]$="%(AF.GetAt(jj+1)$)$(ii)"; 
    // INITIATE FIT RANGE 
    range AddFitCol=%(OutputR)!; 
    AddFitCol.Addcol(); 
    int FitColN=AddFitCol.nCols; 
    range NewFitCol=%(OutputR)!wcol(FitColN); 
    NewFitCol.width=10; 
    NewFitCol[L]$="%(Filter.GetAt(gg)$) FitY"; 
    NewFitCol[C]$="Boltzmann for %(Filter.GetAt(gg)$)"; 
    //get Max bzw. Peaks 
    RowUpper%(MainSA.GetAt(aa)$)=58; //educated guess if 
peakfind failed 
    RowLower%(MainSA.GetAt(aa)$)=30; 
//    type "DEBUG: %(MainSA.GetAt(aa)$), %(Filter.GetAt(gg)$): 
No Peak found. Using $(RowUpper%(MainSA.GetAt(aa)$)) and 
$(RowLower%(MainSA.GetAt(aa)$)) as Upper and Lower value, respectively"; 
    if (PDPeak1R[fsample]$!="--" && PDPeak2R[fsample]$!="--
") { 
     RowUpper1p=TempToRow(PDPeak2R[fsample]); 
     RowUpper2p=TempToRow(PDPeak1R[fsample]); 
     RowUpper3p=TempToRow(PDPeak2R[fsample]); 
     RowUpper4p=TempToRow(PDPeak2R[fsample]); 
     RowLower1p=TempToRow(TableMinR[fsample]); 
     RowLower2p=TempToRow(TableMinR[fsample]); 
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     RowLower3p=TempToRow(DiffPeakR[fsample]);//v.28: 
PDPeak1R -> DiffPeakR 
     RowLower4p=TempToRow(DiffLocalMinR[fsample]); 
//     type "DEBUG: %(MainSA.GetAt(aa)$), 
%(Filter.GetAt(gg)$): TWO Peaks found. Using $(RowUpper%(MainSA.GetAt(aa)$)) and 
$(RowLower%(MainSA.GetAt(aa)$)) as Upper and Lower value, respectively"; 
    }  
    if (PDPeak1R[fsample]$!="--" && PDPeak2R[fsample]$=="--
") { 
     RowUpper1p=TempToRow(PDPeak1R[fsample]); 
     RowUpper2p=TempToRow(DiffPeakR[fsample]); 
     RowUpper3p=TempToRow(PDPeak1R[fsample]); 
     RowUpper4p=TempToRow(PDPeak1R[fsample]); 
     RowLower1p=TempToRow(TableMinR[fsample]); 
     RowLower2p=TempToRow(TableMinR[fsample]); 
     RowLower3p=TempToRow(DiffPeakR[fsample]); 
     RowLower4p=TempToRow(DiffLocalMinR[fsample]); 
//     type "DEBUG: %(MainSA.GetAt(aa)$), 
%(Filter.GetAt(gg)$): ONE Peak found. Using $(RowUpper%(MainSA.GetAt(aa)$)) and 
$(RowLower%(MainSA.GetAt(aa)$)) as Upper and Lower value, respectively"; 
    }  
    if 
(RowUpper%(MainSA.GetAt(aa)$)>RowLower%(MainSA.GetAt(aa)$)) { 
     RowUpper=RowUpper%(MainSA.GetAt(aa)$); 
     RowLower=RowLower%(MainSA.GetAt(aa)$); 
//     type "DEBUG: %(MainSA.GetAt(aa)$), 
%(Filter.GetAt(gg)$): Right slope: Peak=$(RowUpper). Min=$(RowLower)"; 
    } else { 
     RowLower=RowUpper%(MainSA.GetAt(aa)$); 
     RowUpper=RowLower%(MainSA.GetAt(aa)$); 
//     type "DEBUG: %(MainSA.GetAt(aa)$), 
%(Filter.GetAt(gg)$): Left slope: Peak=$(RowUpper). Min=$(RowLower)"; 
    } 
    range 
FitY=%(OutputR)!wcol(gg+2)[$(RowLower):$(RowUpper)];  
    range FitX=%(OutputR)!1; 
    // FIT! 
    nlbegin iy:=FitY func:=Boltzmann nltree:=tt; 
    nlfit; 
    NewFitCol=fit(FitX); 
    rFitA1[$(fsample)] = $(tt.A1); 
    rFitA2[$(fsample)] = $(tt.A2); 
    rFitx0[$(fsample)] = $(tt.x0); 
    rFitdx[$(fsample)] = $(tt.dx); 
    nlend; 
    // report data 
    DataR[jj+1]=$(tt.x0); 
    // PLOT 
    plotxy iy:=%(OutputR)!(1,$(gg+2)) plot:=202 
ogl:=[%(MainSA.GetAt(aa)$)SingleFITPlot%(AF.GetAt(jj+1)$)$(ii)-$(gg)]; 
    plotxy iy:=%(OutputR)!(1,$(FitColN)) plot:=200 
ogl:=[%(MainSA.GetAt(aa)$)SingleFITPlot%(AF.GetAt(jj+1)$)$(ii)-$(gg)] 
color:=color(red); 
    //change Graph style 
    yl.text$="Fluorescence intensity [a.u.]"; 
    layer.y.label.divideBy=1000; 
    layer.y.label.suf$="k"; 
    //move legend 
    legend.y = layer1.y.to - legend.dy / 2; 
    legend.x = layer1.x.from + legend.dx / 2; 
    layer.x.from=StartTemp; // x-axis start from 
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    layer.x.to=plotxto; // smart x-scale 
    //add title label 
    label -j 1 -s -sa -n title Position 
%(AF.GetAt(jj+1)$)$(ii), %(FileName$)\n%([SampleBook$]1!wcol(ii)[jj+1]$); 
    title.fsize=28; 
    title.y = layer.y.to + title.dy / 2; 
    //add upper arrow 
    int xUpA=RowToTemp(RowUpper);// x value as Temp 
    range yUpAR=%(OutputR)!wcol(gg+2); 
    int yUpA=yUpAR[RowUpper]; 
    int y2UpA=(((layer.y.to-layer.y.from)/10)+yUpA);// y+20% 
    draw -n "Lup%(AF.GetAt(jj+1)$)$(ii)" -l 
{xUpA,yUpA,xUpA,y2UpA}; 
    Lup%(AF.GetAt(jj+1)$)$(ii).arrowbeginwidth=15; 
    Lup%(AF.GetAt(jj+1)$)$(ii).arrowbeginshape=4; 
    Lup%(AF.GetAt(jj+1)$)$(ii).color=4; 
    //add label to arrow 
    string labeltext$="$(xUpA)°C"; 
    label -s -a 0 0 -n Tup%(AF.GetAt(jj+1)$)$(ii) 
%(labeltext$); 
    Tup%(AF.GetAt(jj+1)$)$(ii).x=$(xUpA); 
   
 Tup%(AF.GetAt(jj+1)$)$(ii).y=$(y2UpA)+Tup%(AF.GetAt(jj+1)$)$(ii).dy/2; 
    Tup%(AF.GetAt(jj+1)$)$(ii).color=4; 
    //add lower arrow 
    int xLowA=RowToTemp(RowLower);// x value as Temp 
    range yLowAR=%(OutputR)!wcol(gg+2); 
    int yLowA=yLowAR[RowLower]; 
    int y2LowA=(((layer.y.to-layer.y.from)/10)+yLowA);// 
y+20% 
    draw -n "Llow%(AF.GetAt(jj+1)$)$(ii)" -l 
{xLowA,yLowA,xLowA,y2LowA}; 
    Llow%(AF.GetAt(jj+1)$)$(ii).arrowbeginwidth=15; 
    Llow%(AF.GetAt(jj+1)$)$(ii).arrowbeginshape=4; 
    Llow%(AF.GetAt(jj+1)$)$(ii).color=4; 
    //add label to arrow 
    string labeltext$="$(xLowA)°C"; 
    label -s -a 0 0 -n Tlow%(AF.GetAt(jj+1)$)$(ii) 
%(labeltext$); 
    Tlow%(AF.GetAt(jj+1)$)$(ii).x=$(xLowA); 
   
 Tlow%(AF.GetAt(jj+1)$)$(ii).y=$(y2LowA)+Tlow%(AF.GetAt(jj+1)$)$(ii).dy/2; 
    Tlow%(AF.GetAt(jj+1)$)$(ii).color=4; 
    //draw X at x0 
    double xCross=tt.x0;// x value as Temp 
    double yCross=(tt.A1-tt.A2)/2+tt.A2; //Ladies and 
Gentlemen, let's keep it simple ;-) 
    //double yCross=tt.A2+(tt.A1-tt.A2)/(1 + 
exp(0/tt.dx));//Ladies and Gentlemen, the Boltzmann function 
    int dyCross=((layer.y.to-layer.y.from)/10);// +% 
    draw -n "hCross%(AF.GetAt(jj+1)$)$(ii)" -l {xCross-
5,yCross,xCross+5,yCross}; 
    draw -n "vCross%(AF.GetAt(jj+1)$)$(ii)" -l 
{xCross,yCross-dyCross,xCross,yCross+dyCross}; 
    hCross%(AF.GetAt(jj+1)$)$(ii).color=4; 
    vCross%(AF.GetAt(jj+1)$)$(ii).color=4; 
    //add label to cross 
    string labeltext$="$(tt.x0)°C"; 
    label -s -a 0 0 -n TInfl%(AF.GetAt(jj+1)$)$(ii) 
%(labeltext$); 
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 TInfl%(AF.GetAt(jj+1)$)$(ii).x=$(xCross)+TInfl%(AF.GetAt(jj+1)$)$(ii).dx/2+2
; 
    TInfl%(AF.GetAt(jj+1)$)$(ii).y=$(yCross)-
TInfl%(AF.GetAt(jj+1)$)$(ii).dy/2; 
    TInfl%(AF.GetAt(jj+1)$)$(ii).color=4; 
    
    // Calculate ONSET TEMPERATURE 
    double slope=(tt.A2-tt.A1)/(4*tt.dx); // slope at Tm 
    double y_x0=(tt.A1-tt.A2)/2+tt.A2; 
    double intercept=y_x0-(slope*tt.x0); //y-intercept 
    double ton=-intercept/slope; //y-axis intersection 
    double ton2=(tt.A1-intercept)/slope; // (I) Tonset. 
Horizontal tangent intersection. dT = Distance between Onset temperature (I) and 
the corresponding melting temperature 
    double ton3=ton2-(tt.x0-ton2);  // (II) Tonset. 2x dT 
    //reporting 
    DataTonR[jj+1]=ton3; 
    rTon[$(fsample)]=ton3; 
    if (ton<0) { ton=0; } //bugfix 
    //h-line at A1 and  
    draw -n "hTon%(AF.GetAt(jj+1)$)$(ii)" -d 2 -l 
{StartTemp,tt.A1,ton2,tt.A1}; 
    draw -n "sTon%(AF.GetAt(jj+1)$)$(ii)" -d 2 -l 
{ton2,tt.A1,tt.x0,y_x0}; 
    hTon%(AF.GetAt(jj+1)$)$(ii).color=6; 
    sTon%(AF.GetAt(jj+1)$)$(ii).color=6; 
    //add onset arrow 2 
    int yton2A=tt.A1; //label needs an integer as input-
variable ... 
    draw -n "Lton2%(AF.GetAt(jj+1)$)$(ii)" -l 
{ton2,yton2A,ton2+8,yton2A}; 
    Lton2%(AF.GetAt(jj+1)$)$(ii).arrowbeginwidth=15; 
    Lton2%(AF.GetAt(jj+1)$)$(ii).arrowbeginshape=4; 
    Lton2%(AF.GetAt(jj+1)$)$(ii).color=6; //6 = pink 
    //add label to new lines 
    string labeltext$="$(ton2)°C (I)"; 
    label -s -a 10 10 -n Tton2%(AF.GetAt(jj+1)$)$(ii) 
%(labeltext$); 
    Tton2%(AF.GetAt(jj+1)$)$(ii).color=6; 
   
 Tton2%(AF.GetAt(jj+1)$)$(ii).x=ton2+Tton2%(AF.GetAt(jj+1)$)$(ii).dx/2+9; 
   
 Tton2%(AF.GetAt(jj+1)$)$(ii).y=yton2A;//+(Tton2%(AF.GetAt(jj+1)$)$(ii).dy/2)
; 
    //add onset arrow 3 
    int yton3A=tt.A1; //label needs an integer as input-
variable ... 
    int y2ton3A=yton3A-((layer.y.to-layer.y.from)/10); 
    draw -n "Lton3%(AF.GetAt(jj+1)$)$(ii)" -l 
{ton3,yton3A,ton3,y2ton3A}; 
    Lton3%(AF.GetAt(jj+1)$)$(ii).arrowbeginwidth=15; 
    Lton3%(AF.GetAt(jj+1)$)$(ii).arrowbeginshape=4; 
    Lton3%(AF.GetAt(jj+1)$)$(ii).color=6; //6 = pink 
    //add label to new lines 
    string labeltext$="$(ton3)°C (II)"; 
    label -s -a 10 10 -n Tton3%(AF.GetAt(jj+1)$)$(ii) 
%(labeltext$); 
    Tton3%(AF.GetAt(jj+1)$)$(ii).color=6; 
   
 Tton3%(AF.GetAt(jj+1)$)$(ii).x=ton3+(Tton3%(AF.GetAt(jj+1)$)$(ii).dx/2)+1; 
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    Tton3%(AF.GetAt(jj+1)$)$(ii).y=y2ton3A; 
    //finally, insert graphs 
    insertGraph 
gname:=%(MainSA.GetAt(aa)$)SingleFITPlot%(AF.GetAt(jj+1)$)$(ii)-$(gg) 
cell:=[PlotBook$]%(MainSA.GetAt(aa)$)FitCurves$(gg)!wcol(ii)[jj+1] resizecell:=1; 
   } 
   //change sheet style 
   range 
PlotBookCol=[PlotBook$]%(MainSA.GetAt(aa)$)FitCurves$(gg)!col($(ii)); 
   PlotBookCol[L]$="Well plate col. #$(ii)"; //longname 
   PlotBookCol[C]$="%(Filter.GetAt(gg)$)"; 
   PlotBookCol.type=2; //disregard col type 
  } 
 } 
} 
// rename books 
FitBook$="FitBook"; 
win -r %(tempFitBookName$) %(FitBook$); 
TonBook$="TonBook"; 
win -r %(tempTonBookName$) %(TonBook$); 
// I/O 
type "Fitting... done.\n%(FitBook$), TonBook... done."; 
 
 
 
// SUBSECTION: GENERATE FINAL PLOTS (merge results) 
 
loop (aa,1,3) { 
 loop(gg,StartFitFilter,Filter.GetSize()) { 
  loop(ii,StartCol,StopCol) { 
   loop(jj,0,7) { 
    fsample = ($(jj)*12)+$(ii); 
    // show signal strength (experimental) 
    range dataR = 
[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(gg+2); 
    absSignalstrength = 
round(max(dataR)/DetectorLimit[$(gg)]*100,1); 
    relSignalstrength = round((max(dataR)-
min(dataR))/DetectorLimit[$(gg)]*100,1); 
    string labeltext$ = "signal 
strength\nabs=$(absSignalstrength)%\nrel=$(relSignalstrength)%"; 
    win -o 
%(MainSA.GetAt(aa)$)SingleFITPlot%(AF.GetAt(jj+1)$)$(ii)-$(gg) { 
     label -p 100 100 -s -sa -n 
TSS%(AF.GetAt(jj+1)$)$(ii) %(labeltext$); 
     TSS%(AF.GetAt(jj+1)$)$(ii).fsize=16; 
    } 
    //add first derivative maxima, e.g., inflections 
    range 
SplinedDiffPeakCenters=[SplineBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(gg*2+4); 
    range 
Readings=[ResBook$]%(AF.GetAt(jj+1)$)$(ii)!wcol(gg+2); 
    loop (vv,1,SplinedDiffPeakCenters.nrows) { 
     win -o 
%(MainSA.GetAt(aa)$)SingleFITPlot%(AF.GetAt(jj+1)$)$(ii)-$(gg) { 
      int xfdi = SplinedDiffPeakCenters[vv]; 
      int x2fdi = layer.x.to; 
      int roundedTemp=Round(xfdi,0); 
      int yfdi = 
Readings[TempToRow($(roundedTemp))]; //optimize with interpolation (Iu-Il)*R+Il 
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      draw -n Lfdi%(AF.GetAt(jj+1)$)$(ii)$(vv) -l 
{xfdi,yfdi,x2fdi,yfdi}; 
     
 Lfdi%(AF.GetAt(jj+1)$)$(ii)$(vv).arrowbeginwidth=15; 
     
 Lfdi%(AF.GetAt(jj+1)$)$(ii)$(vv).arrowbeginshape=4; 
      Lfdi%(AF.GetAt(jj+1)$)$(ii)$(vv).color=15; 
      //add label to new lines 
      string 
labeltext$="$(SplinedDiffPeakCenters[vv])°C"; 
      label -s -a 10 10 -n 
Tfdi%(AF.GetAt(jj+1)$)$(ii)$(vv) %(labeltext$); 
      Tfdi%(AF.GetAt(jj+1)$)$(ii)$(vv).color=15; 
     
 Tfdi%(AF.GetAt(jj+1)$)$(ii)$(vv).x=x2fdi+(Tfdi%(AF.GetAt(jj+1)$)$(ii)$(vv).d
x/2)+1; 
      Tfdi%(AF.GetAt(jj+1)$)$(ii)$(vv).y=yfdi; 
     } 
    } 
   } 
  } 
 } 
} 
// I/O 
type "Merging ... done."; 
 
 
// SECTION: TERMINATION 
 
//report script runtime 
string date2$=%[%[$(@D, D13),>" "], 4:5]; 
int min2=%(date2$); 
string date2$=%[%[$(@D, D13),>" "], 7:8]; 
int sec2=%(date2$); 
if (sec1>=sec2) { 
 min=min2-min1-1; 
 secnd=60+sec2-sec1; 
} else { 
 min=min2-min1; 
 secnd=sec2-sec1; 
} 
type "Script finished after $(min)min$(secnd)sec."; 
 
